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Antibiotic-Conjugated Polyacrylate Nanoparticles: New Opportunities for Development 
of Anti-MRSA Agents 
 
 
Yang Wang 
 
 
ABSTRACT 
 
 
N-Thiolated β-lactams represent a novel family of antibacterial agents, whose in vitro activity is 
confined largely to Staphylococcus species, including multidrug-resistant forms of S. aureus. N-Thiolated 
β-lactams have recently been shown to possess intriguing biological activities which are addressed in 
Chapter II. Current development of nanoparticles as a new drug delivery vehicle is described in Chapter III. 
Chapter IV and V described the current research in our laboratories focusing on the synthesis and 
characterization of emulsified polyacrylate/polyacrylamide nanoparticle antibacterials for drug delivery of 
water-insoluble antibiotics. These nanoparticles can be prepared in aqueous media directly from 
acrylate/acrylamide monomers through free radical microemulsion polymerization. These emulsions 
contain antibiotic-conjugated polyacrylate nanospheres measuring 30-60 nm in diameter and have 
enhanced antibacterial activity against drug resistant S. aureus (MRSA) through what we believe is a novel 
mechanism. 
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CHAPTER 1 CLINICAL DEVELOPMENT OF NEW 
MRSA ANTIBIOTICS 
 
 
1.1 Introduction 
 
Antibiotics, one of the most significant accomplishments of this past century, have prolonged lives 
with their ability to control bacterial infections, such as pneumonia, tuberculosis, dysentery and cholera. It 
was Pasteur who introduced the term of antibiosis meaning that one microorganism kills another, and it was 
much later that this concept was implemented in the form of an actual antibiotic.1 In 1929, Alexander 
Fleming discovered that a broth of Penicillium notatum inhibits the growth of Staphylococcus aureus on an 
agar plate and three years later, he named this active substance “Penicillin”. Figure 1.1 (Merck & Co., Inc.) 
shows how the growth of bacteria on the agar in a culture dish has been inhibited by the three circular 
colonies of the fungus Penicillium notatum.2 The antibiotic penicillin, diffusing outward from the colonies, 
is responsible for this effect. Today, penicillin is made from cultures of Penicillium chrysogenum that has 
been specially adapted for high yields. Later on, the first clinical trial with penicillin as an antibacterial 
therapy was undertaken in 1941. 
 
 
 
Figure 1.1: Picture of inhibition of bacteria on an agar by fungus Penicillium notatum. 
 
In 1945, Dorothy Hodgkin and Barbara Roger-Low determined the molecular structure of 
penicillin G by crystallography (Figure 1.2). Penicillin F is a structurally related substance studied in Great 
Britain in the 1940’s, which has a different amido side chain arising from the use of 3-hexenoic acid in 
place of phenylacetic acid in the culture media. 
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Figure 1.2: Structures of penicillin G and penicillin F. 
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Since the 1940s, β-lactam antibiotics have been playing an important role in the treatment of 
microbial infections as a result of their high antibacterial activity and low toxicity. The β-lactams get their 
name from the characteristic structure of the four-membered ring. The history of β-lactam antibiotics began 
with the discovery of the penicillins3 and continued with the development of cephalosporins.4 Penicillins 
include penicillin G, a natural product, and two semi-synthetic products, ampicillin and amoxicillin. Over 
two dozen of analogues of cephalosporins are in current use and most of them are semi-synthetics derived 
from the secretion of the mold Cephalosporium. Both have been widely used and studied. Structures of 
analogues of penicillins and cephalosporins are demonstrated in Figure 1.3.  
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Figure 1.3: Analogues of penicillins and cephalosporins. 
 
During the 1960s and 70s, other types of β-lactam antibiotics with biological activities against S. 
aureus, as well as other bacteria strains, were discovered either from natural sources or synthetic pathways. 
Families of clinically-prescribed β-lactam antibiotics are illustrated in Figure 1.4. 
 
Penicillins
N
O
SN
H
R`
R``
COOH
R
O
N
O
N
H
R
COOH
HO
Carbapenams
N
O
SN
H
X
COOH
HO
Penams
N
O
N
HR
O
S
COOH
R'
Nocardicins
N
O
N
HR
O
HOOC
R'
OH N
O
R'
SO3H
N
H
O
MonobactamsCephalosporins  
 
 
Figure 1.4: Structures of families of β-lactam antibiotics.  
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β-Lactams work by interfering with bacterial cell wall biosynthesis. The walls of bacteria are 
made of a complex polymeric material called peptidoglycan, which contains both amino acids and sugars. 
The sugars are of two kinds, a nitrogen-containing hexose called N-acetylglucosamine (NAG), and N-
acetylmuramic acid (NAM) (Figure 1.5). These two generate a linear polymer of NAG alternating with 
NAM and they are linked by a glycosidic bond. The side chains attached to each NAM contain 4 or 5 
amino acids.  
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Figure 1.5: Structure of peptidoglycan. 
 
β-Lactams bind to and inhibit bacterial enzymes that catalyze cross-linking reactions of peptides 
on peptidoglycan strands of a growing cell wall.5 Upon binding, a serine residue within the active site 
attacks the β-lactam carbonyl, forming an irreversible penicillin-enzyme complex. This acylation reaction 
renders the enzyme inactive (Scheme 1.1). 
 
 
Scheme 1.1: Proposed mechanism of the transpeptidation reaction (a) and the inhibition of the 
transpeptidase enzymes by penicillin (b). 
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The structural similarity of β-lactams to the natural D-Ala-D-Ala-terminated substrate, and the 
strong acylating ability of the β-lactam ring, results in the affinity of β-lactams to these transpeptidase.  It 
has been proposed that penicillin imitates a conformation of the enzyme’s substrate, D-alanyl-D-alanine, in 
the transpeptidase active site 6 (Figure 1.6). 
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Figure 1.6: Conformational representations of penicillin and acyl-D-Ala-D-Ala. 
 
1.2 Antibiotics Resistance 
 
1.2.1 Intrinsic Resistance and Acquired Resistance 
The development of antibiotics for clinical use has cured and controlled previously untreatable 
bacterial diseases, but unfortunately, they may also bring new problems after being used easily and 
excessively. As with any medication, antibiotics can produce side effects, such as allergic reactions and 
impairment of organ function, as of the liver or kidneys. Moreover, antibiotic treatment may create 
resistance in the target organisms that cause infection and against which antibiotic therapy is directed. Thus, 
over time, antimicrobial agents typically lose their effectiveness as they are used. In the early β-lactam 
literature, it was reported that many bacteria strains showed increased resistance to the penicillin shortly 
after it was introduced into the public. In the 1940s, an enzyme named “penicillinase” was isolated from a 
strain of Escherichia coli and found to be responsible for the therapeutic failure of penicillin in 
Staphylococcus aureus, a common cause of hospital infections.7 Since then, a number of related enzymes 
(Penicillinases) have been discovered that inactivate β-lactams through bond cleavage.  
 
Another major factor that accounts for bacterial resistance is the inability of β-lactam antibiotics to 
penetrate the outer bacterial cell membrane. This is a particular problem associated with Gram-negative 
bacteria as a result of their complex protein, lipid, and lipopolysaccharide membrane. This permeability 
barrier is responsible for the resistance of Pseudomonas aeruginosa to many β-lactam antibiotics. Some 
bacteria are intrinsically resistant to other antibiotics, for example, Gram-positive bacteria are much less 
susceptible to polymixins than Gram-negative bacteria.8 
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Many bacteria acquire resistance to one or more of the antibiotics to which they were formerly 
susceptible. For example, resistance of Shigella, causing gastrointestinal illness, to ampicillin grew from 
32% to 67% in the decade from 1985-1995 in the U.S.9 Bacteria develop resistance by acquiring genes 
encoding proteins that protect them from the effects of the antibiotics. In some cases, the genes arise by 
mutation; in others, they are acquired from other bacteria that are already resistant to the antibiotic. The 
genes are often found on plasmids which spread easily from one bacterium to another-even from one 
species of bacterium to another. As mentioned previously, penicillinase enzymes provide protection against 
most β-lactam antibiotics by breaking the amide bond on the β-lactam ring. 
 
 
1.2.2 Urgent Problems of Resistance 
Several types of antibiotic resistance are currently undergoing rapid evolution and spread and they 
may leave current antibiotics with little of no effectiveness against their target organisms. One of the most 
important microbes to develop resistance is methicillin-resistant Staphylococcus aureus (MRSA). It is a 
multi-drug resistant pathogen whose insensitivity to most antibiotics has evolved over the span of five 
decades. Staphylococcus aureus, a species of bacteria which is often referred to as "staph", can live 
harmlessly on many skin surfaces, especially around portals such as the nose, mouth, genitals, and rectum. 
But when the skin is punctured or broken, S. aureus can enter the wound and cause an infection. S. aureus 
can cause folliculitis, boils, scalded skin syndrome, impetigo, toxic shock syndrome, cellulitis, and other 
types of infections. After the discovery of penicillin by Alexander Fleming in 1928 and the scale-up 
production processes of Flory and Chain, S. aureus infections became treatable by penicillin, and 
eventually by a variety of penicillin analogues. The efficacy of these drugs has steadily declined since their 
initial conception, due to the ability of S. aureus to acquire resistance mechanisms. Methicillin resistant 
Staphylococcus aureus (MRSA), was first discovered in 1961 which was only one year after clinical trials 
of methicillin.10 The percentage of S. aureus strains with resistance to standard β-lactam antibiotics has 
doubled over the past fourteen years, from 30% to 60%.     
 
MRSA infections are commonly acquired during treatments in a hospital setting. For example, a 
patient may visit a hospital for a puncture wound and become infected with MRSA. With low drug 
efficacies against these infections, it often becomes quite difficult to treat MRSA. Even other types of 
antibiotics, such as Vancomycin, considered the last line of defense against MRSA, are now exhibiting 
lower efficacy levels due to acquired resistance.  
 
 
1.3 Clinical Development of Anti-MRSA Antibiotics 
 
1.3.1 β-Lactam Antibiotics 
Recent structure-activity relationship (SAR) studies of cephalosporins and penems have shown 
enhanced binding to transpeptidases and heightened resistance to β-lactamase enzymes. Traditional 
cephalosporins are poor inhibitors of penicillin-binding proteins (PBPs) and are considered ineffective for 
the treatment of MRSA. During the 1990s, new semi-synthetic analogues were produced to enhance 
bioactivity and stability. At the same time, other anti-MRSA β-lactams, carbapenems, were developed by 
Merck & Co and SmithKline Beecham.11 However, the investigations of these newly-designed antibiotics 
were discontinued or suspended by 2001.  
 
N-Thiolated β-lactams (Figure 1.7) are a novel class of synthetic antibiotics for MRSA whose 
mode of action does not involve the inhibition of cell wall biosynthesis.12 Further study of this family of 
antibacterial agents, one of the subjects of this dissertation, is presented in chapter two.  
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Figure 1.7: Structure of N-thiolated β-lactams. 
 
 
1.3.2 Glycopeptides and Vancomycin 
Glycopeptides represent the most successful family of MRSA antibiotics and remain the choice 
for the treatment of MRSA diseases. Glycopeptides interfere with synthesis of the bacterial cell wall but by 
a different mechanism than the β-lactams. Vancomycin (Figure 1.8) is a widely-used glycopeptide in the 
U.S. that acts by binding to the D-alanine on the end of the peptidoglycan bridge to prevent interstrand 
cross-linking. It has become the antibiotic of last resort as resistance to the other antibiotics has become 
more and more common. 
 
 
 
Figure 1.8: Structure of vancomycin. 
 
1.3.3 Oxazolidinones 
Oxazolidinones are bacteriostatic antibiotics that inhibit protein synthesis by binding to two 
separate ribosomal subunits (30S and 50S).13 Linezolid (Zyvox®) (Figure 1.9) is the first of a new class of 
antimicrobial agents to be approved for clinical use by the U.S. Food and Drug Administration in 2000. The 
drug is a total synthetic compound, which lessens the likelihood of naturally occurring resistance 
mechanisms. It has excellent activity against virtually all important Gram-positive pathogens, including 
methicillin-resistant Staphylococci, penicillin-resistant Pneumococci, macrolide-resistant Streptococci, and 
vancomycin-resistant Enterococci.14 
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Figure 1.9: Structure of linezolid. 
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1.3.4 Quinolones and Fluoroquinolones 
Quinolones and fluoroquinolones form a group of broad-spectrum antibiotics related to nalidixic 
acid (Figure 1.10). Quinolones act by inhibiting the bacterial DNA gyrase and/or the topoisomerase IV 
enzyme in S. aureus. Thus, they inhibit DNA replication and act bacteriocidally. They are considered to be 
a chemotherapeutic agent as opposed to a true antibiotic since they prevent replication of the bacterial cell 
by interfering with the genetic replication of the bacterium. 
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Figure 1.10: Structures of quinolone DK-507k and olamufloxacin, fluoroquinolones DW-116 and BMS-
284756 and nalidixic acid. 
 
1.4 Conclusions 
 
The frequency of antibiotic resistance has continued to rise despite concerted efforts to develop 
new drugs and improve the traditional antibiotics efficiency. Tremendous effort to discover new anti-
MRSA antibiotics has been put forth, and β-lactams continue to be the most heavily investigated class due 
to the enduring ability to fight infection while maintaining low toxicity in humans.  
 
However, future therapies cannot be devised by analogue synthesis of pre-existing antibiotics 
alone. Compounds with novel modes of action must be developed as S. aureus continues to evolve new 
mechanisms and new levels of resistance to current antibiotics. In chapter two, the synthesis and structure-
activity relationships of the novel anti-MRSA antibiotics called "N-methylthio β-lactams" are described. 
Recent developments of nanotechnology-based polymer for the delivery of the antibiotics are described in 
chapter three. A novel synthesized polyacrylate/acrylamide nanoparticle for drug delivery of water-
insoluble antibiotics is described in chapters four and five. 
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CHAPTER 2 SYNTHESIS AND BIOLOGICAL 
PROPERTIES OF C3-SUBSTITUTED N-THIOLATED β-
LACTAMS 
2.1 Introduction 
 
N-Methylthio β-lactams 1 represent a new family of antibiotics that inhibit the growth of 
Staphylococcus bacteria15 (Figure 2.1). Previous research in the Turos group has shown that  the initial lead 
compound 2 has antibacterial activity against Staphylococcus aureus and methicillin resistant S. aureus 
(MRSA).16,17 Some initial structure-activity studies were performed to determine what structural features 
give the N-thiolated β-lactam its antibacterial activity. The N-methylthio substituent is essential for activity; 
however, the C4 alkynyl substituent can be replaced with E or Z alkenyl, alkyl, aryl, or heteroaryl without 
the loss of biological activity.18 
                                  
The N-thiolated β-lactams are highly lipophilic molecules which are in contrast to the penicillins, 
cephalosporins, penems, carbapenems and monobactams, structurally similar β-lactams that contain an 
acidic or ionic moiety adjacent to the lactam nitrogen. Traditional β-lactam antibiotics require this 
functional group for binding to the penicillin binding proteins.19 These new antibiotics do not cause any 
morphological defects in bacterial cells, which are expected of an inhibitor of cell wall synthesis such as 
the penicillins.  The mode of action, although still ill-defined, clearly differs from the traditional β-lactam 
antibiotics.   
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Figure 2.1: N-thiolated β-lactam 1 and initial lead β-lactam 2. 
 
This chapter examines an additional element of the structure-activity relationship (SAR) studies of 
N-thiolated β-lactams, one in which antibiotics containing sulfonate and amino substituents at the C3 
position on the lactam ring (Figure 2.2). Compared to methoxy lactam 1, the sulfonate is greater than 
methoxy in electron-withdrawing ability, while the amino group is greater than methoxy in basicity and 
polarity. These changes might affect the biological activities against MRSA. The synthesis and biological 
evaluation of the lactams against a panel of common bacteria consisting of 9 clinical strains of methicillin-
resistant S. aureus (MRSA) is reported, as well as some additional microbes. The information gathered 
from the experiments presented in this chapter can in effect be applied towards the understanding the 
lactam's mode of action in bacteria.  
  
9
N
O SCH3
RSO2O H H
3
N
O SCH3
H
R2R1N H
4
Cl Cl
 
 
Figure 2.2: C3-sulfonated N-thiolated β-lactam 3 and C3-amino β-lactam 4. 
 
2.2 Synthesis of C3-Sulfonate N-Thiolated β-Lactams 
 
C3-Sulfonate-substituted β-lactams 3 were prepared by the series of reactions illustrated in Scheme 
2.1. The five stage sequence was initiated by the synthesis of N-(4-methoxyphenyl) imine 6 from 
benzaldehyde (5) and p-anisidine. Staudinger coupling of acetoxyacetyl chloride (7) and imine 6 by a 
formal [2+2] cycloaddition afforded exclusively the cis-(3S,4R)-substituted β-lactam 8 as a racemic 
mixture. Base hydrolysis formed alcohol 9 and the following SN2-type sulfonation provided β-lactams 10.  
Following oxidative cleavage of the p-anisyl residue by aqueous ceric ammonium nitrate, the N-
protio lactam 11 was thiolated using readily available sulfenylating reagents to provide the N-thiolated β-
lactams 3 in 6 steps. The yields of the reactions were variable depending on the substituents located at C3 
the ring. The following section details each reaction involved in the synthesis of N-thiolated β-lactams. 
 
Scheme 2.1: General synthetic route to lactam 3.  
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R = H, Cl 
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2.2.1 Synthesis of C-Aryl (imines) 6 
N-(4-Methoxyphenyl)imines 6 were prepared from the condensation of benzaldehyde (5a) or o-
chlorobenzaldehyde (5b) and p-anisidine (Scheme 2.2). Prior to the reaction, the p-anisidine was 
recrystallized in water heated to ~ 60 oC and dried in vacuo.20 While the two aldehydes were used without 
further purification, when necessary, the acid contaminant was removed by washing with 10% sodium 
bicarbonate or distilling at atmospheric pressure.21 The aldehyde and p-anisidine were dissolved in dry 
methylene chloride and stirred at room temperature for 1-2 hrs. Approximately 1 mg of camphorsulfonic 
acid (CSA) was added to the mixture and heating to reflux was sometimes applied to promote the 
condensation of the starting materials. In most instances, conversion to the imine was completed within 1 
hour and could be followed by thin layer chromatography (TLC). The resulting imine was then 
recrystallized in methanol to get rid of the excess of the anisidine and give the final product, N-(4-
methoxyphenyl) imines 6.    
 
 
Scheme 2.2: Synthesis of N-aryl (imines) 6. 
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2.2.2 Synthesis of N-Aryl Protected β-Lactams by Staudinger Coupling 
 
The most frequently described procedure for preparing monocyclic β-lactams is Staudinger 
coupling. 22  This reaction involves a formal [2+2] cycloaddition of acetoxyacetyl chloride (7) or an 
activated carboxylic acid23  to an imine (6), and was the methodology employed to synthesize N-aryl 
protected β-lactams 8a and 8b (Scheme 2.3).  
 
 
Scheme 2.3: Synthesis of N-aryl protected β-lactam 8 by Staudinger [2+2] condensation. 
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The mechanism of β-lactam formation in the synthesis of 8 is depicted in Scheme 2.4. N-Aryl 
imines 6 exist primarily in the E-configuration24 and form cis β-lactams 8 by a kinetic pathway. Orthogonal 
attack of the imine on the least hindered side of the activated carbonyl center generates a zwitterionic 
intermediate, which can interconvert via the anionic intermediate, reverts back to the starting materials, or 
leads to cis and trans β-lactams. Generally, the cis cycloadduct is obtained when the acyl chloride is added 
dropwise to a solution of the imine and tertiary amine base, and it is the major or exclusive stereoisomer.25 
On the other hand, it is found that when the tertiary amine base is added to a solution of the imine and the 
acyl chloride, a variable mixture of the cis and trans cycloadducts are obtained in which the trans 
configuration is the major or in some cases the exclusive product.26,27 The relative stereochemistry of the β-
lactam 8 can be determined by 1H NMR analysis.  For cis β-lactams the coupling constant for the protons 
on C3 and C4 ring is about 4-5 Hz, and for trans β-lactams the coupling constant is around 2-3 Hz. 
 
Scheme 2.4: Proposed mechanism of β-lactam formation by Staudinger reaction. 
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The yields of the Staudinger reaction involving acetoxyacetyl chlorides (7) varied greatly 
depending on the solvent and temperature. Staudinger coupling reactions typically require a tertiary amine 
base such as triethylamine or ethyldiisopropylamine (eg. Hünig's base). The former was utilized for most 
reactions but could be replaced by Hünig's base with little effect on the isolated yields. A minimum of three 
equivalents of base was needed to enable the reaction to go to completion. Mechanistically, the excess is 
required to (1) generate the activated carbonyl group, (2) serve as a proton scavenger, and (3) act as a 
nucleophile (Nu-) in formation of the anionic intermediate. 
 
Synthesis of the ketene precursor (7) is described in Scheme 2.5. Acetoxyacetic acid (12) was 
prepared from glycolic acid and acetyl chloride in quantitative yield, and reacted with thionyl chloride to 
form acetoxyacetyl chloride (7) in 75% yield after distillation. The methodology for synthesizing 12 shown 
in Scheme 2.5 is practical in providing the costly commercially-available product. 
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Scheme 2.5: Synthesis of acetoxyacetyl chloride (7).  
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2.2.3 Hydrolysis of N-Aryl Protected β-Lactams 8a and 8b 
  
Hydrolysis of N-aryl protected β-lactams 8a and 8b was performed in a basic solution, eg. KOH in 
methanol, at 0 oC, as shown in Scheme 2.6. The yields of the hydrolysis are usually good, ranging from 
93% to quantitative.  
 
Scheme 2.6: Hydrolysis of N-Aryl Protected β-Lactams 8a and 8b. 
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2.2.4 Synthesis of C3-Sulfonate N-Aryl Protected β-Lactams 10 
Three different types of sulfonate groups were introduced onto β-lactams 9a as shown in Scheme 
2.7. Sodium hydride in dry methylene chloride was used to deprotonate the hydroxyl proton on the C3- 
lactam and the corresponding sulfonyl chloride was added to form an analogue of C3-sulfonated N-aryl β-
lactams 10. Yields of isolated, chromatographed product ranged from 75-93%. 
 
Scheme 2.7: Formation of C3-Sulfonate N-Aryl Protected β-Lactams 10a-c.  
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2.2.5 Dearylation of C3-Sulfonate N-Aryl Protected β-Lactams 10 with Ceric 
Ammonium Nitrate 
Kronenthal28 reported a general method to remove the p-anisyl moiety of protected β-lactams 
using ceric ammonium nitrate (CAN) in aqueous acetonitrile. The same procedure was applied in the 
synthesis of N-methylthio β-lactams by the conversion of N-anisyl lactams 10 to N-protio lactams 11. The 
β-lactam 10 was dissolved into acetonitrile and cooled to 0 oC in an ice bath for 15 min. Generally, for 1.0 
g of starting material, 30 mL of acetonitrile was used.  Three equivalents of ceric ammonium nitrate was 
then dissolved in 43 mL of water and added dropwise to the solution of the lactam. The reaction mixture 
turned from clear and colorless to red and clear. During the oxidation, the electron-rich aromatic ring 
permited cleavage by a radical generating species such as CAN. The reaction proceeded through 
intermediate 13 (Scheme 2.8) which decomposed to the dearylated β-lactam and benzoquinone when 
washed with a 5% sodium bisulfite solution. Attempts to increase the reaction yield included (1) 
maintaining the reaction temperature at 0 oC; (2) vigorous stirring; (3) diluting the reaction mixture and (4) 
altering the workup procedure to remove the quinone. 
 
Scheme 2.8: Oxidative dearylation of β-lactams 10. 
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2.2.6 N-Methylation of C3-Sulfonate β-Lactams 
The method of introducing a methythio substituent onto the lactam nitrogen was reported by 
Miller using N-methylthiophthalimide (14).29  The reaction employed a mild base such as triethylamine or 
Hünig's base under reflux conditions in a low boiling, nonpolar aprotic solvent (Scheme 2.9). The synthesis 
of 14 was carried out in the following manner (Scheme 2.10).30 From methyl disulfide, 1.2 equivalents of 
bromine was used to generate the methylsulfenyl bromide in situ, which was then cannulated into a flask 
containing 1 equivalent of phthalimide in a mixture of pyridine and acetonitrile. 
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Scheme 2.9: Synthesis of N-methythio β-lactams 3 using N-methylthiophthalimide.10,11 
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Scheme 2.10: Synthesis of N-methylthiophthalimide (14). 
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Reactions involving sulfur transfer reagent 14 were found to be efficient and reliable, and became 
the method of choice for the N-methylthiolation of all the C3 sulfonated β-lactams prepared in this study. 
  
 
 
2.2.7 The Structure-Activity Profiling of C3-Sulfonated β-Lactam 3  
 
2.2.7.1  Microbiological Evaluation of 3a, 3b and 3c Using Kirby-Bauer Testing 
The SAR studies were initiated with the microbial screening of C3-sulfonate N-thiolated β-lactams 
3a, 3b and 3c. As a control, penicillin G and vancomycin were included in the series for comparison. The 
β-lactams were individually tested for antibacterial activity against methicillin-susceptible and methicillin-
resistant S. aureus strains. Compounds were evaluated in vitro by well diffusion on agar plates (Kirby-
Bauer) in accordance with the guidelines recommended by the National Committee for Clinical Laboratory 
Standards (NCCLS).31 Initially, the well variation of the test was applied to assess the susceptibility. The 
plates were prepared by cutting 6 mm circular holes into the inoculated medium and applying 20 µg of the 
test drug in dimethyl sulfoxide (DMSO) to the wells. Following 24 hrs incubation, the zones of growth 
inhibition were measured in millimeters (from 3 trials) to determine the relative potency of the drug (Figure 
2.3). 
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Zone of Inhibition
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Figure 2.3: Kirby-Bauer well diffusion assay on agar plate measuring zone of inhibition. 
 
Nine MRSA strains were used, including one from ATTC sources, and 8 clinical isolates which 
were obtained from Lakeland Regional Medical Center, and identified as USF 652-659. All were β-
lactamase-producing strains. The biological activities of C3-sulfonate lactams are shown in Figure 2.4 with 
vertical bars representing the growth inhibition zone size; the blue bars are for methicillin-susceptible S. 
aureus (MSSA), while the red bars are for methicillin-resistant S. aureus (MRSA).  
 
          
                     Pen G                Vancomycin                     3a                            3b                             3c     
 
                             
 
 
 
Figure 2.4: Kirby-Bauer data for analogues 3a-3c against S. aureus and MRSA compared with penicillin G 
(Pen G) and vancomycin.  
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Twenty micrograms of test compound in DMSO solution was used in each case. The values 
indicate the average diameters in mm (of three trials) for the zone of growth inhibition obtained for each 
compound after 24 h of incubation at 37 oC, with a margin of error of ±1 mm. For three C3-sulfonated β-
lactams, their biological activities are higher than penicillin G and slightly stronger than vancomycin. 
Compared to the C3-methoxy lactam 1, the sulfonation on the C3 position of the lactam did not enhance the 
bioactivity. The trend for the activity increases with molecular weight: methyl < phenyl < p-tolyl for the 
MSSA and MRSA strains. 
 
 
2.2.7.2 Minimum Inhibitory Concentration (MIC) Determination  
Serial dilutions of the selected lactam in define TSB media was the initial method of choice to 
determine MICs. The results were neither consistent nor comparable to the potency levels seen with the 
Kirby-Bauer diffusion method. The agar variation, however, provided dependable results that were not 
obtainable by broth dilutions. The agar media was prepared in 48-well microtiter plates and inoculated by 
applying a 1 µl suspension of freshly prepared bacterial cultures 106 cells/ml to the well. Following a 24 
hour incubation period, the plates were examined for growth. The lowest concentration of antibiotic to 
inhibit the visual growth of bacteria was recorded as the MIC.  
 
The same trend in the biological activities of C3-sulfonated β-lactams 3a-c was observed in broth 
MIC testing, which ranged from 64-128 µg/mL. For tosyl compound 3a, MIC’s are around 64 µg/mL 
against both MSSA (ATCC 25923) and one MRSA strain (USF 919), for phenylsulfonyl lactam 3c, 
between 84-128 µg/mL, and approach 128 µg/mL for mesyl derivative 3b.  
 
 
2.2.8 Fluorescent Sulfonated Lactam 18 
 
2.2.8.1 Application to the Study of Mode of Action 
As discussed in chapter 1, the classical β-lactam antibiotics inhibit bacterial growth by interrupting 
cell wall biosynthesis. However, studies of the mode of action show that N-thiolated β-lactams do not 
interrupt the cell wall crosslinking.32 Evidence to this fact includes no changes in cellular morphologies, via 
examination by scanning electron microscopy (SEM) of cells treated with N-thiolated β-lactams, and no 
change in cell wall density as determined by Gram-staining. Dramatic alterations in morphology and cell 
wall thickness occur for the same cells treated with penicillins.  Therefore, it is essential to find out where 
in the cell these drugs are going, what are they interacting with and how do these interactions produce 
inhibitive effects. 
 
One method to determine where these drugs may end up in a bacterial cell involved measuring 
fluorescence uptake. The first idea is to attach a fluorescent group at the C3 position on the β-lactam ring 
via a sulfonate linkage. Dansyl chloride has been used extensively to determine the N-terminal amino acid 
residue of proteins and to prepare fluorescent derivatives of drugs, amino acids, oligonucleotides and 
proteins for detection by numerous chromatographic methods. With this idea in hand, lactam 18 was 
designed for the study of mode of action which contains a dansyl group as the fluorescent tracer.  
 
 
2.2.8.2 Synthesis of Dansyl Substituted Lactam 18 
Synthesis of lactam 18 followed the same procedure as the synthesis mentioned previously for 
lactams 3a-c (Scheme 2.11). However, CAN deprotection of the para-methoxyphenyl (PMP) group on the 
lactam failed due to the decomposition of the lactam ring during the reaction.   
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Scheme 2.11: Synthetic route to make dansyl-substituted β-lactam 11d. 
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Another route examined for the synthesis was to attach the dansyl substituent in the last step. The 
key intermediate shown in Scheme 2.12 is the C3-hydroxy N-methylthio lactam 17. PMP deprotection of 8b 
gave N-protio lactam 15, N-thiolation of the deprotected lactam afforded lactam 16, further K2CO3 
hydrolysis gave C3 hydroxy-lactam 17 and the final SN2 substitution with dansyl chloride gave the 
compound 18. 
 
Scheme 2.12: Alternative route for the synthesis of dansyl-substituted lactam 18. 
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2.2.8.3 Results and Conclusions 
Due to the huge steric effect of the dansyl group, it is likely hard for the lactam to diffuse in the 
agar, thus its bioactivity as determined by Kirby-Bauer assay against MRSA is fairly low, with a zone of 
growth inhibition of around 10 mm. In addition, the fluorescent activity of the dansyl group (~330-340 nm) 
is not strong enough to be traced down in the bacteria due to the auto-fluorescence of the bacteria. 
Therefore, a stronger fluorescent tracer should be selected for the mode of action future studies.  
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Another mothod to determine the mode of action of the lactam is radiolabeling, which was done 
by Dr. Timothy Long.33 Due to the lowest cost and smallest number of “hot” synthetic steps, tritium was 
chosen for the synthesis of radiolabled N-methylthio β-lactam in which all three methyl hydrogens were 
swapped for labels. Unfortunately, the results from this experiment did not show where the drug went, only 
where it did not go. These lactams were not detected in any appreciable levels in cellular fractions 
contatining DNA, RNA, or proteins. At the time, low molecular weight targets were not considered and 
quite possibly the radio-tag was thrown out with the cellular fluid.  A repeat experiment done by Dr. 
Seyoung Jang and Marci also showed that no labeled cellular contents (small proteins) were found even 
with a large amount of radioactivity. 
 
A similar idea to follow the drug’s pathway into the cell was investigated by Dr. Bart Heldreth.34 
The idea was to attach a fluorophore as part of the sulfur side chain, to trace the path of this fluorophore 
through the bacterial cell membrane and into the cell. To see precisely the location within the cell where the 
lactam may interact with its target, a Forster Resonance Energy Transfer (FRET) pair was built into the N-
thiolated β-lactam framework. The principle with FRET is that two functional moieties are installed in the 
framework where the fluorescence wavelength of one, the donor, would overlap with the absorption 
wavelength of the other, the acceptor. In this way the fluorescence of the donor would be quenched by the 
acceptor until the two groups detach (Figure 2.5).  
 
Principle of ForsterResonance Energy Transfer (FRET)
Donor Acceptor
 
Figure 2.5: FRET pair concept. 
 
Also, this FRET phenomenon is greatly distance-dependent. In practice, however, there were 
significant problems, for example, it proved to be difficult to introduce two fluorescent side chains onto the 
lactam due to ring decomposition, thus, preventing formation of the final FRET product. As well, this was 
only, at best, a model system, as the donor fluorophore is simply not red-shifted enough to be used for cell 
structures. In the future, it is important to select a suitable candidate for the FRET system with an 
appropriate fluorescence wavelength: for example, a coumarin/dinitrophenyl FRET paired analogue, if it is 
possible to overcome the difficulties of the synthesis. 
  
 There is an inherent problem with this type of experiment, the lactam reacts with thiols, including 
CoA, in the cytoplasm, and the SMe may be transferred to different targets- FRET studies would only show 
the transfer occurring in the cytoplasm. 
 
2.3 C3-Amino β-Lactams 
 
These studies of the C3-sulfonated lactams 3a-c show that a lipophilic sulfonate group on the 
lactam ring does not increase the bioactivity against MRSA compared to the C3-oxygenated lactam 1. 
Follow-up studies on the structure-activity relationships of C3 substituted analogues were conducted to 
examine the effect of a polar amine-containing group on the bioactivity of N-thiolated β-lactams. Five 
lactams, 19a-e, were selected for these experiments (Figure 2.6).  
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Figure 2.6: C3-amino-substituted analogues 19a-d and azido-lactam 19e. 
 
2.3.1 Synthesis of C3-Amino N-Thiolated β-Lactams 19a-d and Azido-Lactam 19e  
Synthesis of C3-amino-substituted analogues 22a-d was done in four steps from hydroxy lactam 
9b as shown in Scheme 2.13. Moffatt oxidation of 9b with P2O5 in DMSO gave ketolactam 19, which 
underwent reductive amination using an alkyl- or dialkylamine and NaBH(OAc)3 in a mixture of acetic 
acid and dichloroethane, to afford amino adducts 20a-d in good yields.12 The trans stereochemistry was 
established by 1H NMR. These PMP-protected compounds were then converted to N-methylthio products 
19a-d under the usual N-dearylation/N-methylthiolation conditions. In the case of 22a and 22b, the N-
thiolation step occurred cleanly on the lactam nitrogen without affecting the 2o amine at C3. 
 
Scheme 2.13:  Synthesis of C3-amino-substituted lactams 19a-d. 
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Conditions: a.) P2O5, DMSO; b.) RR`NH, NaBH(OAc)3, AcOH, ClCH2CH2Cl; c.) (NH4)2Ce(NO3)6, 
MeCN-H2O, 0 oC; d.) N-methylthiophthalimide, triethylamine, CH2Cl2, reflux. 
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The synthesis of azido β-lactam 19e is shown in Scheme 2.14. Azido lactams can normally be 
prepared by Staudinger coupling of an imine with an α-azidoacetyl chloride. 35  However, it is more 
convenient to access the lactam directly from C3-hydroxy β-lactam 9b. Hydroxy lactam was first converted 
to its mesylate by reaction of its sodium salt with methanesulfonyl chloride in anhydrous CH2Cl2, and then 
displaced with NaN3 in DMF at 80 oC. In this case, trans-disubstituted lactam 23 was obtained exclusively, 
as revealed by the characteristically small proton NMR coupling constant (J = 1.8 Hz) for the β-lactam ring 
protons. The N-protected lactam 23 was then transformed into the N-methythio lactam 19e by N-
dearylation/N-thiolation as described above. 
 
Scheme 2.14: Synthesis of azido β-lactam 19e. 
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Conditions: a) NaH, MsCl, 0 oC to r.t.; then NaN3, DMF, 80 oC; b) (NH4)2Ce(NO3)6, MeCN-H2O, 0 oC; c.) 
N-methylthiophthalimide, triethylamine, CH2Cl2, reflux. 
 
 
 
2.3.2 The Structure-Activity Profiling of C3-Amino β-Lactams 19a-d and C3- Azido 
Lactam 19e 
The five amino-substituted analogues were tested for biological activities against MSSA and 
MRSA by Kirby-Bauer disk diffusion (Figure 2.7). β-Lactam 19a-d turned out to be significantly less 
potent against MRSA than methoxy compound 1 or the C3-azido lactams 19e which had a zone of 
inhibition of about 24 mm against S. aureus and 21 mm for MRSA. In fact, only the N-benzyl substituted 
compound 19b displayed any activity at all against MRSA’s, with average zone sizes of ~9 mm in diameter. 
This weak activity was also observed in the MIC broth testing, with MIC values greater than 256 µg/mL. 
Thus, amino substituents at C3 of these N-methylthio lactams appear to significantly diminish anti-MRSA 
activity. 
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                Pen G.               Vancomycin                19e                     19b                   19a             19c   19d    
 
Figure 2.7: Comparison of the bioactivities of C3-amino β–lactams 19a-e and the reference standard 
antibiotics. 
 
2.4 Additional Biological Activity Screening for N-Thiolated β-Lactam 
Analogues  
 
2.4.1 Other Bacteria Strains: Activity against Bacillus  
Bacillus represents a genus of Gram-positive bacteria which is ubiquitous in nature (soil, water, 
and airborne dust). B. anthracis is the bacterium which causes anthrax in cows, sheep, and sometimes 
humans. The microbe is large, sporeforming rod, 1 - 1.2 µm in width x 3 - 5µm in length having 
characteristic squared ends (Figure 2.8).  
 
If inhaled, spores of B. anthracis rapidly migrate to lymphonodes of the lungs, where they begin to 
germinate and release toxins that cripple the immune response, causing bacteremia, toxemia, and frequently, 
death.36 Concerns about the possible use of B. anthracis as a biological weapon have led to efforts to 
prevent or treat anthrax infections with vaccine or antibacterial drug development, and newer methods for 
detecting the microbe.37,38 
 
            
 
Figure 2.8: Bacillus strains. 
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As previously described, N-thiolated β-lactams, which have a mode of action distinct to that of all 
other β-lactam antibiotics,39 seem to affect cellular processes through transfer of the N organothio group to 
a bacterial thiol. We also note that these lactams exert anti-proliferative properties against only a narrow 
range of bacteria, most significantly, Staphylococcus (including MRSA). This selectivity seems to be 
related to the levels and types of cellular thiols present in each microbe that is sensitive to the lactams, not 
to whether the microbes are Gram-positive or Gram-negative classes. Given that Staphylococcus and 
Bacillus are both prominent members of the Bacillales taxonomic order of bacteria, it will be essential to 
investigate whether these compounds could possess antibacterial properties against Bacillus spp. 
 
 
 
2.4.2 Activities against Bacillus Strains 
 The lead compound in this study was N-methylthio-substituted lactam 1, which has fairly good 
activity against seven Bacillus species. Three different types of analogues of β-lactams were tested for 
Bacillus strains, C3-sulfonated, C3-amino and C3 –amino ester. One representative of the C3-amino ester 
bearing lactams is compound 25, whose synthesis is mentioned in Scheme 2.15. Alanine was first protected 
by Boc2O in the presence of NaOH in aqueous media to give an acid 26, which was then coupled to C3- 
hydroxy lactam 17 using EDCI/DMAP to afford the product 25 in 83% yield. 
 
 
Scheme 2.15: Synthesis of C3-Boc-alanine lactam 25. 
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A select number of differentially substituted β-lactams were individually tested for antibacterial 
activity against B. anthracis and six other species of Bacillus by the Kirby-Bauer method of well diffusion 
on agar plates (Table 2.1). Twenty micrograms of test compound in DMSO solution was used in each case. 
The values indicate the average diameters in mm (of three trials) for the zone of growth inhibition obtained 
for each compound after 24 hour of incubation at 37 oC, with a margin of error of ± 1mm. 
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Table 2.1: Well-diffusion tests against Bacillus anthracis: zone of growth inhibition measured in mm 
 
Compound    B. anthracis    B. globigii    B. thuringensis    B. megaterium    B. coagulans    B. subtilis    B. cereus
3a               19                   12                11                      11                       13                   12                13
3b               10                   8                  10                      0                         10                   10               14 
3c                18                  15                13                      15                        nd                  nd               nd
18                0                    0                   0                        0                         0                     0                 0
19a              0                    0                   0                        0                         0                     0                 0
19b             10                   9                   9                       7                          0                     0                11
19c              0                    0                   0                        0                          0                     0                 0
19d             0                    0                   0                        0                          0                     0                 0
19e             20                  14                 14                      11                        15                   14               17
25               19                  18                 17                      16                        17                   18               20
1                 25                   18                19                      16                       20                   18                21
 
 
 
The first series of compounds examined in this study consists of C3-sulfonate-bearing derivatives 
3a-c. The data show that their bioactivities are dependent on the size and lipophilicity of the sulfonyl side 
chain. Whereas the methanesulfonyl compound 3b is only weakly active against six of the seven Bacillus 
microbes, and totally inactive against B. megaterium, the toluenesulfonyl and phenylsulfonyl variants 3a 
and 3c are appreciably more active against B. anthracis  with an average activity around 13 and 15 mm, 
respectively. 
 
The biological activity trends observed for C3-amino-substituted lactams 19a-d suggest that polar 
side chains at C3 decrease the anti-anthracis activity. Only N-benzylamino compound 19b possesses any 
bioactivity. This parallels what was found previously for MRSA. In addition, replacement of the C3 
methoxy substituent of lactam 1 for an azido group 19e slightly decreases activity.  
 
Finally, the C3 ester lactam 25 with a protected amino acid attached on the ester side chain 
maintained good and uniform bioactivity against all seven Bacillus species. 
 
 
 
2.5 Anticancer Studies of C3-Substituted β-Lactams  
 
One of the major goals in drug discovery is to selectively target tumor cells over normal cells. 
Because of the ease of synthesis and structural manipulation, small molecules with apoptosis-inducing 
ability have great potential to be novel chemotherapeutic agents.40 Initiation, commitment and execution 
are the three fundamental steps of apoptosis.41 In previous studies, one lead N-thiolated β-lactam 1 showed 
the potential activity in inducing DNA strand breakage, inhibiting DNA replication and inducing apoptosis 
in a time- and concentration-dependent manner. 42  Several additional N-thiolated β-lactams with 
substitutions at the C3 position have consequently been screened for their structure-activity relationship. 
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2.5.1 SAR Studies for C3-Sulfonated Lactams 
C3-Sulfonated lactams were 3a-c and 18 assessed for their anti-proliferative pontential in human 
MCF-7 breast cancer cells (Figure 2.9). These experiments were done in collaboration with Dr. Q. Ping 
Dou at Wayne State University. MCF-7 cells were treated with 50 µM of selected lactams for 24 h, 
followed by MTT assay. MCF-7 cells were plated in a 96-well plate and grown to 70-80% confluency 
followed by addition of 50 mM β-lactam for 24 hours. Cells were then incubated with 1 mg/ml MTT for 3 
hours and proliferation rates were determined using a multi-label plate reader (Victor3, Perkin Elmer; ±SD). 
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Figure 2.9: Four C3-sulfonated lactams were selected for anti-cancer studies. 
 
All four lactams 3a-c, and 18 bear good leaving groups on the C3 oxygen, and should essentially 
be equally as potent. However, lactams with large groups, for example, tosyl, phenyl sulfonyl or dansyl 
have very little effect on proliferation, while the lactam 3b with a small mesyl group is the most active 
compound. Mesyl lactam 3b inhibited 57% of MCF-7 cell growth, while the other three lactams have very 
little effect on proliferation (Figure 2.10). A possible explanation for the partial effectiveness is that lactams 
with large groups, e.g, dansyl in lactam 18, is incapable of crossing the cell membrane.  
 
 
Figure 2.10: Structure-activity relationship (SAR) analysis of N-thiolated β-lactams 3b and 18 with DMSO 
as a control.  
 
 
2.5.2 Synthesis and SAR Studies of Racemic and Optical Active C3-Acrylated 
Lactams  
To this point all of the N-thiolated β-lactams that were screened for anticancer activity have been 
in the racemic form; therefore, it was necessary to determine whether one enantiomer is more active than 
the other. Racemic and optical pure forms of C3-acrylate lactam 27 were selected for the SAR study of the 
stereochemistry (Figure 2.11). 
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Figure 2.11: Structures of 27 and its stereoisomers. 
 
 
2.5.2.1 Synthesis of C3-Acrylate β-Lactam 27 and its Stereoisomers 
Our laboratory in collaboration with Dr. Kirpal Bisht’s proved that the racemic β-lactam 8b can be 
resolved via enzymatic resolution using Pseudomonas cepacia lipase (PS-30) to give the (-)-(3S, 4R) 
hydroxy enantiomer 30 and the (+)-(3R, 4S) acetoxy enantiomer 31 in 99% ee (Scheme 2.16).43 
 
Scheme 2.16: Enzymatic kinetic resolution of acetoxy lactam 8b. 
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The enantiomeric purity was determined by 1H NMR in the presence of a chiral shift reagent, (+)-
Eu-(hfc)3. The two compounds 28 and 29 were then separated by column chromatography (EtOAc: Hex= 
1:2), and lactam 28 was then acrylated with acryloyl chloride/NaH in dry methylene chloride for the 
synthesis of (-)-29. 
 
The synthesis of racemic C3-acrylate β-lactam 27 started with C3-hydroxy lactam 9b shown in 
Scheme 2.17. Lactam 9b was acrylated with acryloyl chloride/NaH in dry methylene chloride to give 
compound 30, dearylation of PMP group on the lactam ring afforded 31 and N-thiolation gave the final 
compound 27. 
 
Scheme 2.17: Synthesis of racemic C3-acrylate β-lactam 27. 
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Conditions: a.) Acryloyl chloride, NaH, CH2Cl2; b.) ceric ammonium nitrate, CH3CN, H2O, 0 °C; c.) N-
methylthiophthalimide, CH2Cl2, Hunig's base, reflux. 
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Synthesis of the optical pure lactam (-)-27 is shown in Scheme 2.18 and (+)-27 is illustrated in 
Scheme 2.19. The acrylate group was introduced directly into hydroxy lactam 28 to give compound 32, 
while lactam 29 had to be hydrolyzed to hydroxy lactam 34 before the acrylation occurred.  Theses PMP-
protected lactams were then converted to N-methylthio products under the usual N-dearylation/N-
methylthiolation conditions. 
 
 
Scheme 2.18: Synthesis of (-)-27. 
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Scheme 2.19: Synthesis of (+)-27. 
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2.5.2.2 SAR Anti-Cancer Studies of 27 
Jurkat and YT cells were treated with 59 µM concentration of lactam 1, lactam 27, (+)-lactam 27 
and (-)-lactam 27 for 24 h followed by trypan blue dye exclusion assay (Figure 2.12). It is obvious that 
stereochemistry plays an important role in the activity of N-thiolated β-lactams in their anti-proliferative, 
S/G2-M cell cycle arrest, and apoptosis-inducing properties against cultured human transformed cancer 
cells, but not to the human normal cell line. Lactam 27, which possesses an acrylate moiety on the lactam 
ring, is twice as potent as lactam 1.  
 
 
  
                                                              DMSO        L-1             L-27          (+)-L-27       (-)-L-27   
 
Figure 2.12: (+)-Lactam 27 induces apoptosis selectively in tumorigenic cells. Leukemic Jurkat T and 
nontransformed YT cells were treated with lactam 1 or isomers of lactam 27 at 50 µM for 24 h. Cell death 
is given as a percent of dead cells over total cell population (±SD). 
 
(+)-Lactam 27 induced a very high amount of cell death compared to its isomer (-)-lactam 27, 
98% and 58% respectively. Interestingly, the racemic lactam 27 was almost equally as strong as the R-
isomer. Normal, non-transformed YT cells did not undergo cell death after β-lactam treatment. 
 
Another experiment using a SV-40 transformed (VA-13) and normal (WI-38) human fibroblasts 
demonstrates that (-)-lactam 27 is not an active isomer. A DNA stain of VA-13 and WI-38 fibroblast cell 
lines treated with 50 µM of each lactam for 24 h shows that there is a high degree of detachment and DNA 
condensation in lactam 1, lactam 27 and (+)-lactam 27 treated cells, which are characteristics indicative of 
apoptosis (Figure 2.13).  
 
 
                                                  DMSO          L-1             L-27          (+)-L-27       (-)-L-27 
 
Figure 2.13: Both detached and attached VA-13 and WI-38 fibroblast cell populations were collected and 
stained with the nuclear staining dye Hoechst 33342. Each sample was then analyzed by fluorescence 
microscopy for nuclear morphology. 
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(-)-Lactam 27 showed decreased activity when compared with the racemic lactam 27 and (+)-
lactam 27.  There was a very minor amount of cellular detachment observed in the normal WI-38 
fibroblasts treated with (+)-lactam 27, but all the other lactams showed a high specificity of cell killing to 
the transformed VA-13 cells.   
 
2.6 Animal Testing of Lactam 25 
 
The initial screening for lactam 25 (shown in Figure 2.14a) showed that it was effective in 
tumorigenic cells. Thus, a further study of anti-cancer activity was performed in an animal trial. Female 
athymic nude mice (NCRNU-M) were xenografted by injection of 6 X 106 MDA-MB-231 cells. 15 days 
after the injection, the mice were divided into three groups: solvent control, low dose (0.3 mg/kg) and high 
dose (3 mg/kg) treatment with β-lactam 25 by subcutaneous injection daily. Tumor size was measured 
every 5 days and tumor volume (V) was determined by the equation: V= (L x W2) x 0.5, where L is the 
length and W is the width of a tumor. Tumor volume was calculated and expressed as cubic millimeters 
(Figure 2.14b). TUNEL (Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling) analysis 
of tumor tissues in nude mice generated by human breast cancer MDA-MB-231 cells for DNA damages in 
tumor cells treated by β-lactam HY-14 at 0.3 mg/kg (low dose) or 3 mg/kg (high dose) or solvent as control 
for 30 days. Nuclei stained in dark blue indicate TUNEL-positive.  
 
 
 
     B  
 
Figure 2.14: A) β-Lactam 25 inhibits the tumor growth in nude mice implanted by human breast cancer 
MDA-MB-231 cells. B) TUNEL (Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling) 
analysis of tumor tissues in nude mice generated by human breast cancer MDA-MB-231 cells for DNA 
damages in tumor cells treated by β-lactam 25 at 0.3 mg/kg (low dose) or 3 mg/kg (high dose) or solvent as 
control for 30 days. Nuclei stained in dark blue indicate TUNEL-positive.  
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In conclusion, N-Methylthio β-lactam 25 inhibits 50% of the tumor growth in nude mice treatd 
with 3 mg/kg of lactam 25, this demonstrated unique anticancer property against human leukemic and solid 
tumor cell lines.  
 
 
2.7 Conclusions 
 
Compared to the lactam 1, three synthesized C3-sulfonated β-lactams 3a-c show slightly decreased 
activities against for MSSA and MRSA strains. Activity increases with molecular weight: methyl < phenyl 
< p-tolyl. Another sulfonated fluorescent lactam 18 has low bioactivities against MRSA with zone of 
inhibition less than 10 mm. β-Lactams 19a-d are significantly less potent against MRSA than methoxy 
lactam 1. C3-azido lactam 19e has a zone of inhibition of 24 mm against S. aureus and 21 mm against for 
MRSA. Thus, putting on a more polar group at the C3 position of the lactam dramatically decreases the 
bioactivities against MRSA. 
 
Same results were also obtained for the bioactivity screening against Bacillus strains. Lactams 3a-
c and 19e show some activities against seven Bacillus strains, while the lactams 19a-d have no bioactivity.  
 
Among four sulfonated lactam 3a-c and 18, compound 3b shows the highest activity against 
cancer cell MCF-7. C3-Acrylate lactam 27 induces equal activity as one of its isomers, (+)-27, while the 
other isomer (-)-27 shows decreased activity. A further investigation in an animal model shows that N-
methylthio β-lactam 25 inhibits 50% of the tumor growth in nude mice treated with 3 mg/kg of lactam 25; 
this demonstrated unique anticancer properties against human leukemic and solid tumor cell lines. 
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CHAPTER 3 NANOPARTICLE DELIVERY VEHICLES 
FOR ANTIBIOTICS 
3.1 Introduction  
 
Antibiotics, one of the great innovations of the modern world, were first developed clinically in 
the late 1940s for the treatment of bacterial diseases, and at that time many believed that scourges such as 
tuberculosis, dysentery, cholera, pneumonia, and enteric diseases would no longer threaten humankind.44 
However, misuse and overuse of antibiotics over the past 60 years have resulted in increased bacterial 
resistance, which has been recognized for many decades.45 In order to control the development of antibiotic 
resistance, it is essential to understand the earliest stages of resistance formation. Resistance is rapidly 
spreading, particularly in hospitals where antibiotics are heavily used. The problem is that the more 
antibiotics are used, the more resistance develops.46  
 
Recently there has been a rapid growth in the drug discovery area facilitated by some novel 
technologies such as combinatorial chemistry. Numerous drug candidates have been designed and many of 
these analogues show promising biological activities in vitro and in vivo. However, most of them fail to be 
commercialized because of the problems of unwanted cytotoxicity, no targeting and no controlled release, 
very poor water solubility and low bioavailability.47 Thus, new antibacterial discovery projects have been 
cut since companies have chosen to move into some more lucrative areas, such as chronic illnesses and 
mood disorders for the reasons (1) microbial resistance increases the demand for new antibiotics, but at the 
same time new antibiotics create more resistance and it shortens their useful lifetime; (2) the best 
antibiotics are often reserved by the doctors so that a new antibiotic to which there is less resistance will be 
little used. Therefore, a profit-making company is not likely to be willing to develop new antibiotics for the 
public. Furthermore, since antibiotics generally cure the disease, companies find it more lucrative to fund 
research into treatments for chronic conditions, such as high cholesterol or rheumatoid arthritis, for which 
patients take the drug over years or a lifetime, rather than for just a week or two.  
 
Although the traditional antibiotics possess some drawbacks as mentioned earlier, many of them 
are still in use and could perhaps be made more effective against drug-resistant forms of the pathogen they 
target. Traditionally, these antibiotics are administered orally by capsule or tablet, due to poor stability of 
many antibiotics in the acidic pH of the stomach or poor permeability through the mucus layer, sub-
therapeutic concentrations of the antibiotics often end up reaching the infection site. Thus, better methods 
for delivering antibacterials for either local or sustained release may allow antibiotics to have enhanced 
effectiveness with fewer adverse effects. 
 
Polymer-based drug delivery has proven to be an exciting method for improving performance of 
various antibacterial agents, offering improved solubility and stability, lowering their cytotoxicity, 
affording controlled release and in some cases, targeting to the infection sites.48 One of the important 
polymer-based delivery systems developed over the past 30 years is the nanoparticle, which offers a 
sustained means of delivering small molecular weight drugs. This chapter will discuss several major drug 
delivery systems for antibiotics, including nanoparticles. 
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3.2 Classification of Drug Delivery Systems  
 
Drug delivery systems can be classified into three generations based on their applications. The 
first-generation systems were developed in the early 1970s.49 Microcapsules and microspheres belong to 
this class. Although these are capable of delivering an active substance specifically to the target, they are 
not drug ‘carriers’ since they have to be implanted as closely as possible to the site of action. 50 
 
The second-generation of drug delivery systems, also developed in early 1970s and they are true 
carriers comprised of colloidal particulates less than 1 mm in diameter.51 Liposomes, nanocapsules, and 
nanospheres, belong to this category. They are capable not only of releasing a drug at the target but also of 
carrying it by a general administration. However, after intravenous administration, most colloidal carriers 
are rapidly removed from the circulation by phagocytic cells in the liver and spleen. Therefore, systemic 
clearance of the particulates limits their potential to deliver the drug molecule to the specific sites.52 In the 
past 10 years, efforts have been made to modify the surface properties of these drug delivery systems to 
reduce the deposition of plasma proteins onto the particle and diminish the recognition by phagocytes. 
These delivery systems are now termed as ‘Stealth’ carriers and may remain in the blood stream for a 
longer period of time.53 
 
The third-generation of drug delivery systems are also true carriers and, furthermore, are capable 
of specific recognition by the target.54 For example, monoclonal antibodies,55 liposomes and nanospheres 
conjugated to monoclonal antibodies or other ligands belong to this category.56 Targeted drug delivery 
carriers can be molecular or particulate and the molecular carriers include soluble polymers to which drug 
molecules are covalently attached, sometimes with targeting moieties bound to the same molecule.57 For 
instance, water-soluble cyclodextrins with drug encapsulated inside belongs to this generation. 58   
Numerous reviews have focused on polymer-based delivery systems for bioactive molecules, such as 
anticancer agents.59 
 
 
3.3 Major Development of Delivery Systems for Antibiotics 
 
Many drug delivery systems are designed to improve an antibiotic’s pharmacokinetics and 
bioavailability by providing sustained release mechanisms. The most notable examples include liposomes 
and other lipid-based polymers, hydrogels and nanoparticles. 
 
 
3.3.1 Liposomes  
Liposomes consist of one or more phospholipid bilayers enclosing an aqueous phase. Figure 3.1A 
shows the major groups of phospholipids which have a hydrophilic head and hydrophobic tail. When 
phospholipids are immersed in water they arrange themselves so that their hydrophilic regions point toward 
the water and their hydrophobic regions point away from the water. This unique simultaneously 
hydrophilic/hydrophobic structure of phospholipids is the key to their ability to organize as a bilayer 
formation (Figure 3.1B). Phospholipid bilayers are the core structure of a liposome (Figure 3.1C). 
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Figure 3.1: A) Structure of phospholipids; B) Formation of a phospholipid bilayer structure and C) the 
liposome. 
 
Liposomes were first proposed as carriers of biologically active substances in 1971, and have 
since been comprehensively studied for applications in drug delivery.60 They can be classified as large 
multilamellar liposomes (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles 
(LUVs) depending on their size and the number of lipid bilayers. Water-soluble drugs can be included 
within the aqueous compartments, while lipophilic or amphiphilic compounds can be associated with 
the lipid bilayers (Figure 3.2). In some cases, the resulting structures are better described as lipid 
complexes rather than liposomes, since they do not contain an internal aqueous phase.61  
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Figure 3.2: A complete three-dimensional liposome structure split in half to show its internal structure.  
 
Liposomes can incorporate water-soluble materials as well as oil-soluble materials in different 
regions of the assembly. The mechanism of how a liposome may deliver a drug to a bacterial cell is thought 
to occur through a process called endocytosis. Scheme 3.1 shows a liposome fusing with a cell, which goes 
through a three step sequence.  First the outer layer of the liposome (red) fuses with the outer layer of the 
plasma membrane (brown). Then, the two fused membranes coalesce. Finally, the two inner layers fuse so 
that the drug (green) has access to the cytoplasm. 
 
Scheme 3.11: Hypothetical model for liposome drug delivery. 
 
 
Progress has been made for the application of liposome delivery systems for antibiotics.62  There 
are many recent reviews on liposomes used as drug carriers for antibiotics.63 However, the stability of 
liposomes is often contested and other types of carriers have been studied to improve control in the delivery 
of drugs.  
 
3.3.2 Hydrogels 
Hydrogels are three-dimensional structures of polymer chains that are water-soluble, sometimes 
found as a colloidal gel in which water is the dispersing medium. Hydrogels have the property of swelling 
in aqueous medium but do not dissolve in water.64 The highly swollen environment maintains a high water 
content which helps to promote cell proliferation and cell function. 65  Due to their soft tissue 
biocompatibility and the ease that many bioactive molecules have dispersing in the crosslinked matrix, 
hydrogels are frequently used in controlled release applications for drug delivery (Figure 3.3). 
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Figure 3.3: A hydrogel formation with drug incorporated. 
  
Several applications of hydrogel-based delivery systems for antibiotics have been proved to be 
effective in vitro. 66  For example, two antibiotics, tylosin tartrate and oxytetracycline hydrochloride, 
entrapped in poly (vinyl alcohol) hydrogel have shown good in vitro properties suitable for serving as a 
controlled release system. 67 
 
 
3.3.3 Nanoparticles 
A nanoparticle is a sub-microscopic substance whose diameter is between 1 and 100 nm.68 In 1976, 
Kreuter and Speiser first successfully prepared polyacrylamide nanoparticles in the presence of antigens, 
leading to the development of a vaccine adjuvant.69 Three years later, Couvreur developed a series of poly 
(alkylcyanoacrylate) nanoparticles which are bioresorbable, and are still being used as surgical glues. 70,71 
Several methods have been used in the past for the manufacture of drug nanoparticles.72 Some of the 
conventional techniques include spray drying and ultra-fine milling,73 in which particles with a broad 
distribution can be produced.74 Drug nanoparticles can also be prepared by a precipitation process in which 
polymer being formed is insoluble in its own monomer or in a particular monomer-solvent combination and 
thus precipitates out as it is formed. This normally leads to the formation of a hydrosol which is a colloid 
with water as the dispersing medium. In this case, the nanoparticle growth is difficult to control. 
 
Compared to the development of other delivery systems for antibiotics, there is less attention to 
the development of nanoparticles for delivering antimicrobial agents, and thus few reviews have focused on 
this area. 75  Due to their polymeric properties, nanoparticles may be more stable than liposomes in 
biological fluids and storage.76 Nanoparticles are colloidal polymers that can be used as drug vehicles 
which may give antibacterials a second lease on life. First, some nanoparticle delivery systems exhibit a 
property of controlled release of antibiotics.77  
 
Furthermore, they can increase an antibiotic’s therapeutic efficacy, in vivo stabilities, 
bioavailability, targetability, biodistribution and reduce toxicity. Another major advantage of nanoparticles 
is that they are better at reaching the desired target organs when compared to larger particles, since particles 
bigger than 100 nm do not reach the bone marrow and those larger than 300 nm are unable to penetrate 
heart and lung tissues.78,79 Nanoparticle delivery systems so far include polymer nanoparticles having the 
drug dispersed within the polymer matrix or adsorbed on the surface, and those coated with a biodegradable 
polymer and nanoparticle suspensions for poorly soluble drugs.80  
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Nanoparticles can normally be delivered as an aqueous dispersion by oral administration if 
absorption of the nanoparticle-sized drug carriers can be achieved in the gastrointestinal (GI) tract in useful 
quantities.81 Nanoparticles protect the labile drug molecules from degradation in the gastrointestinal (GI) 
tract and help in targeting therapeutic agents to the infected sites. They also act as a long-circulating drug 
reservoir from which drugs can be slowly released over a prolonged period. Apart from oral administration, 
nanoparticles can also be delivered parenterally through intravenous, subcutaneous, and intraperitoneal 
means.82 Nanoparticles have a higher dissolution rate, higher saturation solubility, and a greater adhesion 
when compared to microparticles.83 Overall, the oral form of immunization and drug delivery has obvious 
advantages over the parenteral form. 
 
Several types of nanoparticles have been investigated for antibacterial applications including 
polyalkylcyanoacrylate, polylactide-co-glycolide (PLGA), and surface-coated metal and magnetic 
nanoparticles (Figure 3.4).84 The discussion that follows describes the efforts to develop each nanoparticle 
system for antibiotics delivery. 
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Figure 3.4: Types of nanoparticle delivery systems. 
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3.4 Poly (alkyl cyanoacrylate) (PACA) Nanoparticles 
 
 Poly (alkyl cyanoacrylate) nanoparticles were first developed by Couvreur et al.85 Due to their size, 
structure, biodegradability and ability to entrap a variety of biologically active substances; poly (alkyl 
cyanoacrylates) (PACA) have been used for drug delivery. 86  These nanoparticles have proved to be 
effective as carriers of oral antibiotics to overcome problems of administration of drugs that are unstable in 
the gastrointestinal tract or are inadequately adsorbed.87 Recent studies show that poly (alkyl cyanoacrylate) 
nanoparticles are biodegradable carriers, and could be an effective colloidal system able to avoid 
mononuclear phagocyte recognition after intravenous injection. For example, poly (ethyl cyanoacrylate) 
nanoparticles coated with polyethyleneglycol (PEG) showed a reduction of phagocytic uptake of 50% after 
90 minutes. 
 
 Poly (alkyl cyanoacrylate) nanoparticles are usually prepared by emulsion polymerization at a pH 
below 3 as shown in Scheme 3.2.88 The polymerization is initiated by a base, for example OH-  from the 
dissociation of water. Therefore, the pH for the reaction has to be acidic in order to prevent excessively 
rapid polymerization and to enable the formation of nanoparticles.  
 
 Surfactants have to be included in the polymerization to prevent the aggregation of nanoparticles 
in the early stage and facilitate the formation of uniformly-sized nanoparticles.89 There are several types of 
poly (alkyl cyanoacrylate) nanoparticles, including poly (ethyl cyanoacrylate), poly (2-ethylbutyl 
cyanoacrylate), poly(isohexyl cyanoacrylate) and poly (isobutyl cyanoacrylate).  
 
Scheme 3.2: Emulsion polymerization of alkyl cyanoacrylate monomer. 
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R=Et, poly(ethyl cyanoacrylate)
      CH(Et)CH2CH2CH3, poly(2-ethylbutyl cyanoacrylate) 
      (CH2)4CH(CH3)2, poly(isohexyl cyanoacrylate)
      CH2CH(CH3)2, poly (isobutyl cyanoacrylate)  
 
 
 
3.4.1 Poly (ethyl cyanoacrylate) Nanoparticles 
A recent study in Fontana’s group has shown that β-lactam antibiotics can be entrapped in 
polyethylcyanoacrylate (PECA) nanoparticles and utilized in aqueous emulsions.90 Various concentrations 
of ampicillin, which is shown in Figure 3.5, was used for the emulsion polymerization using of two 
different surfactants, Pluronic F108 and Pluronic F68 which are nonionic poly polyoxyethylene-
polyoxypropylene block co-polymers with similar hydrophobic-lipophilic balance (HLB) value but 
differing in molecular weight, 8,300 and 14,000, respectively. The general formula of Pluronic surfactant is 
HO(C2H4O)x(-C3H6O)y(C2H4O)xH and the structure is shown in Figure 3.6. They are available in different 
grades which vary from liquids to solids. It is used as an emulsifying agent, solubilising agent, surfactant, 
and wetting agent for antibiotics.   
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Figure 3.5: Structure of ampicillin. 
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Figure 3.6: Structure of surfactant Pluronic F68. 
 
Each sample was studied in terms of particle dimensions, stability, loading capacity, drug release 
profile and antimicrobial activities. Ampicillin-encapsulated PECA nanoparticles have an average size 
around 350 nm, and different drug concentrations in the polymerization do not affect the particle 
dimensions. Studies of degradation of the formed nanoparticles showed that ampicillin-loaded PECA 
nanoparticles were found to be stable at pH 7.4 and the degradation was almost negligible within 5 hr; 
however, the degradation was much quicker at pH 1.1 than degradation at neutral pH; around 70% of 
ampicillin remained intact in the polymer after 3 hr and only 50% of the drug survived degradation after 5 
hr.  
 
In terms of loading efficiency, it was found that the higher the amount of drug added to the 
polymerization, the higher the loading capacity no matter what surfactants were used for polymerization. 
With 10% concentration of ampicillin initially loaded, the loading capacity was 13.2%; while only 2% of 
drug loading efficiency was obtained with drug concentration being 1%. 
 
Ampicillin release from PECA nanoparticles was studied under various conditions by HPLC 
analysis. First, drug release studies performed at pH 7.4 demonstrate that surfactant strongly influenced the 
release rate of the drug from the polymer. Drug release ability was increased with decreasing the 
hydrophilic properties of the surfactant and with increasing the molecular weight of the surfactants. Study 
of drug release was also performed in presence of esterase at pH 7.4. Since the hydrolysis of ester side 
chain is the main route of degradation of PACA nanoparticles91, the degradation process can be catalyzed 
by esterase enzyme.  
 
In particular, the rate of drug release was considerably enhanced and all prepared PECA 
nanoparticles delivered 100% ampicillin. Another drug release profile was done in buffer solution at pH 1.1 
and results show that 70% of drug released within 20 mins, and the release rate is decreased and 50% of 
ampicillin was released after 3 hr and then the amount of drug entrapped in the nanoparticle remains 
constant.  
 
The antimicrobial activity of PECA nanoparticles against E.coli, S. aureus, E. faecalis and S. 
epidermidis was also examined. The MIC values of the nanoparticles showed that antibiotic activity of 
drug-loaded nanoparticles were equal to or slightly higher than that of free ampicillin. For example, 
ampicillin has MICs around 4 µg/mL against E. coli while the nanoparticle slightly enhanced the activity 
with MICs around 2 µg/mL. The same result was also obtained from bioactivity assay for S. epidermidis. 
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Three years after the development of ampicillin-loaded poly (ethyl cyanoacrylate) nanoparticles, 
Fontana et al. also reported amoxicillin (Figure 3.7) encapsulated PECA nanoparticles coated by 
polyethyleneglycol (PEG) via emulsion polymerization using surfactant Pluronic F68.92  
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Figure 3.7: Structure of amoxicillin. 
 
The particle sizes and the surface charge were analyzed for different batches of PECA 
nanoparticles. The experimental data showed that average particle size dropped as the molecular weight of 
PEG increased. For example, nanoparticles prepared in the absence of PEG coating has an average size of 
320 nm, while nanoparticles coated with PEG 600 has an average size of 280 nm, and when the molecular 
weight of PEG increased to 4000,  the average size dropped to 220 nm. Same trend was found for the 
surface charge. Zeta potential value dropped from -18.9 ± 1.5 to -5.1 ± 1.1 as PEG molecular weight 
increased from 600 to 4000.  
 
Amoxicillin release from PECA nanoparticles was studied by HPLC analysis and showed that at 
pH 7.4 the rate of drug release rises as the molecular weight of the PEG increases; however, in human 
plasma, drug release is decreased as molecular weight of PEG increases. This can be explained that in 
human plasma, esterases catalyze the degradation of the nanoparticles by hydrolysis of the ester linkage of 
the side chain. The study of the amount of the drug entrapped in PECA nanoparticles at pH 1.1 showed that 
the drug release is complete within 20 min and the amount of residual entrapped amoxicillin remains 
constant. This observation implies that PECA nanoparticles can be used for site-specific antibiotic delivery 
in the stomach.  
 
For the design of colloidal drug delivery systems, it is essential to avoid the phagocytic cell 
populations within the mononuclear phagocyte system (MPS). Studies on the phagocytic uptake of PECA 
nanoparticles by murine macrophages showed that PEG-coated nanoparticles were less subjected to 
phagocytosis than PEG-uncoated nanoparticles. The phagocytic uptake of PECA nanoparticles coated with 
PEG 2000 and PEG 4000 was reduced 50% and 70%, respectively after 90 min compared to the uncoated 
PECA nanoparticles. This illustrates that PEG-coated PECA nanoparticles could be a colloidal system 
which is able to avoid MPS recognition.  
 
 
3.4.2 Ciprofloxacin-Loaded Poly (2-ethylbutyl cyanoacrylate) Nanoparticles 
Couvreur et al. also studied the effectiveness of cipro-encapsulated poly (2-ethylbutyl 
cyanoacrylate) (PEBCA) nanoparticles, (Figure 3.8) which were prepared by anionic emulsion 
polymerization) as shown in Scheme 3.3. Nanoparticles were freeze-dried for 24 hour under a vacuum in 
order to stabilize the preparation during storage.93 
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Figure 3.8: Structure of ciprofloxacin. 
 
Scheme 3.3: Formation of cipro-attached polyalkyl cyanoacrylate nanoparticles. 
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The particle size of the PEBCA, which was prepared in the presence of ciprofloxacin, was 
dramatically increased from 130 nm to 275 nm compared with that obtained in the absence of the drug. 
Comparative size measurements before and after freeze-drying showed no significant modifications in 
either the drug-loaded and unloaded nanoparticle size.  
 
Cipro-loading efficiency was analyzed by HPLC method. After complete polymerization initiated 
with 0.5 mg/mL concentration of drug and enzymatic degradation, 51.5% of ciprofloxacin was chemically 
intact in the nanoparticle suspension. 18% was the free drug which was unbound to the nanoparticle and the 
rest 30.5% was undetectable by HPLC. The 30.5% of undetectable cipro might covalently bind to the 
polymer, since cipro could act as a polymerization initiator, and this would not be released in the presence 
of esterase and not recovered by HPLC analysis. However, it is still debatable as to whether this 30.5% of 
undetectable cipro correlates to the drug covalently attached to PEBCA nanoparticle, or whether the drug is 
chemically degraded during the polymerization. 
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Drug release from the colloidal carrier in medium containing esterase was found to be very slow in 
the esterase-enriched medium, while in the absence of esterase, no dramatic drug release was observed after 
48 hr. This suggests that the release resulted from bioerosion of the polymer matrix. Only 22.3% of cipro 
drug was released after 6 hours and the release reached a maximum of 62.7% after 48 hours. 
 
Figure 3.9 shows the equilibrium between the free form of cipro and its zwitterionic form. Since 
polymerization was processed by an anionic mechanism94 and the nitrogen of the free amine on cipro is 
able to provide an electron pair, the following nucleophilic attack occurs to form a bond between the 
methylene group of the monomer and the cipro. 
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Figure 3.9: Equilibrium between the free base form and the hydrochloride form of the cipro. 
 
19F-NMR analysis confirmed that ciprofloxacin entrapped into nanoparticles was only in the 
zwitterionic form. The measurements of molecular weight suggest the participation of the antibiotic as an 
anionic polymerization initiator, leading to the formation of a chemical bond between the drug and polymer. 
Figure 3.10 shows a proposed model describing the association of ciprofloxacin with poly (alkyl  
cyanoacrylate) nanoparticles obtained by emulsion polymerization.95  
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Figure 3.10: Schematic model for ciprofloxacin-loaded nanoparticle formation, according to the 
physicochemical studies and as a function of the amount of ciprofloxacin initially added to the medium: 
51.5% of ciprofloxacin entrapped inside the matrix as a chemically unmodified form; 18% of unbound 
ciprofloxacin (hydrochloride form); 30.5% of undetectable ciprofloxacin. 
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Studies of microbiological activities of cipro-incorporated PEBCA nanoparticles demonstrated 
that the binding of ciprofloxacin drug to the nanoparticles did not change either its MIC or MBC for S. 
typhimurium strain C53. Indeed, the MIC value was 0.062 µg/mL and the MBC value was 0.5 µg/mL for 
both the nanoparticles and the free form of the drug. 
 
 
3.4.3 Poly (isobutyl cyanoacrylate) and Poly (isohexyl cyanoacrylate) 
Nanoparticles  
3.4.3.1 β-Lactam Loaded Nanoparticles 
Couvreur et al prepared polymerizations of poly (isobutyl cyanoacrylate) (PIBCA) and poly 
(isohexyl cyanoacrylate) (PIHCA) nanoparticles with ampicillin and gentamicin (Figure 3.11) entrapped.96 
Both drug-encapsulated nanoparticles were then freeze-dried for 48 hr and resuspension of the solid  
nanoparticle was carried out by addition of D.I. water.  
 
 
 
Figure 3.11: Structure of gentamicin. 
 
For drug-unloaded poly (isobutyl cyanoacrylate) (PIBCA) and poly (isohexyl cyanoacrylate) 
(PIHCA) nanoparticles, the average diameters of particle size were 132 nm and 149 nm, respectively.  The 
particle size for both systems was increased dramatically as the initial amount of drug loading was 
increased. For example, an average size of 145 nm nanoparticle was obtained with 250 µg/mL of initial 
amount of ampicillin was loaded, with the concentration of drug loading increased to 2000 µg/mL, the 
particle size was increased to 200 nm. As mentioned earlier, drug-entrapped PIBCA and PIHCA 
nanoparticles were easily resuspended in water after the freeze-drying process, and there is no significant 
change of particle size before or after freeze-drying. 
 
Analysis of the drug loading efficiency was then carried out on the supernatant liquid of drug-
loaded nanoparticles after ultracentrifugation for 1 hr. A reverse-phase HPLC profile showed that 75% of 
the quantity of ampicillin (up to 1 mg/mL) could be encapsulated within the nanoparticles, for poly 
(isobutyl cyanoacrylate) nanoparticles. For poly (isohexyl cyanoacrylate) nanoparticles, 82% of the 
quantity of drug was bound in the nanoparticles, using an initial concentration of 1 mg/mL. Due to the 
possible degradation of ampicillin in the aqueous acidic media of the polymerization, a freeze-dried 
formulation was also developed to be able to reproduce with respect to both size and drug content.  
 
The polymer degradation rate was dependent on the length of the alkyl chain, while bio-erosion 
was prolonged with increasing alkyl chain length. Furthermore, the rate of drug release also depended on 
the polymer degradation which may occur through an enzymatic pathway. In the presence of esterases, the 
release of ampicillin was about 60% after 10 hr, and only 20% of drug was released from the nanoparticle 
in the absence of esterase. Thus, esterase significantly increased the release of drug from 
polyisobutylcyanoacrylate nanoparticles. On the contrary, the enzyme did not affect the drug release profile 
for poly (isohexyl cyanoacrylate) nanoparticles. 35% of the drug content was released after 24 hr in the 
presence of esterase, and about 34% without esterase. This may be due to the steric overcrowding of the 
longer alkyl chain in PIHCA that reduces the accessibility of the ester function to the esterases.  
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Entrapment of ampicillin into poly (isohexyl cyanoacrylate) nanoparticles was found to improve 
dramatically the therapeutic efficiency of drug in intracellular infections of the mouse.97,98 For Salmonella 
typhimurium infected mice, a total dose of 0.8 mg of ampicillin bound to nanoparticles had the same effect 
as three doses of 32 mg each of the free drug. The therapeutic index of ampicillin, based on mouse 
mortality, was increased by 120-fold when encapsulated in poly (isohexyl cyanoacrylate) naoparticles. 
Toward Listeria monocytogenes infection, the therapeutic index of ampicillin based on liver bacterial 
counts rose at least 20-fold after its linkage to nanoparticles.99 Ultrastructural autoradiography showed that 
the ampicillin-loaded PIHCA nanoparticle could affect the bacterial wall and act by diffusing through the 
cell.100 Thus, the enhanced antibacterial effect may have resulted from both direct targeting of bacteria by 
antibiotic-loaded nanoparticles and by diffusion of the antibiotic into the cell. One explanation for this 
tremendous enhancement of efficacy of ampicillin-loaded nanoparticles observed in both Salmonella 
typhimurium and Listeria monocytogenes infected mice is that the cellular uptake of ampicillin was much 
better when it was encapsulated in nanoparticles when it was free. Previous observations have suggested 
that nanoparticles are internalized via endocytosis. The free drug does not diffuse through the lysosomal 
membrane due to their ionic character at neutral extracellular pH.101 Another explanation for the high 
efficiency of drug-encapsulated nanoparticles may be the fact that nanoparticles were found to be rapidly 
captured by the liver and the spleen, resulting in an increase of ampicilllin concentration in these organs. 
 
 
3.4.3.2 Cipro-Loaded PIBCA and PIHCA Nanoparticles 
Since β-lactam antibiotics are only active upon dividing bacteria, other antibacterial agents that act 
independently are required for eradicating both dividing and non-dividing bacteria.102 Ciprofloxacin, a 
monofluorinated quinolone, is an excellent combination drug with β-lactams because of its mode of action 
and good tissue diffusion. Couvreur et al and Fawaz et al studied the effectiveness of cipro-encapsulated 
poly (isohexyl cyanoacrylate) (PIHCA)/poly (isobutyl cyanoacrylate) (PIBCA) nanoparticles, which were 
prepared by emulsion polymerization.103,104  
 
The nanoparticle size was measured to be 305 nm for cipro-loaded PIHCA nanoparticle and 195 
nm for PIBCA nanoparticles. The size of ciprofloxacin-entrapped nanoparticle was larger than unloaded 
nanoparticle which has an average of 180 nm. The drug entrapment efficiency for cipro-loaded PIHCA 
nanoparticles was 82% when 500 µg/mL concentration of initial drug was loaded at pH 2.5.  
 
Studies of efficacy against Mycobacterium avium complex (MAC) in human macrophages proved 
that the association of ciprofloxacin with PIBCA nanoparticles resulted in an increase compared to the 
solution of free drug. Antimicrobial activity of cipro-loaded PIBCA nanoparticles against MAC in human 
macrophages was higher compared with a solution of free drug.105 When a concentration of 8 µg/mL of 
cipro was loaded to the nanoparticles, cfu was reduced by 1.1 and 1.2 log units at days 4 and 7, respectively. 
While for the solution of free drug, cfu only reduced by 0.65 and 0.85. 
 
 
3.5 PLGA Nanoparticles 
 
Polylactide/polylactide-co-glycolide (PLA/PLGA) nanoparticles can be prepared as biodegradable 
nanospheres which are useful for prolonged drug release and targeting drugs to specific infection sites 
(Scheme 3.4). PLGA nanoparticles are normally prepared by means of a water-in-oil-in-water (W/O/W) 
emulsification-solvent evaporation method. PLGA nanoparticles could be used in many applications 
including biodegradable delivery of ophthalmic drugs that they can enhance the bioavailability of the 
antibiotic in eye drops.106 Due to the biocompatibility and biodegradability of PLA/PLGA nanoparticles, 
different types of drugs have been associated into these polymeric materials for delivery, including 
ciprofloxacin, penicillin G and gentamicin. 
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Scheme 3.4: Formation of PLGA.  
C
CH3
x
HO
O
O
H2
C C
y
O
O
Polylactide-co-glycolide (PLGA)
O
O
O
O
+
HOCH2COOH
Lactide
Glycolic acid = glycolide  
 
 
 
3.5.1 PLGA Nanoparticles Delivering Hydrophobic Drugs 
 
3.5.1.1 Ciprofloxacin-Loaded PLGA Nanoparticles 
Ludwig first reported that ciprofloxacin could be incorporated into PLGA nanoparticles by 
W/O/W emulsification-solvent evaporation followed by high-pressure homogenization. 107  Different 
preparation parameters slightly affect the physicochemical properties of the nanoparticles. The average 
particle size of the nanoparticles was 234.68 ± 2.5 nm which was reduced to 188.66 nm when the particles 
were homogenized for two more cycles. The zeta potential of the nanoparticles was -6.01 mV. The 
entrapment efficiency of PLGA nanoparticle with 2.5% concentration of ciprofloxacin initially loaded to 
the nanoparticles is 61%, which corresponds to an absolute drug loading of 25 µg of ciprofloxacin HCl/mg 
of nanoparticles.  
The cipro release profile was determined based on different nanoparticle preparation conditions as 
well. Four different preparation formulations were used to form PLGA nanoparticles including different 
ratios of oil to water (O:W) with different homogenization cycles. Experimental data demonstrated that 
nanoparticles prepared with an O:W ratio 2.5 with one homogenization cycle had the highest rate of drug 
release. On the contrary, the lowest rate of cipro release was observed from nanoparticles prepared with an 
O:W ratio of 1.5 with three homogenization cycles. Therefore, the drug release from the PLGA 
nanoparticles can be controlled by varying the number of homogenization cycles and the O:W ratio. 
 
 The cipro release patterns from the nanoparticles were also measured by dispersing in four 
different solutions before gamma-sterilization (Figure 3.12). The drug release in hydroxyethylcellulose 
(HEC) solution, which is a cellulose ether, was comparable and slightly slower than in mannitol, a non-
viscous reference solution. Carbopol® (CP) 980 caused a small decrease in the rate of drug release, and the 
release kinetics was slowest when the nanoparticles were dispersed in Poloxamer.  
 
 
Figure 3.12: Release of ciprofloxacin from nanoparticles dispersed in solutions of mannitol or other 
viscosifying agents. Diamonds stand for nanoparticles dispersed in mannitol solution (reference solution), 
triangles for dispersion in hydroxyethylcellulose (HEC), circles for dispersion in poloxamer and squares for 
dispersion in Carbopol 980. 
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The antibacterial activities of the cipro-loaded nanoparticles were assessed in comparison with a 
ciprofloxacin aqueous solution and nanoparticles without drug attached by measuring the minimum 
inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) against P. aeruginosa 
and S. aureus for 4 days. The experimental data showed that cipro-loaded nanoparticles have similar 
activities against both bacteria as the free drug itself, although 100% of the drug was not been released for 
100% after 24 hr. Therefore, the ciprofloxacin concentration in the cipro-attached nanoparticles was 
enough to kill both bacteria to the same extent as in the aqueous solution. 
 
 
3.5.1.2 Benzathine Penicillin G Loaded PLGA Nanoemulsions and Nanocapsules 
Emulsions of benzathine penicillin G-encapsulated nanoparticles (Figure 3.13) can be produced by 
the spontaneous emulsification process108 which is a phenomenon that occurs when two immiscible liquids 
are placed in contact with each other and emulsify without the aid of any external thermal or mechanical 
energy source. Nanocapsules of PLGA were prepared according to the interfacial deposition of a pre-
formed polymer shown in.109 The formed nanoemulsion had a mean diameter of 207 ± 8 nm, and the 
nanocapsules were spherical in shape and had an average diameter of 180 ± 52 nm.110 The penicillin 
encapsulation efficiency in the nanocapsules was very high, 85%. Nanoemulsion maintained stability for 
more than 5 months at 4°C with practical no change in the particle size, ranging from 207 nm to 216 nm. 
The nanocapsules were only stabile for 120 days at either 25°C or 4°C. After this time, the nanocapsule 
suspension started to degrade and it was proved by transmission electron microscopy (TEM) showing that a 
second particle population of 2 µm appeared. 
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Figure 3.13: Structure of benzathine penicillin G. 
 
The release studies of Penicillin G from nanoemulsions and nanocapsules in vitro showed a 
similar trend. However, the release rate from nanocapsules was a little faster than from nanoemulsion due 
to the lower stability of nanocapsules. The whole amount of drug was released within 120 min and 180 min, 
for nanoemulsion and nanocapsule, respectively. This might be due to the difference of the oily phase 
property that alter the oil-water partition coeeficient.111 In order to slow the degradation of PenG and the 
nanocapsules, the freeze-drying method could be used as an alternative way for storage of the nanocapsules. 
 
 
 
3.5.2 PLA/PLGA Nanoparticles Loading a Hydrophilic Drug: Gentamicin 
Gamazo et al. has developed polylactide (PLA) and polylactide-co-glycolide (PLGA) 
nanoparticles as a delivery system for the cationic and highly hydrophilic antibiotic gentamicin sulfate 
(GS).112 Gentamicin sulfate consists of gentamicin C1, C2, C1a, C2a shown in Figure 3.14. 
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Figure 3.14: Structure of gentamicin. 
 
Gentamicin sulfate (GS) was encapsulated in PLGA microspheres (MS) by spray drying and 
water/oil/water (W1/O)/W2 solvent evaporation. Two PLGA 50:50 formulations with 2 and 10% GS 
loading were prepared under these two methods. Both preparations yielded a comparable distribution of 
particle sizes averaging approximately 300 nm. Conversely, encapsulation efficiency was significantly 
higher with spray drying, 45% with 8.9 µg/mg concentration of GS loaded initially, than with solvent 
evaporation which is up to 13% when 2.7 µg/mg concentration of GS loaded .  
 
For the nanoparticles prepared by spray drying using different five types of PLA/PLGA 
microspheres of similar molecular weight but different hydrophobicity, the encapsulation efficiency 
generally increased with polymer hydrophilicity, except for the hydrophilic copolymer PLGA 50:50H 
(letter H names end-group uncapped polymers) carrying carboxylic end-groups.  
 
GS encapsulated efficiency (EE) was also depended on normal drug loading, for example, PLGA 
50:50 with 2% loading at a pH 6.0 buffer solution had the highest efficiency, 45%; with 6% of loading, EE 
dropped to 15%, and further loading up to 10% concentration did not affect the EE.  
 
 
Finally, the encapsulated-gentamicin PLGA nanospheres were studied by an antibacterial assay 
using an aqueous incubation medium. The assay measured the growth inhibition of S. aureus on Muller 
Hinton agar. The bioactivity was found to remain the same level after microencapsulation, nanosphere 
storage and incubation in aqueous media. The results suggest that PLA/PLGA nanospheres prepared by 
spray drying may be an appropriate delivery system for this amino glycoside antibiotic, since the 
appropriate particle size should be suitable for monocyte-macrophage uptake and may therefore be useful 
in the treatment of intracellular Brucella infections. 
 
 
 
3.6 Surface-Coated Metal Nanoparticles 
 
There is currently considerable interest in the size-dependent chemical, physical, and structural 
properties of metal nanoparticles, triggered in part by specific applications in catalysts, sensors, and 
microelectronics. To achieve these unique metal nanoparticles, one must be able to tailor only the surface 
structures of a nanoparticle (Figure 3.15). Gold and silicon have been selected to be coated with different 
antibiotics as a means for enhanced drug delivery and the discussion that follows describes the details of 
each development. 
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Figure 3.15: Metal nanoparticle can be coated on the surface with bioactive molecules. 
 
 
3.6.1 Drug Coated Gold Nanoparticles 
The attractiveness of using gold as a nanoparticle substance includes the ability to prepare 
monodispersed colloidal nanoparticles having a certain diameter range, along with the availability of 
surface-enhanced Raman scattering.113 Gold nanoparticles have served as a versatile platform for exploring 
many basic applications including DNA, proteins, or small bioactive molecules delivery.114,115 Antibiotics 
have been surface-coated onto gold nanoparticles as a model system against antimicrobial drug resistance. 
Comparing with antibiotics that are attached to flexible polymers, gold nanoparticles have a well-developed 
surface chemistry, a controllable geometry, rigidity, and chemical stability.116,117 Moreover, unlike other 
polymeric-based nanoparticles, gold nanoparticles not only are smaller in size (4 to 5 nm in diameter, ~103 
times smaller) than a typical bacterium, but also maintain a constant shape and size in solution. 
 
 
3.6.1.1 Vancomycin on gold nanoparticles 
Xu’s group successfully synthesized vancomycin-attached gold nanoparticles (Scheme 3.5) and 
illustrated in vitro antibacterial activities against vancomycin-resistant enterococci (VRE). 118  These 
nanoparticles were prepared by treatment of 4-5 nm gold nanoparticles with an aqueous solution of 
bis(vancomycin) cystamide.  
 
Scheme 3.5: Formation of vancomycin-attached gold nanoparticles. 
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X-ray photoelectron spectroscopy (XPS) of Van-gold nanoparticle proved the formation of a gold-
S bond. This was also confirmed by the UV-vis spectrum of an aqueous solution of Van-coated gold 
nanoparticles indicating that vancomycin was attached to the gold nanoparticle. 
 
Figure 3.16 shows a possible multivalent interaction between a vancomycin-capped gold 
nanoparticle and a vancomycin-resistance enterococci (VRE) strain. Vancomycin prevents the biosynthesis 
of the peptidoglycan layer of the bacteria cell wall by binding to L-Lys-D-Ala-D-Ala termini of the 
peptidoglycan.119 VRE is resistant to vancomycin because of its mutated its terminal pentapeptide structure 
from D-Ala- D-Ala to D-Ala- D-Lac, which substantially lowers its affinity to vancomycin about 103 times 
decrease.120 Thus, use of a more rigid vancomycin-linked metal nanoparticle allows for higher binding with 
VRE strains and exhibits enhanced to potent activity against VRE. 
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Figure 3.16: A possible interaction between vancomycin-capped gold nanoparticle and a VRE strain.  
 
An in vitro activity study showed that the free drug, vancomycin, has little activity against all 
three types of VRE strains; however, Van-attached gold nanoparticles exhibit excellent activity against all 
VRE strains, and presumably act as a rigid polyvalent inhibitor of vancomycin-resistant enterococci (VRE). 
Minimum inhibition concentrations (MICs) of Van-gold nanoparticles are around 2-4 µg/mL while the 
MICs for the free form of vancomycin is around 64-128 µg/mL. Van-gold nanoparticles also have good 
activity against an E. coli strain with MICs of 8 µg/mL. This implies that this nanoparticle system may 
provide a useful model for the determination of multi/polyvalent of ligand-receptor pairs. 
 
 
3.6.1.2 Ciprofloxacin Attached Gold Nanoparticles  
The antibacterial drug ciprofloxacin has also been coated onto gold nanoparticles.121 Two different 
gold nanoparticles with mean diameters, 4 and 20 nm, were coated with about 65 and 585 drug molecules, 
respectively. The cipro-gold particles are stable in the dry state as well as at room temperature.  
 
Voltammetric and spectroscopic studies showed that the nitrogen on the piperazine moiety of 
ciprofloxacin was responsible for binding to the gold nanoparticles (Figure 3.17), and the voltammetric 
characteristics of cipro adsorbed on 4 nm sized gold nanoparticle were similar to that of the nanoparticles 
with 20 nm size.  
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Figure 3.17: Cipro-gold nanoparticles. 
 
Moreover, the rate of release of the cipro from gold nanoparticles is faster in basic medium than at 
pH 7 and the kinetics depend on the particle size. For instant, gold nanoparticle of small size (4 nm) release 
molecules faster than the larger particles (20 nm). Since the bound cipro is fluorescent, this property could 
be used in biological investigations.  
 
 
3.6.1.3 Toxicity Studies of Gold Nanoparticles 
Recent development of gold nanoparticles demonstrates the versatility of these systems in 
biological applications. Their interactions with cells have been studied in detail by Rotello et al. 122 To 
investigate the toxicity of gold nanoparticles, one cationic nanoparticle and one anionic nanoparticle were 
fabricated for testing with each monolayer consisting of 70 charged thiols and 30 unsubstituted thiols 
attached (Figure 3.18).  
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Figure 3.18: Structures of gold nanoparticles for cytotoxicity testing. 
 
Both gold nanoparticles were tested for toxicity in red blood cell and bacteria cell (E. coli). The 
LC 50 values showed a 2-3 fold increase was required for the bacterial cells (3.1 µg/mL and > 28 µg/mL, 
respectively). This moderate increase can be explained as being due to the nature of the bacterial assay, in 
which a low-density cross-linked agar will decrease the mobility of both cells and nanoparticles. Another 
explanation could be the increase protection by the outer membrane and the cell wall of E. coli, requiring a 
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higher nanoparticle concentration to completely kill the bacteria. In summary, gold nanoparticles 
functionalized with cationic side chains are moderately toxic while anionic nanoparticles are nontoxic, and 
the toxicity is related to their interaction with the cell membrane. 
 
 
3.6.2 Porous Hollow Silica Nanoparticles 
Owing to high chemical and thermal stabilities, as well as large surface areas and good 
compatibilities with other materials, porous silica has found wide applications in the fields of selective 
separation, catalysis and dielectric materials.123 A growing interest has also been directed toward drug 
delivery. Chen et al. first presented a novel pathway for the synthesis of porous hollow silica nanoparticles 
(PHSNP), which adopted nanosized calcium carbonate as a structure-directing template. 124  Antibiotic 
Cefradine (Figure 3.19) was then employed as a drug molecule for the PHSNP system Figure 3.20. 
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Figure 3.19: Molecular structure of cefradine. 
 
 
Figure 3.20: Formation of porous hollow silica nanoparticle. 
 
Preparation of drug adsorbed porous hollow silica nanoparticles (PHSNP) involves mixing the 
synthesized PHSNP powder and an aqueous solution of cefradine in a suspension followed by evaporation 
and drying. Transmission electron microscopy (TEM) images of synthesized cefradine-adsorbed PHSNP 
showed that spherical nanoparticles with a diameter of 60–70 nm and wall thickness of approximately 
10 nm were formed. Brunauer, Emmett, and Teller (BET) surface areas indicated that the pore volumn of 
the carrier was reduced greatly, from 867 to 277 m2/g after entrapping cefradine, which revealed that most 
pores in the wall of PHSNP had been filled with cefradine.  
 
In vitro release studies of cefradine indicated that PHSNP followed a three-stage pattern. The first 
stage was a rapid release of cefradine with around 74% in 20 minutes. The following stage was a slow 
increase of cefradine release from 74% to 82% within 10 hours, at which point a plateau was reached. The 
release profile indicated that cefradine was released from the pore channels in the wall and inside the 
hollow part of PHSNP, respectively. Therefore, the PHSNP carrier exhibited a controlled release effect that 
can perhaps be exploited for drug delivery. 
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3.7 Magnetic Nanoparticles 
 
Magnetic nanoparticles offer exciting new opportunities toward developing effective drug delivery 
systems, as it is feasible to produce, characterize, and specifically tailor their functional properties for drug 
delivery applications.125,126 Several magnetic nanoparticle have been synthesized, such magnetite (Fe3O4), 
and recent reviews on this area describe the applications in biomedicine field using magnetic 
nanoparticles.127 First, magnetic nanoparticles have sizes from 2 to 20 nm that place them at dimensions 
comparable to those of a virus (20–500 nm), a protein (5–50 nm) or a gene (2 nm wide and 10–100 nm 
long). Second, the nanoparticles are magnetic, which means that they obey Coulomb's law, and can be 
manipulated by an external magnetic field gradient (Figure 3.21). Additionally, nanoparticles have a large 
surface area that can be modified to attach biological agents, i.e. a bioactive molecule, or a ligand for 
targeting. The most frequently used synthetic routes for the preparation of magnetic nanoparticles include 
synthesis in solution and by aerosol/vapor methods.128  
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Figure 3.21: Magnetic nanoparticle delivery system. 
 
Xu et al. reported that FePt magnetic nanoparticles could capture and detect vancomycin-resistant 
enterococci (VRE) and other Gram-positive bacteria at a concentration of ~ 101 cfu/mL within an hour.129 
In their studies, a broad spectrum antibiotic, vancomycin was attached to the surface of the FePt 
nanoparticles (3-4 nm in diameter) by binding to the terminal peptide, D-Ala-D-Ala which is on the cell 
wall of a Gram-positive bacterium via hydrogen bonding. The conjugate of Van-FePt magnetic 
nanoparticle showed a high selectivity for Gram-positive bacteria such as Staphylococcus aureus (8 
cfu/mL), S. epidermidis (10 cfu/mL) and a coagulase negative staphylococci (4 cfu/mL). Also, optical and 
scanning electron microscopy (SEM) profiles proved that the magnetic nanoparticles captured VRE, a life-
threatening pathogen, at a concentration of 101-102 cfu/mL via polyvalent interactions. 
 
 
3.8 Conclusions and Future Perspectives in Antibiotics Delivery 
      
It is obvious from this brief review of the current literature that modern drug delivery 
developments are being applied to antimicrobial therapy, including liposomes and nanoparticles. They 
show an improved therapeutic index compared with the free antibiotics. Their higher efficiency could be 
explained by the natural targeting of colloidal carriers certain cells that mainly dominates bacteria and are 
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normally not reachable by the free antibiotics. Another major advantage of drug delivery systems is 
reduced toxicity and other side effects compared with the traditional antimicrobial agents. However, each 
system has its own advantages and the limitations as well and this makes the revolution in treatment of 
infectious diseases seem somehow distant. Due to the limited range of cellular target and the fast-growing 
planktonical resistance in vivo, most drug delivery systems have not successfully survived in vivo studies 
although they have shown great enhancement of in vitro activity. Attempts to improve the biocompatibility 
of drug delivery systems in vivo have to be made and other major issues, such as toxicity, are also need to 
be resolved. 
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CHAPTER 4 NOVEL POLYACRYLATE 
NANOPARTICLES FOR DELIVERY OF β-LACTAM 
ANTIBIOTICS 
4.1 Introduction 
 
There are significant efforts underway to develop polymer-based nanotechnology for drug 
delivery. New drug delivery vehicles, such as nanoparticles, offer a promising way to improve the 
bioavailability, efficacy of the pharmaceutical compounds and in some cases, targeting to the specific 
sites.130 Most applications for nanoparticle-based delivery are for anticancer molecules, but less attention is 
being put into the antibiotics area. 131  Several systems have been successfully applied to delivery of 
antimicrobial agent, including antibiotic-encapsulated poly (alkyl cyanoacrylate) nanoparticles, 132 
biodegradable PLGA’s,133  surface-coated metal nanoparticles134  and magnetic nanoparticles,135  each of 
which possess their own advantages and limitations. Recently, the Turos group investigated a conceptually 
different strategy for delivery of anti-MRSA antibiotics. This newly-designed system is based on synthetic 
polyacrylate nanoparticles that are made by emulsion polymerization, and the unique feature of the 
methodology is that the nanoparticle is built from its constituents in one step without further chemical 
modification. In this way, the antibiotic is covalently attached to the polymer backbone instead of being 
encapsulated. Such nanoparticle antibiotics provide an innovative approach for treating infections caused 
by methicillin-resistant Staphylococcus aureus.136 This chapter will present the preparation, physical and 
biological properties of the antibiotic-attached polyacrylate nanoparticles.  
 
 
4.2 Emulsion Polymerization  
4.2.1 Introduction 
Emulsion polymerization is a technologically and commercially important reaction initially 
developed for the production of synthetic rubber latex during the Second World War. 137  Nowadays, 
emulsion polymerization is the basis of a massive global industry that continues to explore its versatility for 
the control of the properties of polymer latexes. Some of the major applications of emulsion polymers 
available in the market include polyvinyl acetate homopolymers and copolymers, styrene butadiene latexes, 
and acrylic emulsions.138 These emulsions are mostly applied in adhesives, paints, paper coating and textile 
coatings.139  
 
An emulsion is a stable colloidal suspension consisting of an immiscible liquid dispersed and held 
in another liquid by a substance called an “emulsifier”. Emulsion polymerization takes place with a mixture 
of two immiscible liquids. The bulk phase is typically aqueous, and the oil phase comprises the monomer. 
A surfactant is added to generate the micelles. The product of emulsion polymerization is called a “latex”. 
The most common type of emulsion polymerization is an oil-in-water emulsion, in which droplets of 
monomer (the oil) are emulsified with surfactants in a continuous phase of water. Water soluble polymers, 
such as certain polyvinyl alcohols or hydroxyethyl celluloses, can also be used to act as 
emulsifiers/stabilizers.  
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Most emulsion polymerizations are performed under free radical conditions. The leading theory 
for the mechanism of free-radical emulsion polymerization is summarized in Figure 4.1. First, surfactants 
emulsify the monomer in a water continuous phase and help create micelles in the water. Micelles only 
form when the concentration of surfactant is greater than the critical micellar concentration (CMC), and the 
when the temperature of the system is greater than the critical micellar temperature, or Krafft temperature.  
 
 
Figure 4.1: Adapted schematic illustration of an emulsion polymerization. 
In aqueous solution, water molecules surrounding hydrophobic parts of surfactant molecules form 
hydrogen bonds to make a "cage" in which the hydrophobic part of surfactant molecule (Figure 4.2) is 
enclosed. When micelles are formed, the hydrophobic parts of the surfactant are no longer in contact with 
the surrounding water. Micelles can exist in different shapes, including spherical, cylindrical, discoidal, or 
even vesicular. They are largely controlled by the molecular geometry of the surfactant and the solution 
conditions (temperature, salt type and concentration, etc.) as well.  
Hydrophilic head
Hydrophobic tail
 
 
 
Figure 4.2: Illustration of formation of spherical micelles with an interior composed of the hydrocarbon 
chains and a surface of the polar head groups facing water. 
 
 Next, small amounts of monomer diffuse through the water to the micelle. Initiator, which is 
usually water-soluble and introduced into the water phase, reacts with the monomer in the micelles. 
Initiator typically reacts with the micelle and not the monomer droplets since the micelles in total contain a 
much larger surface area than the fewer, larger monomer droplets. Once polymerization starts, the micelle 
is referred to as a particle. Polymer particles can grow to extremely high molecular weights, 
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especially if the initiator concentration is low. That makes the radical concentration and the rate of 
termination low as well. Sometimes a chain transfer agent is added to the mix to keep the molecular weight 
from getting too high.  The propagation process involves the monomer migrating from the large monomer 
droplets to the micelles for sustaining polymerization. More monomer from the droplets diffuses to the 
growing micelle/particle, where more initiators will eventually react. Monomer droplets and initiator are 
continuously and slowly added to maintain their levels in the system as the particles grow. When the 
monomer droplets have been completely consumed, the initiator is typically added in for a little while 
longer to consume any residual monomer. The final product is a 'dispersion' of polymer particles in water, 
also known as a polymer colloid, or a latex. 
 
 
 
4.2.2 Advantages of Emulsion Polymerization and Applications 
The continuous water phase is an excellent conductor of heat of the reaction and allows the heat of 
the reaction to be removed from the system. Since polymer molecules are contained within the particles, 
viscosity remains close to that of water and is not dependent on molecular weight. The final product can be 
used as is and does not generally need to be altered. Most emulsion polymerizations using a free-radical 
polymerization method can be carried out as a batch reaction, in which all reactants are completely added 
to the reaction vessel at the start of the polymerization. In many cases, emulsion polymerization is 
performed as a starve-fed reaction in which a portion of al monomers is added to the reactor over time and 
the copolymer composition will approximate the relative proportions of the monomers in the feed. This 
process normally insures a good distribution of monomers into the polymer backbone chain. 
 
 
4.3 Microemulsion Polymerization 
 
Emulsions are typically classified into three types based on the characteristics: macroemulsion, 
miniemulsion or microemulsion. A major distinction between these three categories is the size of the 
droplets. A second major difference is the stability of the emulsion. Figure 4.3 shows a general trend in the 
relationship between size and stability of these three types. 
 
 
 
Figure 4.3: Schematic representation of relative stability as a function of droplet size of the three classes of 
emulsions. 
Microemulsion polymerization is the latest in the family of polymerization techniques, discovered 
in 1943 by Hoar and Schulman. 140 , 141 A microemulsion is an optically transparent, isotropic, and 
thermodynamically stable microdispersion consisting of water, oil (monomer), and amphiphile (emulsifier, 
coemulsifier, etc.). These transparent oil-in-water micro-dispersions have small spherical droplets varying 
from 10 to 100 nm, and microemulsion polymerization is the only technique that can produce uniform 
particle size in this range.  
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There are four components in a typical microemulsion polymerization: the continuous phase, a 
surfactant, an initiator and the monomer. The bulk phase is typically water. Surfactants that are used to 
create the micelles which retain the oil soluble monomer, are essential for preparing these emulsions. The 
surfactants charge can be altered with cationic, anionic and nonionic ionic, and these can also be mixed to 
alter intrinsic characteristics of the specific surfactants in solution.142 Surfactant concentration also has a 
strong effect on the polymer produced.143 The need for high surfactant concentrations, which can become 
costly, is a disadvantage of microemulsion polymerization. There have been recent attempts to reduce the 
amount of surfactant to a few percent.144 In microemulsion polymerization, radical initiators are the most 
common. The position of radical initiators within the system can be strategically placed. For example, 
initiators can be soluble in the continuous phase, inside the micelle, and also at the micelle interface 
itself.145 Different monomers of varying solubility and functionality also can be used.146 Other chemicals 
can be added to the microemulsion to alter the characteristics of the microemulsion or the properties of the 
polymerized product, such as salts or cosurfactants for the use of forming condensed surface of the 
microdroplet.147  
 
 
 
4.4 Main Components for Microemulsion Polymerization 
4.4.1 Choice of Monomer 
Polymerization involves the linking together of small molecules of monomer to form a long chain 
polymer molecule known as a macromolecule. Scheme 4.1 depicts a polymerization where M represents 
both a monomer and a monomer unit in the polymer chain. 
 
Scheme 4.1: Schematic illustration of a polymerization. 
 
x M polymerization M
x
Monomer Polymer  
 
 Monomers in latex have to meet several requirements: (1) satisfy the polymer end-use needs for 
certain properties; (2) assure latex compatibility with pigments and fillers and (3) the latex have to be stable 
during pumping, blending, etc. Moreover, the reactivity of a monomer is strongly dependent on the ability 
of its substituent group(s) to stabilize the corresponding polymeric radical. The most reactive are monomers 
having substituent group(s) which can stabilize a radical by delocalization of the unpaired electron (i.e. 
resonance). 
 
A variety of functional monomers can be copolymerized with the principle monomers as well. 
These functional monomers are usually used in a small amount, typically 1-3% in a formulation.148 In this 
research, microemulsion polymerization was carried out with a highly water-insoluble antibiotic as the 
functional monomer in aqueous solution.  
 
 
4.4.2 Choice of Co-Monomer 
A monomer which is used to mix with another monomer for a polymerization reaction is being 
defined as a co-monomer. Most commercial polymers prepared by free-radical polymerization are in fact 
copolymers formed by the simultaneous polymerization of two or more monomers, and the inclusion of a 
second monomer greatly complicates the reaction kinetics. Usually the desired bulk properties of polymers 
can not be achieved by using only one monomer, and therefore comonomer(s) are essential for 
polymerization.  
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Choice of co-monomers is entirely dependent on the chemical and physical properties of the drug 
monomer. It is critical that the commercial or synthetically modified monomers are able to play two roles 
in the polymerization process: (1) as the co-monomers for the radical polymerization and (2) as the solvent 
for dissolving the synthetically modified drug monomers in order to make homogenous liquid phase.  
 
 
4.4.3 Choice of Surfactant 
Surfactant is an abbreviation for surface-active agent, which is characterized by its tendency to 
accumulate at interfaces. All surfactant molecules consist of at least two parts, one which is soluble in a 
specific fluid and one which is insoluble. The hydrophilic part is referred to as the head group and the 
hydrophobic part as the tail.149 Hydrophilic head groups of the surfactants are normally ionic, and the most 
common ionic surfactants are sodium oleate, hexadecyltrimethylammonium bromide, 
cetyltrimethylammonium bromide (CTAB), and sodium dodecylsulfate (SDS).150 There are also nonionic 
surfactants such as poly (ethylene oxide) glycol ethers. 
 
Surfactants are a key formulation variable in emulsion polymerization. They act to stabilize the 
monomer droplets in an emulsion form, serve to solubilize monomer within surfactant micelles and 
stabilize the formed latex particles as well as the particles which continue to grow during polymerization.  
 
Surfactants also determine the size and the size distribution of the particles formed during 
emulsion polymerization. Generally, polymerization carried out at or below the critical micelle 
concentration (CMC) will lead to the formation of more uniformly-sized particles. Surfactants are usually 
used in the range of 1-6% by weight to the monomer. 
 
 The primary classification of surfactants is based on the charge of the polar head groups. It is 
common practice to divide surfactants into four classes: anionics, cationics, non- ionics and zwitterionics. 
The latter class contains both an anionic and a cationic charge under normal conditions. Carboxylate, 
sulfate, sulfonate and phosphate are the polar groups found in anionic surfactants (Figure 4.4). 
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Figure 4.4: Structures of the anionic surfactants. 
 
Non-ionics surfactants have either polyether or polyhydroxyl as the polar group as shown in 
Fiugre 4.5. 
 
 
  
57
Fatty alcohol ethoxylate
Fatty amine ethoxylate
O
O
O
O
OH
N
O
O
O
O
OH
O
O
OH
 
 
 
Figure 4.5: Structures of the non-ionic surfactants. 
 
The vast majority of cationic surfactants are based on the nitrogen atom carrying the cationic 
charge (Figure 4.6). Both amine and quaternary ammonium-based products are commonly used. 
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Figure 4.6: Structures of the cationic surfactants. 
 
Zwitterionic surfactants contain two charged groups of different sign. Whereas the positive charge 
is mostly ammonium, the negative charge may vary, although carboxylate is by far the most common. 
(Figure 4.7) 
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Figure 4.7: Structures of the zwitterionic surfactants. 
 
4.4.4 Choice of Radical Initiator 
The initiator is normally water-soluble and the most commonly used water-soluble initiator is an 
inorganic salt of persulfuric acid, such as potassium persulfate (Figure 4.8). It dissociates into two sulfate 
radical anions which can initiate the polymerization.  
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Figure 4.8: Structures of potassium persulfate initiator. 
Redox radicals, typically generated by an oxidizing agent and a reducing agent, are usually used 
for polymerization at low temperatures. The formation of radicals in aqueous solution requires that 
molecular oxygen must be purged from the reaction with an inert gas, such as nitrogen. Oxygen has been 
shown to be effective in the consumption of radicals.151 Therefore, the removal of oxygen from the solution 
immediately prior to initiation prolongs the lifetime of the radicals. 
 
 
4.4.5 Choice of Aqueous Media 
The major component of an emulsion polymerization is the aqueous media. As a continuous phase, 
although inert, water acts to maintain a low viscosity and provides for good heat transfer. Water also acts as 
the medium of transfer from the monomer droplets to particles, the locus of initiator decomposition and the 
medium of dynamic exchange of surfactant between the phase.152  
 
It is necessary to use de-ionized water or nano-pure water for emulsion polymerization since the 
ions or metals can be normally the radical scavenger.153 In some cases, buffer solution is used depending on 
the surfactant and the particle stability.  
 
 
4.4.6 Choice of Polymerization Temperature 
Effect of temperature upon the rate of emulsion polymerization must be considered. The reaction 
temperature that was applied in our polymerization was kept at 70 °C, and it was found that higher or lower 
temperature did not give the desired nanoparticle morphology and uniform size.   
 
 
 
4.5 Polyacrylate Emulsion 
 
Acrylates, or esters of acrylic acid, are sufficiently water soluble to be used in emulsion 
polymerization.154 Because these monomers are low-viscosity liquids with reasonably high boiling points, 
they are conveniently handled on an industrial scale. These monomers yield rubbery polymers when 
copolymerized due to their flexibility, adhesion, tackiness and weatherability. 155  In most cases, the 
monomers are mixed with water and surfactant to form a pre-emulsion which is then fed into the reactor 
where the polymerization is run, typically at atmospheric pressure using temperatures between 60 and 90 
oC, and at a pH between approximately 3 to 9. At greater extremes of pH, acrylic monomers are subject to 
hydrolysis. The polymers, however, are usually quite stable to acidic and basic conditions. 
 
Emulsion polymerization of acrylates shown in Scheme 4.2 generally involves the use of low 
molecular weight, liquid acrylate monomers, and consequently more sophisticated acrylate monomers 
could undergo emulsion polymerization with mild reaction conditions. Due to their stability and various 
functionalities, polyacrylates have been developed as surgical adhesives and for controlled drug release.  
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Scheme 4.2: Formation of polyacrylates. 
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4.5.1 Prior Applications of Polyacrylate Emulsion in the Biomedical Area 
Prior work by Worley et al. showed that oxazolidinone acrylates undergo radical-promoted 
emulsion polymerization, and they are efficient biocides in their monomeric form in aqueous solution, and 
when polymerized, they can be coated on glass, plastic, and fibrous materials for use as surface-active 
disinfection agents. 156  These substituted oxazolidinones are reacted with several acryloyl chloride 
derivatives to give the desired monomers that can then homopolymerize to give polymeric oxazolidinones 
which are then activated by halogenating (Scheme 4.3). This suggests that additional types of lipophilic 
groupings that might include an active antibacterial drug could likewise be introduced in this way.157  
 
 
Scheme 4.3: Synthesis of Polymeric N-Halamines. 
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4.5.2 Recent Development of Polyacrylate Emulsion in Antibacterial Application 
More recently, in his dissertation, Dr. Jeung-Yeop Shim described the first application of a 
methodology to synthesize poly (ethyl acrylate) nanoparticle containing an N-thiolated β-lactam 
antibiotic.158 The reaction he described is under free-radical emulsion polymerization condition shown in 
Scheme 4.4 and Scheme 4.5. Enough amount of drug monomer (5%) had to be incorporated into the 
polymer for characterization by NMR. The maxima amount of lactam 27 that could be dissolved in ethyl 
acrylate comonomer was around 30% (w/w) for successful preparation of poly (ethyl acrylate-lactam). 
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Scheme 4.4: Synthesis of poly (ethyl acrylate) NP 1. 
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Scheme 4.5: General scheme for emulsion polymerization of poly (ethyl acrylate-lactam 27) nanoparticles 
NP 5a. 
O
N
ClS
O
H3C
N
O SCH3
O
O Cl
O
O
Et
O
+
microemulsion
polymerization OO
Et
water, 70oC
NP 5a27  
 
 
ß-lactam 27
Ethyl acrylate
Surfactant
Radical initiator
298 mg
1000 mg
39 mg
13 mg
Water 4 ml
components amount
FormulationandRxnConditions
Rxn Temp 70 oC  
 
 
 
The water-insoluble, highly crystalline N-methylthio β–lactam acrylate 27 along with a 
comonomer, ethyl acrylate undergoes an emulsion polymerization in water which leads to the formation of 
a latex suspension. In this process, the lactam antibacterial drug is covalently attached to the polyacrylate 
chain. A vial containing this latex shows the paint-like consistency of this emulsified mixture (Figure 4.9). 
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Figure 4.9: A bottle of polyacrylate emulsion. 
 
Analysis of the emulsion polymers prepared above was done by 1H NMR and scanning electron 
microscopy (SEM). The biological activity of polyacrylate nanoparticles containing drug 27 was also 
described in his dissertation. 
 
 
4.5.2.1 1H NMR 
1H NMR spectra for the dry films obtained by coalescing the nanoparticle emulsions of homopoly 
(ethyl acrylate) NP 1 and the copolymer NP 5a are shown in Figure 4.10. Signals at 2.6, 5.6 and 6.1 ppm 
are assigned to SCH3, C4-H and C3-H of the polymerized β-lactam, respectively. The olefin protons of the 
original acrylate in the range of 5.8-6.2 ppm do not show in the spectrum. That indicates that all of the 
monomeric lactam acrylate and ethyl acrylate was converted to polymeric particles. 
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Figure 4.10: NMR for homopoly (ethyl acrylate) NP 1 and poly (ethyl acrylate-lactam 27) NP 5a. 
 
4.5.2.2 Film formation 
Film formation refers to the entire sequence from aqueous latex dispersion to the fully developed 
coating. It involves three major steps. First, evaporation of water from the emulsion brings the particles 
close enough. Second, as more water evaporates, the particles undergo deformation to form a void-free 
solid structure. Finally, fusion occurs among these particles to give a mechanically strong film. A drawing 
depicting this process was shown in Figure 4.11. 
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Figure 4.11: Adapted illustration of the formation of film from the latex particles.  
 
In the case of the polyacrylate nanoparticle emulsions, J.Y. Shim showed that a dried film can be 
easily prepared by slow evaporating, either on glass or any solid surface presented in Figure 4.12. 
 
                      
                                                                              
 
Figure 4.12: Evaporation of emulsion produces a thermoplastic thin film. 
 
4.5.2.3 Scanning Electron Microscopy (SEM) 
The morphology and the particle size of the nanoparticles were analyzed by scanning electron 
microscopy (SEM) in the College of Engineering at University of South Florida. For scanning electron 
microscopy analysis, a sample of the nanoparticle emulsion was prepared by high dilution (3,000-fold) of 
the emulsion in D.I. water with evaporation under a N2-stream prior to coating by gold sputter under high 
vacuum. The gold-coated nanoparticles were then observed by SEM (Hitachi S 800). 
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Figure 4.13: Scanning electron microscopy (SEM) of polyacrylate nanoparticles. 
 
Scanning electron microscopy indicates that the polyacrylate emulsions are comprised of spherical 
nanoparticles, with particle diameters being uniformly within the 40 to 100 nm range. The average sizes 
and size distribution of the particles are somewhat dependent on the experimental conditions of 
polymerization, and on the ratios of the acrylate monomers. 
 
 
4.5.2.4 Studies of the Microbiological Activities of Nanoparticle Emulsions 
The studies of the microbiological activities were performed with the microbial screening of 
nanoparticle emulsions and the monomer drug 27. As a control, homopoly (ethyl acrylate) NP 1 was 
included in the series for comparison. The β-lactam monomer and its polymer were individually tested for 
antibacterial activity against methicillin-susceptible and methicillin-resistant S. aureus strains. All media 
and supplies were purchased from Fischer Scientific. All bacteria analyzed were purchased from Hardy 
Diagnostics (from ATCC sources), or were clinical isolates obtained from Lakeland Regional Medical 
Center and identified as USF 652-659. 
 
1. Kirby-Bauer Assay 
Compounds were evaluated in vitro by well diffusion on agar plates (Kirby-Bauer) in accordance 
with the guidelines recommended by the National Committee for Clinical Laboratory Standards 
(NCCLS).159 Five milliliters of sterile phosphate buffered saline (PBS) was inoculated with the desired 
bacteria and the concentration was adjusted to 0.5 McFarland Standard.  The bacteria-containing solution 
was then streaked evenly onto a Muller-Hinton agar plate and wells were drilled into the agar using sterile 
1-3 µL pipette tips. Usually 1 mg of drug monomer was dissolved in 1 mL of DMSO, and for nanoparticle 
emulsion containing drugs, the original emulsion has to be diluted to 1 mg/mL which corresponds to the 
drug concentration. The wells were filled with 20 µL of antimicrobial solution or nanoparticle emulsion 
and the plates were then incubated for 24 hours at 37 oC.  Zones of inhibition were determined for each 
well using a millimeter scale.  
 
 
2. Broth Dilution Minimal Inhibitory Concentration (MIC) Assay 
Lactam monomers and nanoparticles were also evaluated in vitro by broth dilution minimal 
inhibitory concentration assay using Standard NCCLS protocol M7-A5.160 Comparison of the resulting 
zones of inhibition and broth MIC values of all monomers and nanoparticles NP 1, NP 5a against S. aureus 
(ATCC 25923) and a strain of MRSA (ATCC 43300) are illustrated in Table 4.1. Homopoly (ethyl acrylate) 
NP 1 is the control experiment and NP 5a contains 30% w/w of lactam drug 27 in the nanoparticle.  
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Table 4.1: Antibacterial activity of the antimicrobial monomer (27) and the resulting nanoparticle emulsion 
NP 5a with the control emulsion NP 1. All zone of inhibition (ZOI) results are reported for 20 µg of both 
drug monomer and the emulsion. Minimal inhibitory concentration (MIC) results were obtained using 
either broth dilution or agar dilution assay procedures. 
 
MRSA (919) S. aureus (849) Compound 
ZOI (mm) MIC (µg/mL) ZOI MIC 
NP 1 
27 
NP 5a 
0 
14 
0 
>256 
128 
64 
0 
14 
0 
>256 
128 
64 
 
 
The data in Table 4.1 indicates that the antibiotic-conjugated polyacrylate nanoparticle NP 5a has 
slightly enhanced anti-MRSA activities compared to the free acrylated forms of lactam 27 against S. aureus 
and MRSA. Moreover, homopoly (ethyl acrylate) NP 1 has no activity at all and its MICs are greater than 
256 µg/mL. There is also another crucial observation that the antibacterial testing of poly (ethyl acrylate-
lactam 27) nanoparticles was not successful because the samples were not stable. This is also proved by the 
fact that the emulsion would precipitate heavily when the broth MIC assays in broth were performed. The 
precipitate would form in the broth, not on top of the emulsion, and thus cloud the broth more than the 
bacterial growth. Since the amount of bacterial growth is determined by optical density (OD), we could not 
accurately determine if a high OD value was from bacterial growth or if it was from the precipitated 
emulsion. Thus, polymer component will be changed from ethyl acrylate to butyl acrylate-styrene for 
further investigation. 
 
 
4.6 Expansion of Polyacrylate Emulsions 
 
4.6.1 Preparation of Poly (butyl acrylate and styrene) Nanoparticles 
As mentioned previously, poly (ethyl acrylate) nanoparticle with lactam 27 covalently attached 
does not exhibit a significant enhancement in the bioactivity against S. aureus and MRSA. Moreover, the 
solubility of β-lactam 27 in ethyl acrylate is fairly low, and considerable ethyl acrylate co-monomer is 
required to completely dissolve the drug monomer, for example, 10:1 is the minimum molar ratio of ethyl 
acrylate to lactam. Thus, a better polyacrylate emulsion formulation with different monomer components 
was needed for the successful preparation of the emulsions and the determination of bioactivity. 
 
Styrene is a relatively high boiling liquid and can be copolymerized with many monomers such as 
acrylates. Styrene is comparable tough and hard as a comonomer and it may provide a different physical 
properties of the film dried from the emulsion. One typical example of poly (styrene-acrylate) copolymer is 
poly (styrene-butyl acrylate) latex, which has been widely used in coatings, adhesives, and so on due to its 
good performance and relatively cheap price. Scheme 4.6 illustrates the preparation of poly (butylacrylate-
styrene) nanoparticles NP 3.  
 
The general emulsion polymerization procedure employed for this system involves a mixture of 
liquid acrylates, for example, butyl acrylate and styrene, heated at 70oC, and the mixture is then pre-
emulsified in purified water containing 3% w/w of sodium dodecylsulfate, a surfactant typically used in 
styrene-acrylic latexes, with rapid stirring. The resulting homogenous solution of micelles is then treated 
with potassium persulfate (1% w/w), a radical initiator, to induce free radical polymerization.  
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Scheme 4.6: General scheme for emulsion polymerization of polystyrene NP 2 and poly (butyl acrylate-
styrene) NP 3. 
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 To determine if the particle size of the polyacrylate emulsion can be uniform and reproducible, a 
series of five poly (butyl acrylate-styrene) emulsions were prepared under the same formulation and 
reaction condition named as NP 3a-3e. 
 
To investigate the effect of the reaction time and the formulation on particle size, another three 
poly (butyl acrylate-styrene) copolymers NP 3a* was prepared using a longer reaction time (12 hr), while 
NP 3f and NP 3f* were prepared with less surfactant (1%) and initiator (0.5%) and NP 3f* was reacted for 
a longer time (12 hr). Detailed formulation and reaction conditions are shown in Figure 4.14. 
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Figure 4.14: Formulations and reaction conditions for three polymers. 
 
4.6.2 Synthesis of Poly (butyl acrylate-methyl methacrylate) Nanoparticles NP 4 
Another combination of comonomers is butyl acrylate and methyl methacrylate. Methyl 
methacrylate (MMA) is a clear and colorless liquid and its outstanding properties include weatherability 
and scratch resistance. Scheme 4.7 illustrates the preparation of poly (butyl acrylate-styrene) nanoparticles 
NP 3 and poly (butyl acrylate-methyl methacrylate) nanoparticle NP 4.  
 
Scheme 4.7: Procedure for emulsion polymerization of poly (butyl acrylate-methyl methacrylate) NP 4. 
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Figure 4.15: Formulation of preparation of NP 4. 
  
67
4.6.3 Poly (butyl acrylate-styrene-lactam 27) NP 5b 
Different amounts of lactam 27 (1, 2, 3 and 4 %) (w/w) were used for preparation of poly 
(butylacrylate-styrene-lactam) nanoparticles NP 5b-f (Scheme 4.8). 
 
Scheme 4.8: Poly (butyl acrylate-styrene-lactam 27) NP 5b-f nanoparticles with different % (w/w) of drug 
content. 
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4.6.4 Physical Properties of Poly (butyl acrylate-styrene) and Poly (butyl acrylate-
methyl methacrylate) Nanoparticle Emulsions 
Analysis of the emulsion polymers prepared above was done by 1H NMR, scanning electron 
microscopy (SEM), transmission electron microscopy (TEM), dynamic light scattering (DLS), and zeta 
potential analysis. Stability studies were also performed at different temperatures and in different pH buffer 
solutions.  
 
4.6.4.1 1H NMR Analysis 
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1H NMR spectra comparison for emulsions of homopoly (styrene) NP 2 and poly (butyl acrylate-
styrene) NP 3 is shown in Figure 4.16. Signals between 6.5 and 7.3 represent the styrene phenyl ring, and 
signals between 3.65 and 4.1 represent the butyl group of butyl acrylate. No acrylate moiety from 
monomers appears in both NMR spectra, indicating the complete conversion of monomers to polymer. 
  
 
Figure 4.16: NMR comparison of poly (styrene) NP 2 and poly (butyl acrylate-styrene) NP 3. 
 
4.6.4.2 Film Formation 
A similar film was formed by evaporation of water from the emulsions NP 3, NP 5, while a white 
powder was formed from the poly (styrene) NP 2. The film prepared by slow evaporation of poly (butyl 
acrylate-methyl methacrylate) nanoparticle emulsions NP 4 seems to be stronger and more stretchy than the 
others. 
 
 
4.6.4.3 Scanning and Transmission Electron Microscopy (SEM and TEM) 
Scanning electron microscopy (SEM) analysis of the particle size of the emulsions was done with 
the same procedure as described in section 4.5.2.3. Since the nanoparticles were normally coated with a 
gold layer for SEM analysis, the particle size is slight larger than itself. A more accurate methodology is 
performed by transmission electron microscopy (TEM). Transmission electron microscopy (TEM) analysis 
was performed on a FEI Morgagni 268D Electron Microscop in the biology department at University of 
South Florida. The initial emulsion solution is diluted down to a 10-10 concentration using nanopure water, 
then the solution is drop cast onto a Formvar-coated copper grid. The water content is evaporated by 
applying a cool stream of air to the drop, and the grid is subsequently view on the microscope. 
 
Scanning and transmission electron microscopy indicate that poly (butyl acrylate-styrene) 
nanoparticles NP 3, nanoparticles NP 5b-f containing drugs and poly (butyl acrylate-methyl methacrylate) 
annoparticles NP 4 formed in this manner are all comprised of spherical nanoparticles, with particle 
diameters being uniformly within the 40 to 100 nm range (Figure 4.17). The average sizes and size 
distribution of the particles are somewhat dependent on the experimental conditions of polymerization, and 
on the ratios of the acrylate monomers. Further studies of particle size of the nanoparticles prepared under 
different formulations were done by DLS. 
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               (a) (b)  
 
Figure 4.17: Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) of 
polyacrylate nanoparticles. 
 
4.6.4.4 Dynamic Light Scattering (DLS) 
To investigate the size distribution of the nanoparticle emulsions, a dynamic light scattering (DLS) 
analysis was performed on a UPA 150 Honeywell MicroTrac at the University of Florida Particle 
Engineering Research Center. One drop of concentrated emulsion solution (20% solid content) was placed 
in a 10 mL well filled with nanopure water. Analysis was performed for 3 runs of 180 seconds per run per 
sample. The theory behind the dynamic light scattering analysis is that when a beam of light passes through 
a colloidal dispersion, the particles or droplets scatter some of the light in all directions. When the particles 
are very small compared with the wavelength of the light, the intensity of the scattered light is uniform in 
all directions (Rayleigh scattering); for larger particles which are above approximately 250 nm in diameter, 
the intensity is angle dependent (Mie scattering). 
 
Figure 4.18 demonstrates dynamic light scattering of a nanoparticle containing an average particle 
size of 40 nm in diameter with a narrow distribution. 
 
 
 
Figure 4.18: Particle size and distribution analysis by dynamic light scattering (DLS). 
 
4.6.4.5 Zeta Potential Analysis 
Zeta potential is a function of the surface charge of the particle which is dependent on the interface 
and the nature and composition of the surrounding medium in which the particle is suspended. The 
principal of determining zeta potential by micro electrophoresis is very simple. A controlled electric field is 
applied via electrodes immersed in the sample suspension and this causes the charged particles to move 
towards the electrode of opposite polarity. Viscous forces acting upon the moving particle tend to oppose 
this motion and equilibrium is rapidly established between the effects of the electrostatic attraction and the 
viscous drag. The particles therefore reach a constant "terminal" velocity. 
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The zeta potential value of each emulsion sample was obtained on a Brookhaven ZetaPALS. The 
emulsion solution was diluted to 1.5% (~ pH = 7) of solid content using nanopure water for analysis. For 
each analysis, 2 × 10 runs per sample was performed. The dispersant viscosity of the emulsion solution was 
determined to be 0.8872cP, and the dielectric constant of the medium was 78.55.  Table 4.2 summarizes the 
particle size and zeta potential value for each prepared polyacrylate nanoparticles NP 2-5. 
 
 
Table 4.2:Particle size and zeta potential analysis of nanoparticles NP 2-5. 
Nanoparticles Nanoparticle 
Description 
Average Particle 
Size (nm) 
Zeta Potential (mV) 
NP 2 
NP 3 
NP 4 
Polystyrene 
Poly (BA-sty) § 
Poly (BA-MMA) 
38.2 
See table 4.3 
52.2 
ND 
See table 4.3 
ND 
NP 5b 
NP 5c 
NP 5d 
NP 5e 
NP 5f 
Poly (BA-sty) with drug 27 (1%) 
Poly (BA-sty) with drug 27 (2%) 
Poly (BA-sty) with drug 27 (3%) 
Poly (BA-sty) with drug 27 (4%) 
Poly (BA-sty) with drug 27 (1%)δ 
44.6 
29.3 
33.4 
29.0 
59.3 
-34.9 ± 3.33 
-112.51± 4.70 
ND 
-63.53 ± 3.89 
ND 
 
          
         Poly (BA-sty) §: poly (butylacrylate-styrene) 
         Poly (BA-MMA): poly (butyl acrylate-methyl methacrylate) 
         Poly (BA-sty) with drug 27 (1%)δ: polymer prepared with 1% of surfactant and 0.5% of initiator. 
 
 
  The particle sizes of poly (butyl acrylate-styrene) emulsions prepared either with the drug 
incorporated (NP 5) or without (NP 3) have an average diameter of 35 nm, under the normal conditions in 
Scheme 4.6 as for NP 3. While for poly (butyl acrylate-methyl methacrylate) nanoparticles NP 4, the 
average particle size slightly increased to 52 nm. The zeta potential analysis shows that the polyacrylate 
nanoparticles have a negative charge on the surface, although no clear trend can be drawn from the data 
shown above. 
 
 
4.6.4.6 Reproducibility Studies of Poly (butyl acrylate-styrene) Nanoparticle Synthesis 
Five batches of poly (butyl acrylate-styrene) nanoparticles NP 3a-3e were prepared for the 
investigation of reproducibility of the polymerization formulation and conditions. The average particle size 
of these five polyacrylate nanoparticles (NP 3a-3e) are shown in Table 4.3. 
 
Table 4.3: Dynamic light scattering analysis of poly (butyl acrylate-styrene) NP 3a-3e. 
 
 NP 3a NP 3b NP 3c NP 3d NP 3e 
DLS (nm) 35.2 39.7 39.6 35.6 38.3 
 
 
4.6.4.7 Study of Polymerization Formulations and Reaction Conditions  
To investigate the effect of the reaction conditions and the formulation on particle size, further 
studies were performed with nanoparticle NP 3a* prepared using longer reaction time (12 hr), while 
nanoparticles NP 3f and NP 3f* were prepared with less surfactant (1%) and initiator (0.5%) A longer 
reaction time (12 hr) was carried out for preparation of NP 3f* (Table 4.4).  
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Table 4.4: Dynamic light scattering analysis of poly (butyl acrylate-styrene) nanoparticles NP 3a*, NP 3f 
and NP 3f*. 
 
 NP 3a NP 3a* NP 3f NP 3f* 
DLS (nm) 35.2 37.3 57.2 52.5 
 
 
 In summary, the preparation of polyacrylate nanoparticle is highly reproducible since an average 
particle size of 35.2 nm was obtained from 5 batches of poly (butyl acrylate-styrene) nanoparticles under 
the same conditions and formulation. Lengthening the reaction time from 6 hr to 12 hr does not seem to 
change the particle size, but it rather forms more precipitates from the emulsion and decreases the aqueous 
volume of the emulsion due to evaporation. Decreasing the amount of both surfactant and initiator does 
increase the particle size from 35 nm to 57 nm, as shown in Table 4.4 for NP 3f and NP 3f*. 
 
 
4.6.4.8 Stability Testing 
1. Stability Testing for Poly (butyl acrylate-styrene) Nanoparticles 
 
Three samples were prepared for the studies on the stability of nanoparticle emulsions stored at 
different temperatures. The first sample is the poly (butyl acrylate-styrene) NP 3f, the second sample is the 
poly (butyl acrylate-methyl methacrylate) NP 4 and the last sample is poly (butyl acrylate-styrene) with 
drug 27 (1%) NP 5f prepared with 1% of surfactant and 0.5% of initiator. Each sample was then diluted to 
four different concentrations (10%, 5%, 2.5% and 1.25%) using D.I. water. Each dilution was stored at 
different temperatures: 40 °C, r.t. and 5 °C. Table 4.5, Table 4.6 and Figure 4.19, Figure 4.20 show the 
comparison of average particle size for each dilution of NP 3f and NP 5f after being stored for 3 days.  
 
 
Table 4.5: Average particle size (nm in diameter) for different nanoparticles NP 3f after being stored for 3 
days. 
NP 3f 1.25% 2.5% 5% 10% 
 5oC 
 
r.t 
 
40oC 
62.1 
 
61.7 
 
60.9 
63.4 
 
62.0 
 
65.7 
62.2 
 
63.5 
 
64.2 
63.3 
 
63.3 
 
63.7 
 
 
 
Figure 4.19: Particle size vs. concentration for different concentration of freshly-made polymer NP 3f. 
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Table 4.6: Average particle size (nm in diameter) for different nanoparticles NP 5f after being stored for 3 
days. 
NP 5f 1.25% 2.5% 5% 10% 
 5 oC 
 
r.t 
 
40 oC 
62.1 
 
61.7 
 
60.9 
63.4 
 
62.0 
 
65.7 
62.2 
 
63.5 
 
64.2 
63.3 
 
63.3 
 
63.7 
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Figure 4.20: Particle size vs. concentration for different concentrations of freshly-made polymer NP 5f. 
 
Each dilution of these two samples was then stored at different temperatures (40 °C, r.t. and 5 °C) 
up to four weeks. Table 4.7 and Figure 4.21 shows a comparison of the average particle size for each 
dilution of NP 3f and NP 5f after being stored at 5 °C for one month.  
 
 
Table 4.7: Average particle size (nm in diameter) for different nanoparticles NP 3f and NP 5f after being 
stored for one month at 5 °C. 
 
NP 3f 1.25% 2.5% 5% 10% 
DLS (nm) 59.1 57.7 59.8 60.2 
 
NP 5f 1.25% 2.5% 5% 10% 
DLS (nm) 59.2 55.7 59.0 60.0 
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Figure 4.21: Average particle size vs. concentration for nanoparticle NP 5f stored at 5 °C for one month. 
 
 Since these was no significant change in the average particle size between the freshly-made 
nanoparticles and the one stored at 5 °C for one month. In summary, poly (butyl acrylate-styrene) 
nanoparticles are stable at different temperatures over a period of time. In addition, poly (butyl acrylate-
styrene) has a similar average particle size with the nanoparticles NP 5f which contains covalently attached 
lactam drug 27. 
 
 
2. Stability Testing for Poly (butyl acrylate-methyl methacrylate) Nanoparticles NP 4 
 
Poly (butyl acrylate-methyl methacrylate) nanoparticle sample NP 4 was also prepared. This 
sample was diluted to four different concentrations (10%, 5%, 2.5% and 1.25%) using D.I. water. All 
dilutions of NP 4 were stored at 40 °C, r.t. and 5 °C for one month and their particle sizes were then 
measured. Table 4.8 and Figure 4.22 and 4.23 showed the comparison of average particle size for each 
dilution of NP 4 after being stored for 3 days and one month.  
 
 
Table 4.8: Average particle size (nm in diameter) of diluted samples of NP 4 after being stored for 3 days 
and one month at the indicated temperature. 
 
 
After 3 days 1.25% 2.5% 5% 10% 
NP 4 (5 oC) 
 
r.t 
 
40 oC 
51.6 
 
52.9 
 
70.4 
53.5 
 
48.7 
 
44.5 
47.0 
 
67.8 
 
50.6 
37.6 
 
42.5 
 
102 
After one month 1.25% 2.5% 5% 10% 
NP 4 (5 oC) 
 
r.t 
 
40 oC 
ND 
 
ND 
 
ND 
ND 
 
48.0 
 
ND 
ND 
 
ND 
 
ND 
894.9 
 
45.3(46.0) 
 
418.5 
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Figure 4.22: Average particle sizes of poly (butyl acrylate-methyl methacrylate) nanoparticles NP 4 stored 
at different temperatures. 
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Figure 4.23: Average particle size of poly (butyl acrylate-methyl methacrylate) NP 4 (10% polymer content) 
stored at different temperatures for one month. 
 
 The average sizes of 10% solid-content poly (butyl acrylate-methyl methacrylate) nanoparticle 
polymers stored at either 40 °C, or at 5 °C, were increased dramatically from 40 nm to 400 nm; some of 
them even reached 1 µm. The nanoparticles of different concentrations stored at room temperature seem to 
be stable. In conclusion, poly (butyl acrylate-methyl methacrylate) NP 4 are not stable at 40 °C or 5 °C 
after a month, compared to poly (butyl acrylate-styrene) emulsions, since dramatic changes in particle size 
were observed for poly (butyl acrylate-methyl methacrylate) NP 4. Poly (butyl acrylate-styrene) 
nanoparticles seem to be much more stable at different storage temperatures than poly (butyl acrylate-
methyl methacrylate) emulsions. 
 
 
3. Stability Testing at Different pH Values 
 
 Another stability study was performed to evaluate nanoparticle stability at different pH values. 
Two nanoparticles, NP 3f* (poly (butylacrylate-styrene) with 1% of surfactant and 0.5% of initiator, 12 hr 
reaction time) and NP 3a (poly (butyl acrylate-styrene with 3% of surfactant and 1% of initiator), which 
was in storage at room temperature for 6 months, were used. pH buffer solutions ranging from pH 1-12 
were freshly made and used for stability testing.  
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To prepare these samples, 0.1 mL of these two concentrated emulsions was added to 0.1mL of 
each buffer solution. The resulting solution retained the appearance of the original emulsion, and further 
analysis of particle size by DLS showed that the nanoparticles were stable at both acidic (pH = 1) and basic 
solution (pH = 12) (Table 4.9, 4.10 and Fiugre 4.24, 4.25). The average particle sizes of the original 
nanoparticle emulsions of both samples are also listed as the reference. 
 
Table 4.9: Comparison of average particle size for nanoparticle NP 3f* in different pH buffer solutions. 
 
 Original (Ref.) pH 1 pH 2 pH 11 pH 12 
DLS (nm) 55.2 50.0 51.3 55.1 58.7 
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Figure 4.24: Comparison of particle size at different pH values for nanoparticle emulsions NP 3f*. 
 
Table 4.10: Comparison of average particle size for 6-month old nanoparticle emulsions NP 3a in different 
pH buffer solutions. 
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Figure 4.25: Comparison of particle size for nanoparticle emulsions NP 3a at different pH values. 
 
 
 
 Original (Ref.) pH 1 pH 2 pH 11 pH 12 
DLS (nm) 43.0 nm 42.5 43.7 42.9 39.2 
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From the data above, both samples of poly (butyl acrylate-styrene) nanoparticles NP 3a and NP 
3f* are stable at different pH values, ranging from 1-12. There is no dramatic change for the average 
particle sizes of these two samples and the emulsions after treatment in different pH buffer solutions still 
retain the appearance. In summary, poly (butyl acrylate-styrene) nanoparticles are spherical in size with an 
average of 40 nm. They are stable to storage for one month at different temperatures from 5 °C to 40 °C, 
and to different pH buffer solutions, ranging from pH 1-12.  
 
 
4.6.4.9 Studies of the Microbiological Activity of Nanoparticles NP 5 
Kirby-Bauer testing and broth MIC assays were used to investigate the biological activities of poly 
(butyl acrylate-styrene-lactam) nanoparticles NP 5. Agar dilution minimal inhibitory concentration (MIC) 
assays were also performed for the bioactivity against S. aureus. The concentrations of the emulsions 
analyzed were based on the drug content incorporated in the emulsions, and these concentrations were 
placed in a well of a 24 well plate. Phenol red mannitol agar was added to each well in liquid form to 
produce a total well volume of 1.5 mL. The contents of each well were thoroughly stirred to evenly 
distribute the antimicrobial within the agar. Once solidified, 10 µL of saline containing 107 CFU/ml of the 
desired bacteria is pipetted on top of each agar and the plates are then incubated for 24 hours at 37 oC. 
Bacterial growth is assessed by both visual observation and by colorimetric assay.  
 
Comparison of the zones of inhibition and MIC values of monomer 27 and nanoparticles NP 5a-c 
and 5e against S. aureus (ATCC 25923) and a strain of MRSA (ATCC 43300) are shown in Table 4.11. NP 
5a contains 30% w/w of lactam drug 27 in the nanoparticle and is the control. NP 5b, 5c and 5e have 1%, 
2% and 4% (w/w) drug in the nanoparticle. MIC values refer to the concentration of bound drug (µg/mL) 
needed to completely inhibit bacterial growth for 24 hours. 
 
 
Table 4.11: Antibacterial activity of acrylated monomers 27 and the resulting nanoparticle emulsions NP 5. 
All zone of inhibition (ZOI) results are reported for 20 µg of both drug monomers and emulsions. Minimal 
inhibitory concentration (MIC) results were obtained using either broth dilution or agar dilution assay 
procedures. 
 
MRSA (919) S. aureus (849) Compound 
ZOI (mm) MIC (µg/mL) ZOI MIC 
Monomer 27 14 128 14 128 
NP 5a 0 64 0 64 
NP 5b 7 32 7 32 
NP 5c 8 32 7 32 
NP 5e 7 32 7 32 
 
 
As shown in Table 4.11, the antibiotic-conjugated poly (butyl acrylate-styrene) nanoparticles NP 
5b,c and e showed enhanced anti-MRSA activities compared to the free acrylated forms of the water-
insoluble lactam drug 27 and poly (ethyl acrylate-lactam 27) nanoparticle emulsion NP 5a. Zone of growth 
inhibition of nanoparticle emulsions NP 5b, 5c and 5e are fairly small due to the poor diffusion of the 
emulsions. However, the MIC assay which is a more accurate measurement shows their values are all 
around 32 µg/mL, greater than those of the monomer 27 (128 µg/mL) and the nanoparticle NP 5a (64 
µg/mL). This indicates that the copolymer of butyl acrylate and styrene seems to have increased the 
bioactivity relative to the acrylated monomer 27, and the poly (ethyl acrylate-lactam) nanoparticles NP 5a. 
Finally, these data suggest that butyl acrylate and styrene are the optimal candidate comonomers for further 
investigations of polyacrylate nanoparticles. 
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4.7 Choice of Other Acrylated Drug Monomers 
 
N-Thiolated β-lactam 27 is the starting drug monomer for these investigations, and contains an 
acrylate moiety directly at the C3 position of the lactam ring. Water-insoluble β-lactam 27 represents a new 
family of antibiotics for the treatment of MRSA and it is a good drug monomer for covalent attachment to 
the polyacrylate backbone via emulsion polymerization. To develop more drug candidates, three essential 
factors have to be potentially considered.  The first one is the drug itself which has to consist of an acrylic 
moiety for radical emulsion polymerization; the second factor is that the selected drug monomers have to 
be biologically active after being cleaved off the polymer. The third factor is the linker that connects the 
drug to the polymer, which should be able to break down chemically or enzymatically to release the drug. 
The general features of desired drug monomer are shown in Figure 4.26. 
 
 
LinkerO
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Figure 4.26: General features of the desired drug monomer, and the initial β-lactam monomer 27. 
 
In this study, three other β-lactam antibiotics 37-39 served as the monomer targets for the 
emulsion polymerization (Figure 4.27). Changing the acrylate group from C3 to the C4-phenolic position is 
another interesting model (lactam 37) for study. Also, having two acrylate moieties on one molecule 
(lactam 38) or lengthening the C3 side chain (lactam 39) provide two additional targets that will enable us 
to the effect of different drug entities and linker units on bioactivity. 
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Figure 4.27: Three monomer targets. 
 
4.7.1 Synthesis of C4-Acrylate Lactam 37 
     Changing the location of the acrylate moiety from C3 in lactam 27 to C4 in lactam 37 provides an 
alternative drug monomer for polymerization and biological evaluations.  
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Scheme 4.9 shows the preparation of C4-acrylate lactam 37. C4-Hydroxy benzaldehyde was 
coupled with p-anisidine to give imine 40. Further acrylation of the hydroxyl group on imine 40 gave 
protected imine 41. Staudinger coupling of methoxyacetyl chloride with the protected imine 41, however, 
failed to afford the desired β-lactam. Another route shown in Scheme 4.10 illustrates that Staudinger 
coupling of methoxyacetyl chloride with acetate protected imine 42 successfully gave the C3-methoxy N-
aryl protected β-lactam 43 as a single diastereomer (cis). Hydrolysis of the acetoxy group on the phenyl 
ring under basic conditions gave the C4-phenolic β-lactam 44. Acrylation of the free hydroxyl moiety on 
the β-lactam with acryloyl chloride gave the C4 acryloyl N-aryl protected β-lactam 45. Removal of the PMP 
group with ceric ammonium nitrate (CAN) gave N-dearylated lactam 46. Methylthiolation of 46 with N-
methylthiophthalimide (14) afforded C4-acryloyl N-methylthio β-lactam 37 as a white solid. 
 
 
Scheme 4.9: Attempted synthesis of C4-acrylate N-methylthio β-lactam 37. 
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Scheme 4.10: Alternative route to lactam 37. 
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Conditions: (a) acetylchloride, triethylamine, CH2Cl2,  0 °C-rt, 92%; (b) methoxyacetyl chloride, 
triethylamine, CH2Cl2, rt, 62%; (c) KOH, MeOH, acetone, 0 °C-rt, 87%; (d) triethylamine, acryloyl 
chloride, CH2Cl2, rt, 82%; (e) ceric ammonium nitrate, MeCN, 0 oC, 83%; (f) Hunig’s base, N-
methylthiophthalimide (14), CH2Cl2, reflux, 76%. 
 
 
4.7.2 Synthesis of Diacrylate Lactam 38 
At the initiation of these studies, it was thought the perhaps a more highly crosslinked polymer 
could be formed in the emulsion polymerization if the monomer containing difunctional or multifunctional 
moieties is polymerized together with comonomer(s)161 (Scheme 4.11). Crosslinked particles are of value 
for chromatographic column packings and for thermally stable matting agents.162 Thus, attaching two 
acrylates onto the lactam ring would ideally provide a highly crosslinked polymer via emulsion 
polymerization. This type of crosslinking is usually called homogeneous crosslinking. This was the 
objective of using diacrylate lactam 38 in the polymerization of the nanoparticles. 
 
 
Scheme 4.11: Illustration of crosslinked polymers.  
 
 
      
 
Synthesis of diacrylated lactam 38 is described in Scheme 4.12 starting from imine 42. Staudinger 
coupling of acetoxyacetyl chloride with imine 42 gave C3-acetoxy N-aryl protected β-lactam 47 in 65% 
yield. Hydrolysis of the two acetoxy groups under basic conditions gave the dihydroxy β-lactam 48 in 93% 
yield. Acrylation of free hydroxyl β-lactam with two equivalents of acryloyl chloride under the basic 
condition gave C3- and C4-acryloly N-aryl protected β-lactam 49 in 92% yield. Deprotection of the PMP 
group on the β-lactam with ceric ammonium nitrate (CAN) gave N-dearylated lactam 50, followed by 
methylthiolation with N-methylthiophthalimide (14) to afford C3 and C4 di-acryloyl N-methylthio β-lactam 
38 as a white solid in 72% yield. 
 
 
Scheme 4.12: Synthesis of di-acrylated N-methylthio β-lactam 38. 
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Conditions: (a) Triethylamine, CH2Cl2, rt, 65%; (d) KOH, MeOH, acetone, 0 °C-rt, 93%; (e) triethylamine, 
acryloyl chloride, CH2Cl2, rt, 92%; (f) ceric ammonium nitrate, MeCN/H2O, 0oC, 84%; (g) Hunig’s base, 
N-methylthiophthalimide (14), CH2Cl2, reflux, 65%. 
 
 
4.7.3 Synthesis of C3-Long Chain Triester Lactam 39 
It was next considered important to investigate the properties of the nanoparticles with a triester 
linkage between the drug and polymer backbone, since a longer chain may influence bioactivity and the 
rate of drug release. Thus, lactam 39 was chosen as an additional target for polymerization. 
 
Synthesis of lactam 39 is illustrated in Scheme 4.13. C3-Hydroxy β-lactam 9b was reacted with 
succinic anhydride to afford an acid which was found to be unstable. Without any workup, the resulting 
acid was treated with 2-hydroxyethyl acrylate to give a tri-ester β-lactam 51. Another route to make this 
intermediate was studied using mono-2-acryloyloxyethyl succinate for coupling with the alcohol 9b. 
(Scheme 4.14). Removal of the para-methoxyphenyl (PMP) group with ceric ammonium nitrate (CAN) 
gave the N-dearylated lactam 51. Methylthiolation of 51 with N-methylthiophthalimide (14) afforded C3-
acryloyl β-lactam 39 as a colorless oil. 
 
Scheme 4.13: Synthesis of C3-acryloyl β-lactam 39. 
N
O
HO
Cl
O
9b
O
O
O
+ N
O
O
ClO
HO
O
O
Not Stable
2-hydroxyethyl acrylate
EDCI , DMAP
triethylamine
 
 
 
N
O H
O
ClO
O
OO
O
52
N
O
O
ClO
O
OO
O
O
51
ceric ammonium nitrate
H2O, CH3CN, 0 °C
 
 
 
 
N
O SMe
O
ClO
O
OO
O
39
 N-methylthiophthalimide (14)
 
 CH2Cl2, Hunig's base, reflux
 
 
  
81
Scheme 4.14: Alternative method to make 51. 
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Conditions: a) mono-2-acryloyloxyethyl succinate, EDCI, DMAP, CH2Cl2, r.t, 78%. 
 
 
4.8 Preparation of Polyacrylate Nanoparticles with the Three Drug 
Monomers 37-39 
 
The general emulsion polymerization procedure employed involves dissolving a water-insoluble 
acrylated drug in a butyl acrylate and styrene, at 70oC, and the mixture is then pre-emulsified in purified 
water containing 3% w/w of sodium dodecylsulfate, a surfactant, with rapid stirring. The resulting 
homogenous solution of micelles is then treated with potassium persulfate (1% w/w), a radical initiator, to 
induce free radical polymerization. Different amounts of lactam 37 (1 and 2 %) (w/w) were dissolved in 
different ratios of butyl acrylate/styrene comonomers or ethyl acrylate comonomer for preparation of four 
types of lactam-attached polyacrylate nanoparticles NP 6 (Scheme 4.15). 
 
 
Scheme 4.15: Poly (butylacrylate-styrene-lactam 37) NP 6 with different % (w/w) of drug content. 
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ß-lactam 37
Butyl acrylate
Styrene
Surfactant
Radical initiator
20 mg
700 mg
300 mg
100 mg
25 mg
Water 4 ml
components amount
Formulation for NP 6a
(2% drug content)
Rxn Temp 70 oC
ß-lactam 37
Butyl acrylate
Styrene
Surfactant
Radical initiator
10 mg
800 mg
200 mg
30 mg
10 mg
Water 4 ml
components amount
Formulation for NP 6b
(1% drug content)
Rxn Temp 70 oC
 
 
 
ß-lactam 37
Butyl acrylate
Styrene
Surfactant
Radical initiator
10 mg
700 mg
300 mg
30 mg
10 mg
Water 4 ml
components amount
Formulation for NP 6c
(1% drug content)
Rxn Temp 70 oC
ß-lactam 37
Ethyl acrylate
Surfactant
Radical initiator
10 mg
1000 mg
30 mg
10 mg
Water 4 ml
components amount
Formulation for NP 6d
(1% drug content)
Rxn Temp 70 oC
 
 
  
Lactams 38 and 39 (1 or 2% w/w) were dissolved in butyl acrylate/styrene comonomers for 
preparation of poly (butyl acrylate-styrene-lactam) nanoparticles NP 6 and 7. (Scheme 4.16  and Scheme 
4.17) 
 
 
Scheme 4.16: Poly (butyl acrylate-styrene-lactam 38) NP 7. 
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ß-lactam 38
Butyl acrylate
Styrene
Surfactant
Radical initiator
10 mg
700 mg
300 mg
30 mg
10 mg
Water 4 ml
components amount
Formulation for NP7
(1% drug content)
Rxn Temp 70 oC
 
 
 
Scheme 4.17: Poly (butyl acrylate-styrene-lactam 39) NP 8. 
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To determine whether there is any unreacted lactam monomer or organic impurities in the poly 
(butyl acrylate-styrene-lactam) nanoparticles, continuous extraction of the product emulsions using 
cyclohexane was performed for three continuous days after the preparation of poly (butylacrylate-styrene-
lactam 27) NP 5d to determine the efficiency of the drug monomer incorporated in the polymerization. 
About 1.5 mL of purified emulsion was saved after being extracted every day. Both purified and unpurified 
samples were tested for further physical properties, such as average particle size. Particle sizes of the each 
emulsion after being extracted with cyclohexane were measured by dynamic light scattering (DLS) (Table 
4.12). 
 
Table 4.12: Comparison of particle sizes of nanoparticle emulsion NP 5d after extraction.  
 
 
 
 
 
 
 
 
 
 
 
 
The data in Table 4.12 indicates that there is no dramatic change in particle size after extraction of 
the original emulsion with cyclohexane. The residue from the cyclohexane layer contains mainly the 
impurities from the cyclohexane solvent and there is also no clear indication of unreacted lactam monomer 
27 that was extracted from the emulsion. What was learned from this study was that purification of the 
nanoparticle emulsions by continuous extraction requires distilled cyclohexane or other solvents, which 
should be done for all future nanoparticle preparations to remove residual monomer or organic impurities. 
 
 
 
4.9 Physical Properties of Polyacrylate Nanoparticles NP 6-8 
 
Analysis of the emulsion nanoparticles NP 6-8 was done by 1H NMR, scanning electron 
microscopy (SEM), transmission electron microscopy (TEM), dynamic light scattering (DLS), and zeta 
potential analysis. These methods reveal different information about particle size, morphology, and 
composition. 
 
 
4.9.1 1H NMR 
1H NMR spectra for the dry films obtained by coalescing the nanoparticle emulsions of poly 
styrene NP 2 and the copolymer NP 6a are shown in Figure 4.28. Signals at 3.2 ppm (b) and 4.8 (a) ppm 
are assigned to the CH3O group at the C3 position of the polymerized β-lactam ring and the vicinal ring 
protons, respectively. The olefinic protons of the original acrylate in the range of 5.8-6.2 ppm do not show 
in the spectrum. That indicates that all of the monomeric lactam acrylate and ethyl acrylate was converted 
to polymeric particles.  
 
 
 
Mv (nm) Mn (nm) Ma (nm) 
NP 5d original-1st trial 39.0 34.7 37.4 
NP 5d original-2nd trial 40.1 35.5 38.5 
NP 5d after 1 day extraction 104.0 31.3 36.9 
NP 5d after 2 day extraction-1st trial 154.9 34.1 39.5 
NP 5d after 2 day extraction-2nd trial 163.7 35.5 40.9 
NP 5d after 3 day extraction 155.4 35.0 40.6 
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Figure 4.28: NMR comparison of polystyrene NP 2 and poly (butyl acrylate-styrene-lactam 37) NP 6a. 
 
4.9.2 Film Formation 
Similar films were obtained from emulsions NP 6-8 as illustrated in Figure 4.12.  
 
 
4.9.3 Transmission Electron Microscopy (TEM) 
Particle sizes of nanoparticle emulsions NP 6-8 were measured by transmission electron 
microscopy (TEM). TEM images shown in Figure 4.29 indicate that polyacrylate emulsions formed in this 
manner are comprised of spherical nanoparticles, with particle diameters being uniformly within the 30 to 
60 nm range. The average sizes and size distribution of the particles are somewhat dependent on the 
experimental conditions of polymerization, and on the ratios of the acrylate monomers. Further studies of 
particle size of the nanoparticles prepared under different formulations were done by DLS. 
 
 
                
 
Figure 4.29: Transmission electron microscopy (TEM) of polyacrylate nanoparticles. 
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4.9.4 Dynamic Light Scattering (DLS) and Zeta Potential Analysis 
Dynamic light scattering and zeta potential value of each emulsion were obtained on a Honeywell 
UPA 150 and Brookhaven ZetaPALS. Table 4.13 summarizes the particle size and zeta potential value for 
polyacrylate nanoparticles NP 6-8. 
 
 
Table 4.13: Particle size and zeta potential analysis of nanoparticle NP 6-8. 
Nanoparticles Nanoparticle 
Description 
Average Particle 
Size (nm) 
Zeta Potential (mV) 
NP 6a 
NP 6b 
NP 6c 
NP 6d 
Poly (BA-sty) with drug 37 (2%) 
Poly (BA-sty)a with drug 37 (1%) 
Poly (BA-sty)b with drug 37 (1%) 
Poly (EA) with drug 37 (1%) 
34.4 
29.2 
41.8 
54.9 
-73.78 ± 4.28 
-74.47 ± 2.55 
-57.06 ± 5.23 
-55.02 ± 7.06 
NP 7 Poly (BA-sty) with drug 38 (1%) 33.2 -61.42 ± 3.63 
NP 8 Poly (BA-sty) with drug 39 (1%) 43.8 -68.76 ± 3.66 
 
 
                Poly (BA-sty)a: Poly (butylacrylate-styrene = 8:2) 
  Poly (BA-sty)b: Poly (butylacrylate-styrene = 7:3) 
 
 
 Average particle size of poly (butyl acrylate-styrene) nanoparticles NP 6a-c and NP 7, 8 with a 
lactam drug covalently attached have similar sizes of 30-40 nm, while nanoparticles NP 6d prepared with 
poly (ethyl acrylate-lactam) have a slightly larger size, 55 nm. Zeta potential values of each nanoparticle 
indicate that there is a negative charge on the surface. 
 
 
4.10 Biological Activities of Nanoparticles 
4.10.1  Antibacterial Testing 
Microbiological activities of poly (butyl acrylate-styrene-lactam) nanoparticles NP 6-8 against S. 
aureus and MRSA were investigated by Kirby-Bauer disk diffusion, broth MIC assay and agar dilution 
minimal inhibitory concentration (MIC) determination. All media and supplies were purchased from Fisher 
Scientific. All bacteria analyzed were purchased from Hardy Diagnostics, (from ATCC sources), or were 
clinical isolates obtained from Lakeland Regional Medical Center. 
  
 
4.10.2  Results and Discussion of Antibacterial Testing 
 The zone of inhibition values and MIC values of the monomers 37, 38 and 39 and the 
nanoparticles NP 6-8 against S. aureus (ATCC 25923) and a strain of MRSA (ATCC 43300) are given in 
Table 4.14. Poly (butyl acrylate-styrene) NP 3a was included as a control. NP 6b, NP 7 and NP 8 have 1% 
w/w drug content in the nanoparticle. MIC results refer to the concentration of bound drug (µg/mL) needed 
to completely inhibit bacterial growth for 24 hours. 
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Table 4.14: Antibacterial activity of acrylated monomers 37, 38 and 39 and the resulting nanoparticle 
emulsions NP 6b, NP 7 and NP 8. All zone of inhibition (ZOI) results are reported for samples containing 
20 µg of both drug monomers and emulsions. Minimal inhibitory concentration (MIC) results were 
obtained using either broth dilution or agar dilution assay procedures. 
 
MRSA (919) S. aureus (849) Compound 
ZOI (mm) MIC (µg/mL) ZOI (mm) MIC (µg/mL) 
12 128 12 128 Monomer 37 
NP 6b 10 16 11 16 
13 128 12 128 Monomer 38 
NP 7 13 16 12 16 
10 64 11 64 Monomer 39 
NP 8 13 8 13 8 
NP 3a (control) 0 >256 0 >256 
 
  
The data in Table 4.14 indicates that the antibiotic-conjugated polyacrylate nanoparticles NP 6b, 
NP 7 and NP 8 have enhanced anti-MRSA activities compared to the free acrylated forms of the water-
insoluble drugs 37, 38 and 39. Moreover, poly (butylacrylate-styrene) NP 3a control has no activity at all 
and MICs are greater than 256 µg/mL. Figure 4.30 gives a comparison of the MICs of the drug monomers 
versus their resulting polyacrylate emulsions.  
 
 
Figure 4.30: Comparison of bioactivities of acrylated monomers (27, 37, 38 and 39) and nanoparticles (NP 
1, NP 3a, NP 5a, NP 5b, NP 6b, NP 7 and NP 8). 
 
It is apparent that all N-methythio β-lactam-containing nanoparticles are active against MRSA 
strains as well as the non-resistant strain, S. aureus 849. Increasing the length of the linkage holding the 
antibiotic onto the polymer backbone also seems to affect bioactivity of the nanoparticle. NP 8, which has a 
longer, more flexible linker, has the strongest anti-MRSA properties among all nanoparticles. However, 
changing the location of this linker, as seen in NP 6b, does not appear to alter the activity of the 
nanoparticles. Also, NP 7 prepared from lactam 38, whose two acrylates allow for inter- and intra-strand 
crosslinking, showed the same activity against MRSA as NP 5b. This data suggests that the polyacrylate 
nanoparticles NP 3-8 are all highly crosslinked during the emulsion polymerization process. 
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4.11 Mode of Action Studies 
 
The mechanism for antibacterial activity of these nanoparticles is currently under investigation, 
but is likely related to the overall physical properties of the polymer. The nanoparticles can be viewed as 
interlinked strands of polyacrylates woven into a nanoball, with most of the drug content residing on the 
interior. Spherical morphology is confirmed from the SEM and TEM images, and presumably held together 
by the surfactant, which also prevents aggregation, as well as by covalent crosslinks within the polymer 
matrix (Figure 4.31). This was also observed in atomic force microscopy (AFM) images taken by Kerriann 
Greenhalgh with the assistance from the College of Engineering at University of South Florida, showing 
that the nanoparticles appear as solid spheres with high rigidity. 
 
 
 
Figure 4.31: Transmission electron microscopy (TEM) image showing the polymer strands. 
 
Attempts to further increase the degree of crosslinking in the nanoparticle matrix through the use of 
diacrylated drug 38 does not significantly affect particle size, morphology, or antibacterial activity; NP 7 
has similar physical characteristics as NP 4 - NP 8. (Scheme 4.18) 
 
Scheme 4.18: Poly (butylacrylate-styrene-lactam 38) NP 7. 
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Our experiments confirm that the nanoparticle itself, without the antibiotic attached, has no 
antibacterial properties of its own. Thus, the antibacterial activity observed is not simply an effect of 
membrane dissolution by the surfactant or the polymer. Two possible mechanisms of delivery are depicted 
in Figure 4.32 for the drug-conjugated nanoparticle system. 
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Figure 4.32: Schematic illustrating modes of delivery of an antibiotic-conjugated nanoparticle to a bacterial 
cell. In this depiction, the nanoparticle can release drug either while on the surface of the cell or after entry. 
 
Upon interaction with the bacterial cell, the nanoparticle may undergo morphological deformation 
on the surface of the membrane, exposing the attached drug to bacterial enzymes that hydrolyze the active 
drug from the polymer backbone. From here, the drug can then enter the cell through its usual route. 
Alternatively, the nanoparticles may endocytose into the cell before releasing the antibiotic. Electron 
microscopy studies provide evidence that both pathways are likely occurring for the polyacrylate 
nanoparticles. TEM images of S. aureus cells grown in the presence of the poly (butyl acrylate-styrene) 
nanoparticles NP 3 (without drug) reveal the presence of the intact nanoparticles on the membrane surface 
and within the cell wall, or collapsed against the cell’s surface (Figure 4.33). However, for S. aureus cells 
treated with drug-conjugated poly (butyl acrylate-styrene) nanoparticles NP 5b, no nanoparticles are 
observed inside the cytoplasm of surviving cells, which we speculate could be due to rapid destruction of 
the bacterium that ingests the drug nanoparticle during cell division.163 In vitro screens show that these 
polyacrylate nanoparticles are non-cytotoxic toward human dermal fibroblasts,164 augmenting the favorable 
properties and biocompatibilities of polyacrylate biomaterials. 
 
 
 
Figure 4.33: Transmission electron microscopy (TEM) images of S. aureus cells treated with poly (butyl 
acrylate-styrene) nanoparticles. (A) Sectioned cells with both spherical nanoparticles inside the cell and 
deformed nanoparticles on the surface. (B) Exterior of intact cells interacting with the control nanoparticles. 
The textured appearance in the cytoplasm of the non-dehydrated whole cells results from effervescence 
under the electron beam. (Images taken by Kerriann Greenhalgh) 
 
 
4.12 Conclusions 
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In this chapter, experiments were conducted to prepare, characterize, and assess the bioactivity of 
spherical nanoparticles containing antibacterial agents covalently attached to the polyacrylate backbone. 
This work extends the preliminary experiments of Jeung-Yeop Shim who first developed the technique of 
drug-conjugated nanoparticle polymerization in the Turos laboratory. The primary advantages of this 
process is that poly (acrylate-co-lactam acrylate) nanoparticle spheres prepared by emulsion polymerization 
1) are highly uniform in shape and size, 2) have diameters in the range of 30-70 nm in diameter, 3) possess 
a highly hydrophilic outer surface, and 4) are stable in the temperature range of 5-40 °C and pH range of 1-
12. The most significant biological importance of these antibiotics-conjugated nanoparticles is that they 
have enhanced bioactivity against S. aureus and MRSA.  
 
 
The overriding premise of this methodology is that it allows for the potential enhancement of 
bioavailability and bioactivity of antibiotic drugs which may otherwise possess poor water solubility or are 
rapidly deactivated in vivo. Secondly, since the target drug is presumably covalently bound within the 
interior of the nanoparticles rather than to the exterior surface, the particle may act to secure the drug from 
chemical or enzymatic destruction until safely transported into the cytoplasm of the target cell where the 
drug is released for action. Compared to the prior drug delivery systems which use the bio-active materials 
without modifying its structure, covalently attaching the drug onto the nanoparticles ensures the 
accumulation of a high local concentration within the bacterial cell prior to release. In addition to 
improving the membrane permeability of water-soluble drugs into sites within bacterial cells, possibly  
altering  their  usual  mode  of  action,  this may  also  be  a  particularly effective method for enhancing the 
bioavailability of water-insoluble antibiotics in aqueous media and reducing the side reactions that are the 
main drawbacks of the other drug delivery systems. 
 
In the next chapter, further studies focus on use of amino ester linkages as a means to attach 
antibacterial agents to the polymer matrix in these nanoparticles, and the effect this might have on 
microbiological activity. 
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CHAPTER 5 NOVEL POLYACRYLAMIDE 
NANOPARTICLES FOR DELIVERY OF N-THIOLATED 
β-LACTAM ANTIBIOTICS 
5.1 Introduction 
 
Polymers based on polyacrylamide (PAM) and its derivatives are widely used for their thickening 
properties in paints and as pushing fluids in tertiary oil recovery as drag reduction agents and drilling 
fluids.165 The first polyacrylamide nanoparticle was successfully developed by Kreuter and Speiser in 
1976.166 Recent developments of polyacrylamides show that they are capable of binding different proteins, 
resulting in a wide range of biological activities. 
 
The previous chapter described a new technology based on synthetic polyacrylate nanoparticles 
for delivery of β-lactam antibiotics. Due to the structural similarity between acrylates and acrylamides, it 
was decided to extend this research to another family of polymers based on synthetic functional 
acrylamides, whose properties might make them suitable for a variety of applications related to polymer 
therapeutics.  
 
5.2 Targeted Functional Monomers  
 
 Monomers are building blocks for making polymers, and the desired bulk properties of the 
polymers usually cannot be achieved by using only one monomer. Thus, comonomers or functional 
monomers are needed to each specific application. Herein, a series of functionalized acrylamide monomers 
containing an N-thiolated β-lactam antibiotic are to be prepared for utilization in emulsion polymerization, 
in the manner described in Chapter 4.  
 
 
5.2.1 Introduction  
Acrylamide is an organic compound of white, odorless, flake-like crystals. The greatest use of 
acrylamide is as a coagulant aid in drinking water treatment. Other uses include (1) in improving 
production from oil wells; (2) in making organic chemicals and dyes; (3) in the sizing of paper and textiles; 
(4) in ore processing; (5) in the construction of dam foundations and tunnels. A typical acrylamide is shown 
in Figure 5.1, in which R and R’ can be H, alkyl, aryl, or a variety of other substituents. 
N
O
R'
R  
Figure 5.1: Structure of acrylamide. 
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Polyacrylamides are usually produced by free-radical chain polymerization of acrylamide 
monomers. In this process, an initiator is decomposed via thermal energy or UV light to form one or more 
free radicals that react with a vinyl group CH2=CH-R. The resulting adduct where the unpaired electron, or 
radical, is on the CH-R carbon reacts with another monomer in a chain reaction which leads quickly to a 
high molecular weight material. The polymerization of acrylamide normally takes place in aqueous media. 
As the reaction proceeds, the solution becomes more viscous, and this corresponds to the use of acrylamide 
as a water thickener. In this research, the method of microemulsion polymerization described in chapter 4 
was applied for generating drug-attached poly (acrylamide) nanoparticles for further investigation of their 
antibacterial properties (Scheme 5.1).  
 
Scheme 5.1: Polymerization of acrylamide for drug delivery design. 
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 The synthetic polymeric acrylamides are usually submicron in size and have many advantages in 
drug delivery.167 In general, these polyacrylamides can be used to provide cellular or tissue delivery of 
drugs,168 to improve oral bioavailability,169 and enhance the water solubility of drugs for intravascular 
delivery and improve the stability of the drug against enzymatic degradation.170 Due to their polymeric 
characteristics, one can control the release of the drug from the polymer to achieve a desired therapeutic 
level in target sites for optimal therapeutic effects.171 Moreover, the linkage connecting the drug with the 
polymer might bind to a biospecific ligand by conjugation which could direct the polymer to the target 
tissue or organ.172  
 
 
5.2.2 Functional Acrylamide Monomer 
5.2.2.1 Design of Drug Monomer 
Functional acrylamide monomers have been used previously for preparing polymers and 
copolymers as basic raw materials for water treating, paper, mining, and oil field chemicals, coatings and 
adhesives. Few applications in the biomedical area using acrylamide have however been explored.  
 
The target functional acrylamide monomers shown in Figure 5.2 consist of an acrylamide moiety 
for radical emulsion polymerization, and a biologically active drug (N-thiolated β-lactam) attached through 
a linker that can potentially break down chemically or enzymatically to release the drug from the backbone 
of the nanoparticle.  
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Figure 5.2: Proposed acrylamide functional monomer. 
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5.2.2.2 Choice of Linkage 
A variety of groups can in principle be used as the linkage for connecting the drug entity to the 
acrylamide functional group. An amino acid, short peptide or peptide are among these choices. Twenty α-
amino acids are building blocks of proteins that make up the bulk of cell structure and act as enzymes for 
catalyzing cellular reactions. Some of these amino acids found in proteins also serve functions distinct from 
the formation of peptides and proteins, e.g., tyrosine in the formation of thyroid hormones or glutamate 
acting as a neurotransmitter. There are other amino acids found in the body in either free or combined states 
(i.e. not associated with peptides or proteins). These non-protein associated amino acids perform 
specialized functions.  
The α-amino acids in peptides and proteins (excluding proline) consist of a carboxylic acid (-
COOH) and an amino (-NH2) functional group attached to the same tetrahedral carbon atom. This carbon is 
the α-carbon. Distinct R groups, that distinguish one amino acid from another, also are attached to the 
alpha-carbon (except in the case of glycine where the R group is hydrogen). Based on the variety of R 
substituents that can be present on the α-carbon, those amino acids having a short chain, a branched chain, 
a longer chain or bearing a ring were selected for structure and activity relationship (SAR) studies. The 
representative amino acid used to prepare each type of acrylamide monomer is glycine, alanine, valine, 
proline, methionine and threonine (Figure 5.3). 
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Figure 5.3: Structures of amino acid acrylamides used for emulsion polymerization. 
 
5.3 Synthesis of N-Acrylated Amino Acid Monomers 
 
 N-Acrylated amino acids or their methyl esters were prepared from the reaction between acryloyl 
chloride and the desired amino acid, either in aqueous solution or in a dry organic solvent. Attempts to 
synthesize these six N-acrylated amino acid monomers by direct amidation of acryloyl chloride with the 
amino acid in aqueous solutions afforded satisfactory results only when glycine, alanine, valine, proline and 
methionine were used. For preparation of the threonine derivative, it was necessary to employ the amino 
acid methyl ester instead. The methyl ester was easily obtained by treatment of threonine with SOCl2 in 
methanol. Detailed synthetic procedures for each acrylamide monomer will be described in the following 
section.  
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5.3.1 N-Acryloyl Glycine (53) 
Glycine is a neutral, genetically coded amino acid. It is the only protein-forming amino acid 
without a center of chirality. Glycine helps trigger the release of oxygen to the energy requiring cell-
making process and it is also important in the manufacturing of hormones responsible for a strong immune 
system.173 
 
The procedure for the synthesis of acryloyl-glycine174 is shown in Scheme 5.2. To a mixture of 
glycine and NaOH (2 equivalents) in chilled water was added dropwise 1.2 equivalents of acryloyl chloride 
under cooling at 0 oC. The reaction was stirred at room temperature for 1 hour, and the mixture was 
neutralized with concentrated HCl to pH ~ 3. The precipitated product was filtered with suction and the 
melting point of the solid was determined to be 111-112 oC.  
  
Scheme 5.2: Synthesis of N-acryloyl glycine 53. 
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 Numerous methods have been applied for generating ester bonds between a carboxylic acid and an 
alcohol using different coupling reagents, such as 1,3-dicyclohexylcarbodiimide  
(DCC)/dimethylaminopyridine(DMAP), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide (EDC)/DMAP, 
1-hydroxybenzotriazole (HOBt)/DMAP or diethylphosphoryl cyanide (DEPC) with base. The general 
mechanism involving this coupling reaction starts with the activation of the acid by DCC via 1,2-addition, 
and the resulting O-acrylisourea intermediate is similar in structure to an acid anhydride and acts as an 
acylating agents. Further attack by the alcohol on the activated carbonyl group leads to the ester (Scheme 
5.3). In this case, EDC/DMAP was used due to the ease of the workup.  
 
With the N-acryloyl glycine 53 in hand, the coupling reaction with racemic C3-hydroxy methylthio 
β-lactam 17 was performed under EDC/DMAP conditions to afford lactam 54 in 82% yield (Scheme 5.4). 
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Scheme 5.3: Proposed mechanism of coupling reaction of an acid and an alcohol. 
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Scheme 5.4: Coupling reaction of 53 with lactam 17. 
 
H
N
O
OH
O
+
N
O SCH3
HO
EDCI, DMAP
Dry CH2Cl2, r.t
82%
Cl
N
O SCH3
O
ClO
H
N
O
17
53
54
 
 
 
 
 
 
  
96
 
The structure of amino acid 54 was corroborated by 1H NMR (Figure 5.4). 
 
Figure 5.4: NMR of lactam 54. 
 
5.3.2 N-Acryloyl Alanine (55) 
Alanine is used by the body to build protein and was first isolated in 1879.175 The alpha-carbon in 
alanine is substituted with a methyl group, making it one of the simplest amino acids with respect to 
molecular structure and is one of the most widely used in protein construction. It is also an important 
source of energy for muscle tissue, the brain and central nervous system. It strengthens the immune system 
by producing antibodies and helps in the metabolism of sugars and organic acids. 
  
L-Alanine was dissolved in two equivalents of NaOH solution at 0 oC. To the solution, 1.2 
equivalents of acryloyl chloride was added dropwise. The reaction was stirred at room temperature for 1 hr, 
and the mixture was neutralized with concentrated HCl to pH ~ 3. The precipitated product was filtered 
with suction and the melting point was determined to be 126-128 oC (literature 130 oC)176 (Scheme 5.5). 
 
Scheme 5.5: Synthesis of N-acryloyl L-alanine 55. 
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The structure of amino acid 55 was corroborated by 1H NMR (Figure 5.5). 1H NMR analysis 
demonstrated that the formed amino acid monomer possessed the pattern for the vinyl moiety.  Proton Hc is 
downfield shifted (6.21 ppm, d, J = 4.4 Hz) because of its proximity to the carbonyl group. Protons Ha 
(5.69 ppm, d, J = 4.0 Hz) and Hb (6.05 ppm, d, J = 4.4 Hz) are nonequivalent due to the planar geometry of 
the amide bond. Hence, their coupling to Hc produced split doublet signals. 
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Figure 5.5: 1H NMR analysis of N-acryloyl alanine 55. 
 
The formed N-acryloyl alanine 55 was then reacted with the racemic alcohol 17 using EDC and 
DMAP to afford the lactam 56 in 91 % yield (Scheme 5.6). 
 
Scheme 5.6: Coupling of 55 with lactam 17. 
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1H NMR analysis of lactam 56 confirmed the structure that the split pattern for the proton on the 
α-carbon of the alanine moiety was a quartet (Figure 5.6).  
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Figure 5.6: 1H NMR analysis of lactam 56. 
 
5.3.3 N-Acryloyl Valine (57) 
 Valine is one of the natural amino acids and is coded for in DNA. Valine is an aliphatic amino 
acid that is closely related to leucine and isoleucine both in structure and function. These amino acids are 
extremely hydrophobic and are almost always found in the interior of proteins. Nutritionally, valine is an 
essential amino acid and must be obtained in the diet. Important sources of valine include soy flour, cottage 
cheese, fish, meats, and vegetables. Valine is incorporated into proteins and enzymes at the molar rate of 
6.9 percent when compared to the other amino acids. It also promotes mental vigor, muscle coordination 
and helps calm emotions. 
 
L-Valine was dissolved in two equivalents of NaOH solution at 0 oC. To the solution, 1.2 
equivalents of acryloyl chloride was added dropwise. The reaction was stirred at room temperature for 1 
hour, and the mixture was neutralized with concentrated HCl to pH ~ 3. The precipitated product was 
filtered with suction and the melting point was determined to be 99-101 oC (literature 100 oC)177. The 
formed N-acryloyl valine 57 was then reacted with the racemic alcohol 17 to afford the lactam 58 in 79 % 
yield (Scheme 5.7 and 5.8). The structure of amino acid attached lactam 58 was corroborated by 1H NMR 
(Figure 5.7). 
 
 
Scheme 5.7: Synthesis of N-acryloyl L-valine 57. 
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Scheme 5.8: Coupling of 57 with lactam 17. 
H
N
O
OH
O
+
N
O SCH3
HO
EDCI, DMAP
Dry CH2Cl2, r.t
79 %
Cl
N
O SCH3
O
ClO
H
N
O
17
57
58
 
 
 
 
Figure 5.7: 1H NMR analysis of lactam 58. 
 
 
5.3.4 N-Acryloyl Proline (59) 
Proline is also one of the twenty proteinogenic units which are used in living organisms as the 
building blocks of proteins. The other nineteen amino acids consist of all primary amines, while only 
proline has a secondary amine. The side chain binding to the nitrogen prevents rotation that provides 
proline with unique conformational constraints.178 
 
Proline is a relatively non-polar amino acid, and since it does not have hydrogen on the amide 
group, proline can not act as a hydrogen bond donor. Proline can act as a structural disruptor for α helices, 
and as a turning point in β sheets. Multiple prolines and/or hydroxyprolines in a row can create a proline 
helix which is the predominant structure in collagen.  
 
L-Proline is a non-essential, neutral, genetically coded amino acid. It is extremely important for 
the proper functioning of joints and tendons; also helps maintain and strengthen heart muscles.179 
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To prepare N-acryloyl proline (59), a mixture of L-proline and NaOH (2. equivalents) solution was 
dissolved in chilled water. To the solution, 1.2 equivalents of acryloyl chloride was added dropwise under 
cooling at 0 oC. The reaction was stirred at room temperature for 1 hr, and the mixture was neutralized with 
concentrated HCl to pH ~ 3. The precipitated product was filtered with suction and the melting point was 
found to be 109-110 oC (Scheme 5.9).  
 
Scheme 5.9: Synthesis of N-acryloyl L-proline 59. 
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With the N-acryloyl proline 59 in hand, the coupling reaction with racemic β-lactam 17 was 
performed under EDC/DMAP conditions to afford lactam 60 in 84% yield (Scheme 5.10). The structure of 
amino acid attached lactam 60 was corroborated by 1H NMR (Figure 5.8). 
 
 
Scheme 5.10: Coupling of 59 with lactam 17. 
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Figure 5.8: 1H NMR analysis of lactam 60. 
 
 
5.3.5 N-Acryloyl Methionine (61) 
Methionine is one of the essential amino acids and building blocks of proteins. It cannot be 
produced by the body, and must be provided by the diet. It supplies sulfur and other compounds required 
by the body for normal metabolism and growth. Methionine also has many functions such as (1) prevents 
disorders of the hair, skin and nails;180 (2) helps lower cholesterol levels by increasing the liver's production 
of lecithin;181 (3) reduces liver fat and protects the kidneys; (4) serves as a natural chelating agent for heavy 
metals;182 (5) regulates the formation of ammonia and creates ammonia-free urine which reduces bladder 
irritation and (6) influences hair follicles and promotes hair growth.183 
 
 Some research demonstrated that people with AIDS had low levels of methionine and this may 
explain some aspects of the disease process.184 A preliminary study has suggested that methionine may 
improve memory recall in people with AIDS-related nervous system degeneration.185 Other preliminary 
studies have suggested that methionine may help treat some symptoms of Parkinson’s disease.186 
 
A mixture of L-methionine and NaOH (2 equivalents) was dissolved in chilled water. To the 
solution, 1.2 equivalents of acryloyl chloride was added dropwise under cooling at 0 oC. The reaction was 
then stirred at room temperature for 1 hr, and the mixture was neutralized with concentrated HCl. In this 
case, only a small amount of precipitate was formed after being acidified with concentrated HCl to pH ~ 3. 
Thus, the resulting solution was extracted with ethyl acetate three times and dried over MgSO4 and the 
solvent was evaporated to afford a solid with a melting point of 113-115 oC (Scheme 5.11). 
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Scheme 5.11: Synthesis of N-acryloyl L-methionine 61. 
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The coupling reaction between racemic C3-hydroxy methylthio β-lactam 17 and acryloyl-
methionine 61 was performed under EDC/DMAP conditions to afford lactam 62 in 78 % yield (Scheme 
5.12). The structure of amino acid attached lactam 62 was corroborated by 1H NMR (Figure 5.9). 
 
 
Scheme 5.12: Coupling of 61 with lactam  17. 
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Figure 5.9: 1H NMR analysis of lactam 62. 
 
 
5.3.6 N-Acryloyl Threonine Derivative (64) 
Threonine is an alcohol-containing amino acid that can not be produced by metabolism and must 
be taken from the diet as well. This amino acid plays an important role along with glycine and serine in 
porphyrin metabolism. 187  Excessive use of threonine can cause the formation of too much urea and 
consequently ammonia toxicity in your body. To be used effectively, threonine requires vitamin B6, 
magnesium, and niacin.  
 
Threonine is an important part of many proteins in the body and is necessary for the formation of 
tooth enamel and elastin and collagen which both are needed for healthy skin and wound healing. It is also 
an important amino acid for the nervous system. There are relatively high levels of threonine in the central 
nervous system. It has been used as a supplement to help alleviate anxiety and some cases of depression. 
The role of threonine in the functioning of the nervous system is highlighted by the body's increased 
demand for this amino acid during times of stress. 
 
 Direct amidation of L-threonine with acryloyl chloride failed to afford the desired protected amino 
acid 64 (Scheme 5.13). Thus, its methyl ester derivative, compound 63, was formed with SOCl2 refluxing 
in methanol (Scheme 5.14). The threonine methyl ester was then dissolved in dichloromethane and 1.2 
equivalents of triethylamine was added. The solution was chilled and acryloyl chloride (1.1 equiv) was 
added dropwise. The cooling solution was warmed to room temperature and stirred overnight. The solvents 
were removed in vacuum and the residues were dissolved in ethyl acetate. The crystals (triethylammonium 
hydrochloride) were filtered out and the solution was washed three times with 1 M NaHSO4 and 5% of 
NaHCO3 and once with brine. The organic layer was dried over MgSO4, filtered and concentrated to give 
acryloyl-threonine methyl ester 64.  
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Scheme 5.13: First attempt at synthesizing of N-acryloyl threonine. 
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Scheme 5.14: Another route for the synthesis of N-acryloyl threonine 64. 
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To prepare threonine-linked lactam 65, the racemic C3-hydroxy methylthio β-lactam 17 was first 
converted to an acid by reacting with succinic anhydride. The unstable intermediate was not isolated but 
instead reacted directly with the amino acid 64 under EDC/DMAP conditions to afford lactam 65 in 69 % 
yield (Scheme 5.15). 
 
Scheme 5.15: Coupling of 64 with lactam 17. 
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5.4 Emulsion Polymerization of Acryloyl Amino Acid-Linked 
Nanoparticles 
5.4.1  Procedure and Formulation 
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 As mentioned earlier, polyacrylamides are normally synthesized by free-radical chain 
polymerization. Herein, polyacrylamides of N-acryloyl amino acids or their esters, onto which a β-lactam 
antibiotic is attached, were generated via emulsion polymerization. The general procedure employed for 
this system involved dissolving the water-insoluble drug in a mixture of liquid acrylates, i.e. butyl acrylate 
and styrene, at 70oC, and the mixture was then pre-emulsified in purified water containing 3% w/w of 
sodium dodecylsulfate, a surfactant, with rapid stirring. The resulting homogenous solution of micelles was 
then treated with potassium persulfate (1% w/w), a radical initiator, to induce free radical polymerization. 
Scheme 5.16 illustrates a general procedure for preparation of drug-conjugated polyacrylamide 
nanoparticles. Detailed reaction formulation and reaction conditions are shown in Figure 5.10. 
 
 
Scheme 5.16: Preparation of polyacrylamide nanoparticles (NP 9, 10, 11 and 12). 
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Figure 5.10: Formulations used for the preparation of polyacrylamide nanoparticles NP 9-12. 
 
5.4.2 Physical Properties of Polyacrylamide Nanoparticles 
1H NMR spectra for a dry and stretchy film obtained by coalescing the nanoparticle emulsions of 
co-poly (butyl acrylate-styrene-drug 56) showed that the olefinic protons of the acrylamide in the range of 
5.8-6.2 ppm did not show up in the spectrum. That indicated that all of the monomeric lactam acrylamide, 
butyl acrylate and styrene were converted to polymeric particles. 
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Dynamic light scattering data was acquired on a UPA 150 Honeywell MicroTrac at the University 
of Florida Particle Engineering Research Center. One drop of the concentrated emulsion (20% solid content) 
was placed in a 10 mL well filled with nanopure water. Analysis was performed for 3 runs of 180 seconds 
per run per sample. 
 
Zeta potential value of each emulsion was obtained on a Brookhaven ZetaPALS. The emulsion 
solution was diluted to 1.5% (~ pH = 7) of solid content using nanopure water for analysis and 2 × 10 runs 
per sample was performed. The dispersant viscosity of the emulsion solution was 0.8872cP, and the 
dielectric constant of medium was 78.55.  Table 5.1 summarizes the particle size and zeta potential value 
for each polymer. The average particle size was uniform 35-40 nm in diameter. 
 
Table 5.1: Comparison of average particle size (nm) and surface charge (-mV) of each polyacrylamide 
nanoparticle. 
 
Polymer Linkage in  
monomer 
Dynamic light scattering (nm) Zeta potential (-mV) 
NP 9 Glycine 34.6 -57.02 ± 3.11 
NP 10 Alanine 36.9 -66.45 ± 3.37 
NP 11 Valine 35.6 -61.42 ± 0.41 
NP 12 Proline 39.1 ND 
 
 
 
5.5 Biological Activities against S. aureus and MRSA 
 
All media and supplies were purchased from Fisher Scientific. All bacteria analyzed were 
purchased from Hardy Diagnostics, (ATCC sources), or were clinical isolates obtained from Lakeland 
Regional Medical Center. 
 
The antibacterial activities for both drug monomer and its polymer were determined by the 
standard Kirby-Bauer well diffusion testing and agar dilution minimal inhibitory concentration (MIC) assay. 
For Kirby-Bauer testing, the wells were filled with 20 µL of antimicrobial solution or nanoparticle 
emulsion and the plates were then incubated for 24 hours at 37oC. Zones of inhibition were determined for 
each well using a millimeter scale. For MIC assay, the antimicrobial and polyacrylamide nanoparticle 
emulsion concentrations analyzed were determined by the standard NCCLS protocol M7-A5. The 
concentrations of the emulsions analyzed were based on the drug content incorporated in the emulsions, 
and these concentrations were placed in a pre-determined well of a 24 well plate. Muller Hinton agar was 
added to each well in liquid form to produce a total well volume of 1.5 mL. 
 
 
5.5.1 Monomer Activities against S. aureus and MRSA 
Comparison of the observed zone of inhibition (measured in mm) of all monomers 54-62 against S. 
aureus (ATCC 25923) and a strain of MRSA (ATCC 43300) is illustrated in Figure 5.11. The MIC values 
are presented below each sample as well. 
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Figure 5.11: Comparison of bioactivities of acrylated monomers 54, 56, 58, 60 and 62. 
 
 The amino acid-containing acrylamide lactam monomers showed some correlation between the 
structural features and biological activity. Zones of inhibition showed a trend that with lengthening or 
branching the R group, bioactivities decreased. In the case of glycine-derived lactam 54, the higher activity 
may be attributed to its simple structure; however, lactam 62, having a fairly long side chain with a 
terminal –SCH3 group, exhibited the lowest bioactivities.  
 
The same trend was also found in the MICs profiles of these compounds, 32 µg/mL is the 
concentration for glycine lactam 54, and 64 µg/mL for lactams 56 and 58 with amino acids bearing a 
methyl or isopropyl group. Lactams 60 and 62, each having a ring or longer chain, MICs are around 128 
µg/mL. Thus, increasing lipophilicity in the amino acid side chain leads to a lower degree of biological 
activity. 
 
 
5.5.2 Polymer Activities against S. aureus and MRSA 
 In the present study, polyacrylamide molecules based on amino acids-linked β-lactam drugs were 
prepared from each of the five acrylated amino acid monomers above, and tested for anti-MRSA activity. 
Comparison of the MICs for each polymer system is shown in Figure 5.12. Experimental data showed none 
of the polymers tested in the Kirby Bauer assay expressed significant activity against S. aureus and MRSA, 
indicating that these polymers may not be able to diffuse through the agar at a sufficient concentration to 
inhibit bacteria growth. However, the MICs of the nanoparticles illustrated a slight increase of bioactivity 
against MRSA. For example, for nanoparticle containing valine-attached lactam 58, its MICs increased to 
32 µg/mL compared to its monomer 58 having MICs of 64 µg/mL. Thus, the polyacrylamide nanoparticle 
containing drug did not destroy antibacterial activity. 
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Figure 5.12: Comparison of bioactivities of polyacrylamide nanoparticles versus their monomers. 
 
Since both acryloyl amino acid-linked monomer and nanoparticles show good bioactivities against 
MRSA, and it will be interesting to investigate the potent activities against other bacteria, such as Bacillus, 
or cancer cell line. Prior work on screening of β-lactams with cancer cell shows that N-methylthio β-lactam 
1 has unique anticancer properties against human leukemic and solid tumor cell lines. In Jurkat T (leukemia) 
cells, the lactam 1 was found to inhibit cellular mitosis. Further in vitro screening on Jurkat cells with 
another β-lactam 56, also showed that the acryloyl-alanine-attached lactam 56 exhibited the similar potent 
anticancer activity as lactam 1. With this promising preliminary data, five other acryloyl-amino acid 
attached β-lactams 54, 58, 60, 62 along with three other β-lactams, 65-68 were screened for anticancer 
properties (Figure 5.13). Lactam 25 was investigated further in an animal model as mentioned in chapter 
two. Lactam 67 is another long chain derivative similar to compound 65, and lactam 68 has two hydroxyl 
groups on the lactam which increases the water solubility of the lactam. 
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Figure 5.13: Compounds subjected to anticancer screening in Dr. Q. Ping Dou’s laboratory (Wayne State 
University). 
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Compound 67 bears a similar long chain at the C3 position of the lactam. The synthesis of 67 is 
shown in Scheme 5.17. The synthesis started with methylation of L-methionine with SOCl2 refluxing in 
methanol for 3 hours. The resulting methyl ester 66 was then reacted with the unstable succinic ester of the 
lactam to afford 67 in 72 % yield.  
 
Scheme 5.17: Synthesis of lactam 67.  
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 The preparation of lactam 68 is illustrated in Scheme 5.18. The PMP group of lactam 47 was 
deprotected with CAN to give lactam 69. N-Methylthiolation of 69 with the usual reagent (14) gave 
methylthio lactam 70. Hydrolysis of both acetate groups of 70 using two equivalents of KOH afforded the 
final compound, dihydroxy lactam 68. 
 
Scheme 5.18: Synthesis of di-hydroxy lactam 68. 
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Conditions: a) ceric ammonium nitrate, CH3CN, water, 0 °C; b) N-methylthiophthalimide 14, Hunig’s base, 
dry CH2Cl2, refluxing; c) K2CO3, MeOH, 0 °C. 
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For the anticancer assays, trypan blue was added to Jurkat cells treated with the lactams to 
visualize percentage of cell death at 25 µg/mL and 50 µg/mL drug concentrations (Figure 5.14). β-Lactam 
1 was used as a positive control.  
 
 
 
 
Figure 5.14: Trypan blue staining of Jurkat cells with the lactams after 24 hours of treatment. 
 
At 24 hours it is noted that lactam 60 was the only lactam from this group that was more potent 
than 1. Lactams 65 and 67, two lactams with longer R groups, were the only other lactams with similar 
activity to 1. Figure 5.15 demonstrates the percentage of cell death after 48 hours of treatment with the 
lactams. 
 
 
Figure 5.15: Trypan blue staining of the same Jurkat cells after 48 hours of treatment with the lactams.  
 
It is observed that all lactams induce a lower percentage of cell death after 48 hours versus 24 
hours. The trend of lactam efficacy seems the same as with 24 hours. Lactam 60 appears to be the most 
potent; however 54, a lactam with a shorter R group, appears to have a similar efficacy to 1. Those two 
lactams with longer R groups, seem to have dimished efficacy after 48 hours. 
 
  
111
The following screening was done on human leukemia (HL-60) cells shown in Figure 5.16 and 
Figure 5.17. A different cell line was used to see if the effects of the lactams would be the same, as well as 
to see which cell line responded to the drug effectively. HL 60 was treated with the lactams to visualize 
percentage of cell death at 25 µg/mL, 50 µg/mL and 75 µg/mL drug concentrations. As illustrated, cells 
failed to respond effectively to beta lactam treatment. LLL, which is Z-Leu-Leu-Leu-CHO or MG132, a 
tripeptidyl proteasome inhibitor, was used as a positive control along with lactam 1 throughout the beta 
lactam experiments. 
 β-Lactamtreatment of HL-60 cells afer 24 hours 
 
                            1           25            60           58            54            68            62           65          67     DM  LLL 
 
Figure 5.16: β-Lactam treatment of HL-60 cells after 24 hrs. 
 
 
β-Lactamtreatment of HL-60 cells afer 48 hours 
 
 
Figure 5.17: β-Lactam treatment of HL-60 cells after 48 hours. 
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In summary, with respect to Jurkat cell treatment, lacams 60, 65 and 67 were most effective at 
inducing cell death. It could be assumed from this that increased length of the R group aids in drug function. 
Overall, the combination of a long chain R group and possibly the addition of a ring structure as a 
substituent act to increase drug efficacy.  
 
Acryloyl glycine β-lactam 54 appeared to be more effective in the treatment of HL-60 cells, with 
60 still having high efficacy, and 65 and 67 inducing about the same percent cell death. Using this data it is 
hard to determine if the length of the R group has an effect, however, the side chain ring structure does 
seem to increase drug efficacy. 
 
In conclusion, several acryloyl amino acid-linked monomers show good activities against both 
Jurkat cell and human leukemia (HL-60), and the polyacrylamide nanoparticles prepared from these 
monomers have been submitted for anticancer study. 
 
 
5.6 Conclusions and Future Work 
 
 Nano-sized polymer-based delivery systems have received significant interest all over the world, 
particularly for anticancer agents. Our development in drug delivery using polyacrylate/polyacrylamide 
nanoparticles has resulted in a new vehicle for antibacterial applications. Several essential features of our 
system are (1) the straightforward strategy for preparation of functional drug monomers and polymer 
frameworks in aqueous media using emulsion polymerization, (2) ability to generate small (30-60 nm) and 
uniform nanoparticles with narrow size distribution, and (3) the nanoparticle substance exhibits better 
antibacterial activity against S. aureus and MRSA than its monomer. Additionally, the nondegradable and 
nontoxic nature of polyacrylate/polyacrylamide polymers would ensure that the vehicle itself would not be 
toxic.   
 
 To help understand the mode of action of these nano-sized polymeric antibiotics, or nanobiotics, 
investigations are being conducted. In the future, longer amino acid chain linkers may be used, such as tri-
amino acid, Pro-Hyp-Gly (Hyp = hydroxyproline), which is found most prominently in native collagen, and 
peptides composed solely of these trimers give rise to the most stable triple helices.188  
 
 Another method being developed in our laboratory to track the nanoparticles is to label the 
polymer using fluorescent markers. As mentioned in chapter two, fluorescence has proved to be a versatile 
tool for numerous applications, including the molecular interactions in life science. Moreover, the concept 
of Forster Resonance Energy Transfer (FRET) is especially a promising method. A suitable FRET pair, 
with an appropriate fluorescence wavelength, could provide information on the mechanism. Ideally, a 
fluorescent moiety which functions as a donor will be installed onto the lactam monomer and another 
fluorescent pair will be installed onto a comonomer as an acceptor. Theoretically, the donor will overlap 
with the absorption wavelength of the other, the acceptor. In other words, the fluorescence of the donor 
would be quenched by the acceptor. Therefore, as the donor and acceptor are separated, the quenching 
effect exponentially decreases and the donor “lights up” as its fluorescence is released. This may let us 
know the path of the nanoparticles through the bacteria cell membrane and into the cell. 
 
However, there is no literature yet on fluorescence-active polymeric nanoparticles. Therefore, it 
may open a new area in biological diagnostics if fluorescence-active nanoparticles are successfully 
prepared and applied appropriately to detection of specific biological molecules, such as proteins or 
microbes acting as water dispersed biological sensors or biological imaging agents. There remains a 
considerable amount of room for further exploration on the design and properties of 
polyacrylate/polyacrylamide nanoparticles, both in the drug delivery/drug discovery areas and new 
biomaterials. The research described in this thesis may provide a foundation for building upon existing 
methodologies in each of these areas.  
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CHAPTER 6 MATERIALS AND METHODS  
6.1 Synthetic Procedures  
 
All reagents were purchased from Sigma-Aldrich Chemical Company and used without further 
purification. Solvents were obtained from Fisher Scientific Company. Thin layer chromatography (TLC) 
was carried out using EM Reagent plates with a fluorescence indicator (SiO2-60, F-254). Products were 
purified by flash chromatography using J.T. Baker flash chromatography silica gel (40 µm). 13C NMR 
spectra were proton broad-band decoupled.  
 
 
6.1.1 Preparation of N-Anisylimines (6) 
Aldehyde (1 mmol), anisidine (1 mmol), and 1 mg of camphorsulfonic acid (cat.) were dissolved 
in dichloromethane and stirred at room temperature for 1 hr. TLC showed the disappearance of the starting 
materials and the solvent was then removed in vacuo and the imine was recrystallized from methanol.  
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6.1.2 Preparation of Acid Chlorides  
Methoxyacetyl chloride: To a 250 ml flame dried round bottom flask containing methoxyacetic 
acid (31.38 g, 0.35 mol) was added thionyl chloride (41.4 g, 0.35 mol) dropwise while stirring for 0.5 hr at 
0°C. The ice bath was removed and the mixture reacted for 12 hr at 30°C. The pale yellow solution was 
then distilled to provide pure acid chloride (bp 112-113°C).  
 
H3CO
Cl
O
H3CO
OH
O
+ SOCl2
0 oC then
heat  
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 Acetoxyacetyl chloride (7): To a 250 ml round bottom flask containing glycolic acid (10 g, 0.13 
mol) was added acetyl chloride (20 g, 0.26 mol) dropwise at 0°C. The ice bath was removed and the 
resulting slush dissolved within 30 min after the acetyl chloride addition. After 1 hr, a white precipitate 
forms. Benzene (50 ml) was added and the reaction stirred for an additional 12 hr. The solid was then 
filtered and washed with benzene and ice cold methanol to give pure product 26 in 80% yield (mp 62-
63°C). Afterwards, thionyl chloride (31.8 g, 0.24 mol) was added dropwise at 0°C to a 250 ml flask 
containing acid 26 (24.6 g, 0.24 mol) while stirring. The ice bath was then removed and the resulting slush 
was stirred overnight at 30°C. After 12 hr, the liquid was distilled in vacuo to give the acetoxyacetyl 
chloride in 60% yield from glycolic acid.  
 
 
AcO
Cl
O
HO
OH
O
SOCl2
0 - 50 oCAcCl
AcO
OH
O
+
726  
 
 
6.1.3 Preparation of N-4-Anisyl Azetidin-2-ones 8 
Imine (1 mmol) and N,N-ethyldiisopropylamine (5 mmol) or triethylamine (5 mmol) were added 
to a 250 ml round bottom flask containing dry dichloromethane (50 ml per g of imine) and the mixture was 
chilled in an ice bath to 0 °C. Acid chloride (1.2 eq. 6 mol) in dry methylene chloride (50 ml per g acid) 
was added dropwise (5 ml per min) to the stirring solution. Following addition of the acid chloride, the 
flask was removed from the ice bath and warmed to r.t. The reaction was monitored by thin layer 
chromatography. After water extraction twice, the organic layer was dried with magnesium sulfate, filtered, 
and the crude material was concentrated in vacuo. Diethyl ether or methanol was then added and the 
solution chilled to precipitate the β-lactam. When silica gel chromatography was required for purification, 
separation was achieved with ethyl acetate and hexane mixtures (1:1). 
 
 
N
O
R1O H H
8a: R = H,  R1= Ac
8b: R=Cl, R1= Ac
OCH3
R1O
O Cl
+
N
H
OCH3
triethylamine, or 
Hunig's base
 CH2Cl2
0oC       rt
76a: R = H, R1= Ac
6b: R= Cl, R1= Ac
R
R
 
 
 
cis-3-Acetoxy-N-(4-methoxyphenyl)-4-phenylazetidin-2-one (8a): white solid, mp 153-155 oC. 1H NMR 
(250 MHz, CDCl3) δ 7.34-7.30 (5H, m), 7.28 (2H, d, J = 8.9 Hz), 6.79 (2H, d, J = 8.9 Hz), 5.92 (1H, d, J = 
4.8 Hz), 5.33 (1H, d, J = 4.8 Hz), 3.74 (3H, s), 1.66 (3H, s); 13C NMR (63 MHz, CDCl3) δ 169.1, 161.2, 
156.5, 132.2, 130.2, 128.7, 128.4, 127.8, 118.7, 61.3, 55.3, 19.7. 
 
cis-3-Acetoxy-4-(2-chlorophenyl)-N-(4-methoxyphenyl)azetidin-2-one (8b): white solid, mp 130-132oC. 
1H NMR (250 MHz, CDCl3) δ 7.43 (1H, d, J = 8.9 Hz), 7.32-7.23 (5H, m), 6.83 (2H, d, J = 8.9 Hz), 6.16 
(1H, d, J = 5.0 Hz), 5.78 (1H, d, J = 5.0 Hz), 3.76 (3H, s), 1.76 (3H, s); 13C NMR (63 MHz, CDCl3) δ 168.6, 
161.3, 156.6, 133.8, 130.1, 129.9, 129.7, 128.6, 126.7, 118.5, 114.4, 75.4, 58.1, 55.3, 19.8. 
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6.1.4 Hydrolysis of N-Aryl Protected β-Lactam 8 
To a solution of 8b (1.23 g, 3.56 mmol) in 30 mL of acetone was added a solution of KOH (200 
mg, 3.56 mmol)  in 10 mL of MeOH at 0oC. The hydrolysis was complete after the addition of 
KOH/MeOH as indicated by TLC. The reaction was quenched by adding an equal volume of water upon 
which the product precipitated out of solution. The product was filtered and dried to give 1.07 g of the 
product in 99% yield. 
 
N
O
AcOH H
8a: R=H
8b: R=Cl
OCH3
N
O
HOH H
9a: R=H
9b: R=Cl
OCH3
KOH/MeOH
Acetone 
0 oC
93-100%
R R
 
 
cis-3-Hydroxy-N-(4-methoxyphenyl)-4-phenylazetidin-2-one (9a): white solid, mp 183-184oC. 1H NMR 
(250 MHz, CDCl3) δ 7.48 (1H, d, J = 7.5 Hz), 7.33-7.22 (5H, m), 6.84 (2H, d, J = 8.9 Hz), 5.63 (1H, d, J = 
5.1 Hz), 5.33 (1H, d, J = 5.1 Hz), 4.88 (1H, brs), 3.78 (3H, s); 13C NMR (63 MHz, DMSO-d6) δ 166.6, 
156.1, 133.1, 132.9, 130.9, 129.7, 129.6, 128.9, 127.3, 118.6, 114.9, 77.2, 60.0, 55.6. 
 
cis-4-(2-Chlorophenyl)-3-hydroxy-N-(4-methoxyphenyl)azetidin-2-one (9b): white solid, mp 193-
194oC. 1H NMR (250 MHz, CDCl3) δ 7.48 (1H, d, J = 7.5 Hz), 7.33-7.22 (5H, m), 6.84 (2H, d, J = 8.9 Hz), 
5.63 (1H, d, J = 5.1 Hz), 5.33 (1H, d, J = 5.1 Hz), 4.88 (1H, brs), 3.78 (3H, s); 13C NMR (63 MHz, DMSO-
d6) δ 166.6, 156.1, 133.1, 132.9, 130.9, 129.7, 129.6, 128.9, 127.3, 118.6, 114.9, 77.2, 60.0, 55.6. 
 
 
6.1.5 Substitution of Sulfonate at C3 Lactam 
N
O
HOH H
9a
OCH3
N
O
R1SO2OH H
10
OCH3
NaH, CH2Cl2
sulfonyl chloride
0 oC-r.t
10a: R1 =
Me
Ph
10b: R1 =
10c: R1 =
75%
93%
84%  
 
Synthesis of cis-N-(4-Methoxyphenyl)-3-methylsulfonyl-4-phenylazetidin-2-one (10b): Compound 9a 
(269 mg, 1.00 mmol) was dissolved in dry CH2Cl2 (15 mL), and 60 mg (1.50 mmol) of NaH (60% in 
mineral oil, unwashed) was added. After stirring for 30 min at room temperature the resulting solution was 
then added dropwise methanesulfonyl chloride (115 mg, 1.00 mmol). The resulting solution was stirred at 
rt for 30 min. The solution was washed with brine (3 x 15 mL). The organic layer was dried with anhydrous 
MgSO4, filtered, and evaporated, and the residue was washed with cold MeOH to give 267 mg of 10b as a 
white solid in 93 % yield, mp 158-160°C. 1H NMR (250 MHz, CDCl3) δ 7.48 (2H, d, J = 7.8 Hz), 7.39-
7.26 (7H, m), 6.85 (2H, d, J = 8.7 Hz), 5.94 (1H, d, J = 5.1 Hz), 5.82 (1H, d, J = 5.1 Hz), 3.75 (3H, s), 3.02 
(3H, s); 13C NMR (63 MHz, CDCl3) δ 163.2, 157.3, 132.5, 131.8, 130.2, 129.8, 129.3, 129.1, 128.5, 128.1, 
119.4, 114.9, 102.1, 79.8, 61.9, 55.9, 39.2. 
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cis-N-(4-Methoxyphenyl)-4-phenyl-3-(4-toluenesulfonyl)azetidin-2-one (10a): White solid, mp 148-
151°C, 75% yield. 1H NMR (250 MHz, CDCl3) δ 7.46 (2H, d, J = 7.9 Hz), 7.36-7.28 (8H, m), 6.77 (2H, d, 
J = 8.5 Hz), 5.78 (1H, d, J = 4.9 Hz), 5.28 (1H, d, J = 4.9 Hz), 3.73 (3H, s), 2.43 (3H, s); 13C NMR (63 
MHz, CDCl3) δ 161.2, 157.6, 147.2, 138.8, 133.4, 131.9, 130.2 (2C), 129.3, 128.5, 128.2, 127.8 (2C), 
127.4 (2C), 119.1 (2C), 114.9 (2C), 79.6, 58.1, 55.8, 22.1. 
 
cis-3-Benzenesulfonyl-N-(4-methoxyphenyl)-4-phenylazetidin-2-one (10c): White solid, mp 162-165°C, 
84 % yield. 1H NMR (250 MHz, CDCl3) δ 8.05 (2H, d, J = 4.0 Hz), 7.75-7.60 (5H, m), 7.50-7.18 (5H, m), 
6.79 (2H, d, J = 8.6 Hz), 5.90 (1H, d, J = 5.0 Hz), 5.77 (1H, d, J = 5.0 Hz), 3.74 (3H, s); 13C NMR (63 
MHz, CDCl3) δ 160.7, 157.6, 136.2, 134.5, 133.2, 132.1, 129.6, 129.2, 128.5, 128.2, 127.8 (2C), 127.1 
(2C), 119.3 (2C), 114.8 (2C), 79.6, 62.1, 55.8. 
 
 
6.1.6  N-Dearylation of N-(4-Methoxyphenyl) Substituted Lactams  
 
N
O
R1SO2OH H
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O H
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10 11
OCH3
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To a solution of lactam 10b (0.347 g, 1.00 mmol) in CH3CN (10 mL) at 0 oC was added dropwise 
a solution of ceric ammonium nitrate (1.64 g, 3.00 mmol) in 14.9 mL of water within 20 mins. The reaction 
was stirred for another 15 min and then diluted with EtOAc (30 mL). The resulting solution was washed 
with water (30 mL) extracting with EtOAc (4 × 30 mL). The combined organic layer was then washed with 
5% NaHCO3 (30 mL), extract the aqueous layer with EtOAc (30 mL) twice. The combined organic layer 
was washed with 10% NaHSO3 (2 x 30 mL) till the aqueous layer became clear. Finally organic was 
washed with 5% NaHCO3 (30 mL) and brine (30 mL). The organic layer was dried with anhydrous MgSO4, 
filtered, and evaporated, and the residue was chromatographed on silica gel (1:2 EtOAc/hexanes) to give 
0.216 g of 11b as yellow oil in 90% yield. 1H NMR (250 MHz, CDCl3) δ 7.36-7.19 (5H, m), 6.58 (1H, brs), 
5.71 (1H, d, J = 4.9 Hz), 4.99 (1H, d, J = 4.9 Hz), 2.68 (3H, s); 13C NMR (63 MHz, CDCl3) δ 164.7, 134.2, 
129.6, 129.1, 128.7, 128.5, 127.8, 81.7, 58.2, 39.2. 
 
cis-4-Phenyl-3-(4-toluenesulfonyl)azetidin-2-one (11a): Yellow oil, 85% yield. 1H NMR (250 MHz, 
CDCl3) δ 7.45-7.18 (9H, m), 6.41 (1H, brs), 5.69 (1H, d, J = 2.4 Hz), 4.95 (1H, d, J = 4.7 Hz), 2.41 (3H, s); 
13C NMR (63 MHz, CDCl3) δ 164.3, 136.1, 134.6, 134.4, 130.0, 129.3, 129.0, 128.5, 128.3, 128.2, 126.6 
(2C), 125.1 (2C), 81.6, 58.5. 
 
cis-3-Benzenesulfonyl-4-phenylazetidin-2-one (11c): Yellow oil, 88% yield. 1H NMR (250 MHz, CDCl3) 
δ 8.05 (1H, d, J = 8.0 Hz), 7.78-7.63 (6H, m), 7.48-7.20 (3H, m), 6.42 (1H, brs), 5.83 (1H, d, J = 4.8 Hz), 
5.41 (1H, d, J = 4.8 Hz); 13C NMR (63 MHz, CDCl3) δ 164.2, 136.0, 134.5, 134.3, 129.6, 129.2, 128.9, 
128.5, 128.2, 128.1, 127.3, 127.1, 116.5, 81.5, 58.4. 
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6.1.7 Procedure for the N-Methylthiolation of Lactams 3 
N
O H
R1SO2O H H
N
O
O
SCH3
iPr2EtN, 
CH2Cl2, reflux
N
O SCH3
R1SO2O H H
11 3
14
11a: R1 =
Me
Ph
11b: R1 =
11c: R1 =
3a: R1 =
Me
Ph
3b: R1 =
3c: R1 =
74%
64%
72% 
 
Compound 11b (0.240 g, 1.00 mmol) was dissolved in dry CH2Cl2 (8 mL), and the solution of N-
methylthiophthalimide (0.194 g, 1.00 mmol) in dry CH2Cl2 (4 mL) was added. To the resulting solution 
was then added triethylamine (3 drops). The reaction was refluxed for 2 h and then diluted with CH2Cl2 (20  
mL). The resulting solution was washed with 1% aqueous KOH (2 x 20 mL). The organic layer was dried 
with anhydrous MgSO4, filtered, and evaporated, and the residue was chromatographed (1:3 
EtOAc/hexanes) to give 206 mg of 3b as a yellow solid in 64 % yield. 1H NMR (250 MHz, CDCl3) δ 7.47-
7.26 (5H, m), 5.91 (1H, d, J = 5.3 Hz), 5.54 (1H, d, J = 5.3 Hz), 2.96 (3H, s), 2.53 (3H, s); 13C NMR (63 
MHz) δ 165.7, 133.2, 129.4, 129.0, 128.7, 127.4, 126.0, 79.9, 60.9, 38.0, 20.9. 
 
cis-N-(Methylthio)-4-phenyl-3-(4-toluene-sulfonyl)azetidin-2-one (3a): Yellow solid, mp 85-87°C, 74% 
yield. 1H NMR (250 MHz, CDCl3) δ 7.41-7.26 (5H, m), 7.19-7.15 (4H, m), 5.74 (1H, d, J = 5.0 Hz), 4.88 
(1H, d, J = 5.0 Hz), 2.40 (3H, s), 2.35 (3H, s); 13C NMR (63 MHz, CDCl3) δ 166.4, 145.3, 132.4, 132.0, 
129.8, 129.2, 129.0, 128.5, 127.8 (2C), 126.8 (2C), 80.6, 66.0, 22.1, 21.7.  
  
cis-3-Benzenesulfonyl-N-methylthio-4-phenylazetidin-2-one (3c): Yellow oil, 72% yield. 1H NMR (250 
MHz, CDCl3) δ 7.64-7.57 (3H, m), 7.45-7.39 (2H, m), 7.30-7.21 (5H, m), 5.85 (1H, d, J = 5.1 Hz), 5.46 
(1H, d, J = 5.1 Hz), 2.43 (3H, s); 13C NMR (63 MHz, CDCl3) δ 165.2, 134.5, 133.5, 133.2, 129.2, 128.9, 
128.7, 128.2, 128.0, 127.8, 127.6, 126.7, 125.8, 80.0, 60.8, 20.8.  
 
 
6.1.8 Preparation of Sulfur-Transfer Reagents: N-methylthiophthalimide 14 
In a mixture of pyridine (30 mL) and acetonitrile (38 mL) containing disulfide (41 mmol) and 
phthalimide (41 mmol) at 0 oC, bromine (1.2 eq. 49 mmol in 49 mL of acetonitrile) was added dropwise at 
0°C while stirring within 1 hr. After another 1 hr of stirring, water (150 mL) was added to the solution over 
30 mins and allowed to stand for 1 hr to precipitate the product from the solution. The compound was 
filtered off and recrystalized in MeOH to give the product 14 in 80 % yield as a white solid, mp 176-177 oC.  
 
NH
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O
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S
CH3
14  
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6.1.9 Fluorescent lactam 18 
 
N
O
HOH H
9a
OCH3
N
O
R1SO2OH H
10
OCH3
NaH, CH2Cl2
Dansyl chloride
0 oC-r.t
10d: R1 =
N
 
 
 
cis-4-(2-Chlorophenyl)-3-dansyl-N-(4-methoxyphenyl)-4-(2-chlorophenyl)azetidin-2-one (10d): 
Yellow solid, 55% yield. 1H NMR (250 MHz, CDCl3) δ 7.64-7.57 (3H, m), 7.45-7.39 (2H, m), 7.30-7.21 
(5H, m), 5.85 (1H, d, J = 5.1 Hz), 5.46 (1H, d, J = 5.1 Hz), 2.43 (3H, s), 1.29 (s, 6H); 13C NMR (63 MHz, 
CDCl3) δ 165.2, 134.5, 133.5, 133.2, 129.2, 128.9, 128.7, 128.2, 128.0, 127.8, 127.6, 126.7, 125.8, 80.0, 
60.8. 
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cis-3-Acetoxy-4-(2-chlorophenyl)azetidin-2-one (15): Yellow oil, 93% yield. 1H NMR (250 MHz, CDCl3) 
δ  7.30-7.21 (4H, m), 5.85 (1H, d, J = 5.1 Hz), 5.46 (1H, d, J = 5.1 Hz), 2.16 (3H, s); 13C NMR (63 MHz, 
CDCl3) δ 173.2, 165.2, 134.5, 129.2, 128.9, 128.7, 127.8, 126.7, 80.0, 60.8, 17.8.  
 
cis-3-Acetoxy-4-(2-chlorophenyl)-N-methylthio-azetidin-2-one (16): Yellow solid, 84% yield. 1H NMR 
(250 MHz, CDCl3) δ 7.30-7.21 (4H, m), 5.85 (1H, d, J = 5.1 Hz), 5.46 (1H, d, J = 5.1 Hz), 2.43 (3H, s), 
2.10 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 173.2, 168.2, 135.5, 129.2, 128.9, 128.5, 127.9, 126.7, 80.0, 
60.8, 22.0, 16.8. 
 
cis-4-(2-Chlorophenyl)-3-hydroxy-N-methylthio-azetidin-2-one (17): Yellow solid, 84% yield. 1H NMR 
(250 MHz, CDCl3) δ.30-7.21 (5H, m), 5.26 (1H, d, J = 5.2 Hz), 5.20 (1H, d, J = 5.2 Hz), 2.42 (3H, s); 13C 
NMR (63 MHz, CDCl3) δ 175.2, 168.2, 135.5, 129.2, 128.9, 128.5, 127.9, 126.7, 80.0, 60.8, 22.0. 
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cis-4-(2-Chlorophenyl)-3-dansyl-N-methylthio-azetidin-2-one (18): Yellow solid, 55% yield. 1H NMR 
(250 MHz, CDCl3) δ 7.64-7.57 (3H, m), 7.45-7.39 (2H, m), 7.30-7.21 (5H, m), 5.85 (1H, d, J = 5.1 Hz), 
5.46 (1H, d, J = 5.1 Hz), 2.43 (3H, s), 1.29 (s, 6H); 13C NMR (63 MHz, CDCl3) δ 165.2, 134.5, 133.5, 
133.2, 129.2, 128.9, 128.7, 128.2, 128.0, 127.8, 127.6, 126.7, 125.8, 80.0, 60.8, 22.1. 
 
 
6.1.10 Amino-Substituted Lactam 
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Conditions: a.) P2O5, DMSO; b.) RR`NH, NaBH(OAc)3, AcOH, ClCH2CH2Cl; c.) (NH4)2Ce(NO3)6, 
MeCN-H2O, 0 oC; d.) N-methylthiophthalimide, triethylamine, CH2Cl2, reflux. 
 
 
Synthesis of trans-4-(2-Chlorophenyl)-3-cyclopentylamino-N-(4-methoxyphenyl)azetidin-2-one (21a): 
Cyclopentylamine (35.6 mg, 0.33 mmol) and compound 20 (100 mg, 0.33 mmol) were mixed in 
ClCH2CH2Cl (1.32 mL) and then treated with sodium triacetoxyborohydride (98.6 mg, 0.465 mmol) and 
AcOH (19.8 mg, 0.33 mmol). The mixture was stirred at rt under a N2 atmosphere for 1 h until the reactants 
were consumed completely. The reaction mixture was quenched by adding 1 N NaOH, and the product was 
extracted with ether. The ether extract was washed with brine and dried with MgSO4. The solvent was 
evaporated to give 21a in 88% yield.  
 
trans-4-(2-Chlorophenyl)-3-cyclopentylamino-N-(4-methoxyphenyl)azetidin-2-one (21a): 1H NMR 
(250 MHz, CDCl3) δ 7.30-7.19 (4H, m), 6.90 (2H, d, J = 8.8 Hz), 6.69 (2H, d, J = 8.8 Hz), 4.97 (2H, s), 
3.78 (1H, brs), 3.69 (3H, s), 1.71 (4H, m), 1.33 (4H, m); 13C NMR (63 MHz, CDCl3) δ 165.8, 157.9, 140.2, 
133.2, 130.5, 130.4, 129.5, 129.2, 127.6, 127.4, 119.5, 114.7, 55.4, 50.0, 48.4, 42.8, 33.3, 33.2, 27.9, 27.8. 
 
trans-3-Benzylamino-4-(2-chlorophenyl)-N-(4-methoxyphenyl)azetidin-2-one (21b): 1H NMR (250 
MHz, CDCl3) δ 7.27-7.12 (9H, m), 6.93 (1H, d, J = 8.8 Hz), 6.70 (1H, d, J = 8.8 Hz), 4.96 (2H, s), 4.23 
(2H, d, J = 6.0 Hz), 3.69 (3H, s); 13C NMR (63 MHz, CDCl3) δ 164.0, 161.7, 159.4, 137.8, 134.3, 134.1, 
133.9, 133.8, 130.4, 129.4, 129.0, 128.4, 128.2, 127.9, 127.4, 127.1, 119.0, 114.6, 55.7, 53.4, 51.7, 43.5. 
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trans-4-(2-Chlorophenyl)-3-diethylamino-N-(4-methoxyphenyl)azetidin-2-one (21c): 1H NMR (250 
MHz, CDCl3) δ 7.31-7.10 (4H, m), 6.95 (2H, d, J = 8.8 Hz), 6.65 (2H, d, J = 8.8 Hz), 5.00 (2H, s), 3.67 
(3H, s), 3.18 (2H, q, J = 7.0 Hz), 3.09 (2H, q, J = 7.1 Hz), 1.14  (3H, t, J = 7.0 Hz), 0.60 (3H, t, J = 7.1 Hz); 
13C NMR (63 MHz, CDCl3) δ 165.9, 164.2, 160.7, 134.2, 132.2, 131.1, 129.7, 129.4, 127.5, 114.5, 55.8, 
49.3, 42.3, 37.8, 14.0, 12.2.  
 
trans-3-(2-Chlorophenyl)-3-diisobutylamino-N-(4-methoxyphenyl)azetidin-2-one (21d): 1H NMR (250 
MHz, CDCl3) δ 7.31-7.20 (4H, m), 6.96 (2H, d, J = 8.8 Hz), 6.65 (2H, d, J = 8.8 Hz), 4.98 (2H, s), 3.68 
(3H, s), 2.90 (4H, t, J = 6.6 Hz), 1.90 (1H, m), 1.45 (1H, m), 0.76 (6H, d, J = 6.6 Hz), 0.35 (6H, d, J = 6.6 
Hz); 13C NMR (63 MHz, CDCl3) δ 163.1, 156.2, 136.9, 135.2, 134.2, 134.1, 130.2, 129.4 127.5, 122.3, 
122.2, 114.2, 114.0, 71.9, 60.0, 56.2, 55.0, 41.6, 28.3, 26.8, 20.6, 20.5, 20.3, 20.2. 
 
Procedure for the N-Dearylation of N-(4-Methoxyphenyl)substituted Lactams (22a): To a solution of 
lactam 21a (0.375 g, 1.00 mmol) in CH3CN (2.2 mL) at rt was added dropwise a solution of ceric 
ammonium nitrate (1.64 g, 3.00 mmol) in 1.5 mL of water. The reaction was stirred for 5 min and then 
diluted with EtOAc (20 mL). The resulting solution was washed sequentially with water (20 mL), 5% 
NaHCO3 (2 x 20 mL), 5% NaHSO3 (2 x 20 mL) and brine (20 mL). The organic layer was dried with 
anhydrous MgSO4, filtered, and evaporated, and the residue was chromatographed on silica gel (1:2 
EtOAc/hexanes) to give 0.224 g of 22a as yellow oil in 85% yield.  
 
trans-4-(2-Chlorophenyl)-3-propylaminoazetidin-2-one (22a): 1H NMR (250 MHz, CDCl3) δ 7.88 (1H, 
brs), 7.31- 7.12 (4H, m), 4.73 (1H, d, J = 6.5 Hz), 4.49 (1H, d, J = 6.4 Hz), 3.83 ( 1H, brs), 1.84 (4H, m), 
1.43 (4H, m); 13C NMR (63 MHz, CDCl3) δ 179.5, 140.4, 133.2, 130.4, 129.5, 129.2, 127.6, 55.4, 42.7, 
42.5, 33.3, 33.2, 27.9, 27.6. 
 
trans-3-Benzylamino-4-(2-chlorophenyl)azetidin-2-one (22b): clear oil, 91% yield. 1H NMR (250 MHz, 
CDCl3) δ 7.78 (1H, brs), 7.33-7.16 (9H, m), 4.53 (1H, d, J = 6.3 Hz), 4.42 (1H, d, J = 6.1 Hz); 13C NMR 
(63 MHz, CDCl3) δ 187.6, 160.0, 137.0, 134.7, 130.4, 130.3, 130.1, 130.0, 129.7, 129.6, 129.2, 128.3, 
127.6, 55.7, 51.8, 43.6.   
 
trans-4-(2-Chlorophenyl)-3-diethylaminoazetidin-2-one (22c): clear oil, 84% yield.  1H NMR (250 MHz, 
CDCl3) δ 7.62 (1H, brs), 7.28-7.19 (4H, m), 4.75 (1H, d, J = 5.2 Hz), 4.49 (1H, d, J = 5.2 Hz), 3.18 (2H, q, 
J = 7.1 Hz), 3.09 (2H, q, J = 7.2 Hz), 1.15 (6H, t, J = 7.1 Hz); 13C NMR (63 MHz, CDCl3) δ 165.9, 134.2, 
132.2, 131.1, 129.7, 129.4, 127.5, 55.8, 49.3, 42.3, 37.8, 14.0, 12.2. 
 
trans-4-(2-Chlorophenyl)-3-diisobutylamino-azetidin-2-one (22d): clear oil, 87 % yield. 1H NMR (250 
MHz, CDCl3) δ 7.31-7.20 (4H, m), 6.96 (2H, d, J = 8.8 Hz), 6.65 (2H, d, J = 8.8 Hz), 4.98 (2H, s), 3.68 
(3H, s), 2.90 (4H, t, J = 6.6 Hz), 1.90 (1H, m), 1.45 (1H, m), 0.76 (6H, d, J = 6.6 Hz), 0.35 (6H, d, J = 6.6 
Hz); 13C NMR (63 MHz, CDCl3) δ 163.1, 136.9, 135.2, 134.1, 130.2, 129.4 127.5, 71.9, 56.2, 55.0, 41.6, 
28.3, 26.8, 20.6, 20.5, 20.3, 20.2. 
 
Procedure for the synthesis of N-methylthio lactams (19a): To a solution of 22a (0.035 g, 0.133 mmol) 
in benzene was added N-methylthiophthalimide (0.025 g, 0.133 mmol) and 1 drop of triethylamine. The 
mixture was refluxed overnight and washed with 1% KOH. The organic layer was dried over Na2SO4 and 
the solvent was removed under reduced pressure. The crude material was purified by column 
chromatography (1:4 EtOAc/hexanes) to yield 0.028 g of 19a in 68% yield.  
 
trans-N-Methylthio-3-propylaminoazetidin-2-one (19a): yellow oil, 72% yield. 1H NMR (250 MHz, 
CDCl3) δ 7.33-7.16 (4H, m), 4.51 (1H, d, J = 6.4 Hz), 3.84 (1H, brs), 2.41 (3H, s), 1.85 (4H, m), 1.47 (4H, 
m); 13C NMR (63 MHz, CDCl3) δ 189.5, 140.2, 133.2, 130.4, 129.5, 127.6, 127.4, 48.8, 47.7, 42.7, 33.3, 
33.2, 27.8, 27.7, 20.2. 
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trans-3-Benzylamino-N-methylthioazetidin-2-one (19b): clear oil, 69 % yield. 1H NMR (250 MHz, 
CDCl3) δ 7.25-7.05 (6H, m), 6.61 (3H, m), 4.53 (1H, d, J = 6.3 Hz), 4.42 (1H, d, J = 6.1 Hz), 2.41 (3H, s); 
13C NMR (63 MHz, CDCl3) δ 187.5, 160.0, 137.0, 134.7, 130.4, 130.3, 130.1, 130.0, 129.7, 129.6, 129.2, 
128.3, 127.6, 55.7, 51.8, 43.6, 19.4. 
 
trans-3-Diethylamino-N-methylthioazetidin-2-one (19c): clear oil, 70 % yield. 1H NMR (250 MHz, 
CDCl3) δ 7.62 (1H, brs), 7.28-7.19 (4H, m), 4.75 (1H, d, J = 5.2 Hz), 4.49 (1H, d, J = 5.2 Hz), 3.18 (2H, q, 
J = 7.1 Hz), 3.09 (2H, q, J = 7.2 Hz), 2.41 (3H, s), 1.15 (6H, t, J = 7.1 Hz); 13C NMR (63 MHz, CDCl3) δ 
175.2, 134.5, 129.2, 128.9, 128.7, 128.2, 127.8, 60.8, 54.2, 48.6, 26.2, 25.8, 20.8, 11.4, 11.3. 
 
trans-3-Diisobutylamino-N-methylthioazetidin-2-one (19d): 1H NMR (250 MHz, CDCl3) δ 7.28-7.13 
(4H, m), 4.48 (2H, d, J = 6.2 Hz), 3.59 (2H, d, J = 7.5 Hz), 3.13 (2H, d, J = 7.5 Hz), 1.99 (1H, m) 1.96 (1H, 
m), 0.81 (12H, m); 13C NMR (63 MHz, CDCl3) δ 173.1, 140.2, 136.9, 130.2, 129.4 127.5, 127.2, 49.9, 48.2, 
41.6, 41.3, 39.2, 27.3, 26.8, 23.5, 23.4, 20.2.  
 
6.1.11 Synthesis of Azido Lactam 19e 
 
N
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O
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O
Cl
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9b
24 19e
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1) NaH, MsCl, CH2Cl2
    2)  NaN3, DMF
NSCH3
O
O
Hunig's base, CH2Cl2 
            reflux
 
 
trans-3-Azido-4-(2-chlorophenyl)-N-(4-methoxyphenyl)azetidin-2-one (23): To a solution of β-lactam 
9b (795 mg, 2.5 mmol) in 20 mL of dry CH2Cl2 was added NaH (60% suspension in mineral oil, 125 mg, 5 
mmol) and the mixture was stirred for 15 min. Methanesulfonyl chloride (342 mg, 3 mmol) was then added 
dropwise to the solution, and the resulting solution was stirred at rt for 30 min. The solution was washed 
with brine (3×25 mL), and the organic layer was dried with anhydrous MgSO4, filtered, and evaporated, 
and the residue was washed with cold MeOH to give 830 mg as a white solid in 82% yield. To the solution 
of above compound (405 mg, 1 mmol) in dry DMF was added NaN3 (195 mg, 3 mmol) and the resulting 
solution was heated to 80oC for 24 hr. After cooling to rt, the solution was concentrated under vacuum. The 
crude compound was dissolved in EtOAc and washed with water (3×20 mL), and the organic layer was 
dried with MgSO4, filtered, and evaporated to give 23 in 81% yield. 1H NMR (250 MHz, CDCl3) δ 7.24-
7.10 (4H, m), 6.80-6.74 (2H, m), 5.24 (1H, d, J = 1.8 Hz), 4.44 (1H, d, J = 1.8 Hz), 3.70 (3H, s); 13C NMR 
(63 MHz, CDCl3) δ 164.2, 156.2, 142.5, 133.5, 132.2, 128.9, 128.7, 128.2, 127.9, 126.8, 121.9, 121.5, 
114.2, 113.8, 60.8, 52.2. 
 
trans-3-Azido-4-(2-chlorophenyl)azetidin-2-one (24): 1H NMR (250 MHz, CDCl3) δ 7.38-7.19 (4H, m), 
6.20 (1H, brs), 4.90 (1H, d, J = 1.8 Hz), 4.33 (1H, d, J = 1.8 Hz); 13C NMR (63 MHz, CDCl3) δ 172.1, 
142.3, 132.2, 128.4, 128.2, 128.0, 126.7, 64.2, 44.3. 
 
trans-3-Azido-4-(2-chlorophenyl)-N-methylthio-azetidin-2-one (19e): 1H NMR (250 MHz, CDCl3) δ 
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7.35-7.19 (4H, m), 5.74 (1H, d, J = 1.8 Hz), 4.95 (1H, d, J = 1.8 Hz), 2.37 (3H, s); 13C NMR (63 MHz, 
CDCl3) δ 168.2, 142.5, 133.5, 128.9, 128.7, 128.2, 128.0, 60.8, 52.2, 20.8. 
 
6.1.12 Synthesis of Boc-Protected Lactam 25 
 
N
O
Cl
SCH3
HO
17
DMAP, CH2Cl2
N
O SCH3
OH H
25
Cl
COOH
NH2
COOH
NHBoc
Boc2O, NaOH
26
26,   EDCI O
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cis-3-(2-tert-Butoxycarbonylaminopropionic-ester)-4-(2-chlorophenyl)-N-methylthio-azetidin-2-one 
(25): 1H NMR (250 MHz, CDCl3) δ 7.35-7.19 (4H, m), 5.74 (1H, d, J = 1.8 Hz), 4.95 (1H, d, J = 1.8 Hz), 
2.37 (3H, s); 13C NMR (63 MHz, CDCl3) δ 168.2, 142.5, 133.5, 128.9, 128.7, 128.2, 128.0, 60.8, 52.2, 22.8. 
 
 
6.1.13 Racemic Lactam 27 
 
N
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Cl N
O
O
ClO
N
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O
H
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N
O
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OCH3 OCH3
a. b. c.
Conditions: a.) Acryloyl chloride, NaH, CH2Cl2; b.) ceric ammonium nitrate, CH3CN, H2O, 0 oC; c.) N-methylthio 
phthalimide, CH2Cl2, Hunig's base, reflux.
9b 273130
 
 
Synthesis of cis-3-Acryloyloxy-4-(2-chlorophenyl)-N-(4-methoxyphenyl)azetidin-2-one (30): To a 
solution of β-lactam 9b (2.94 g, 9.7 mmol) in 15 mL of dry CH2Cl2 was added NaH (60 % suspension in 
mineral oil, 582 mg, 14.55 mmol) and the mixture was stirred for 15 min. Acryloyl chloride (1.05 g, 11.6 
mmol) was then added dropwise. The mixture was stirred at r.t for 30 min until the TLC indicating the 
disapperarance of the starting material. The reaction was washed with water twice and combined organic 
layers were dried with MgSO4. The crude material was purified by column chromatography on silica gel 
(CH2Cl2) to give 2.94 g of 30 in 85% as colorless oil. 1H NMR (250 MHz, CDCl3) δ 7.45-7.22 (6H, m), 
6.88 (2H, d, J = 8.8 Hz), 6.31 (1H, d, J = 4.8 Hz), 6.11 (1H, dd, J = 4.8, 15.2Hz), 5.85 (1H, dd, J = 4.9, 
15.4 Hz), 5.81 (1H, d, J = 5.0 Hz), 5.71 (1H, dd, J = 4.8, 15.2 Hz), 3.72 (3H, s). 13C NMR (400 MHz, 
CDCl3) δ 163.9, 161.6, 159.9, 132.5, 130.5, 130.3, 130.0, 128.8, 127.8, 127.0, 126.7, 119.0, 118.9, 114.7, 
114.4, 58.5, 55.6, 30.0. 
 
Procedure for Synthesis of cis-3-Acryloyloxy-4-(2-chlorophenyl)azetidin-2-one (31): To a solution of 
30 (0.25 g, 0.70 mmol) in 7.5 mL of CH3CN at 0 oC was added a solution of ceric ammonium nitrate (1.15 
g, 2.10 mmol) dissolved in 10.4 mL of water dropwise within 20 min. The reaction was 
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allowed to stir at 0 oC for another 20 min, and then was quenched by the addition of 25 mL of water and 
extracted with EtOAc (4 × 25 mL). The combined organic layers were washed with 25 mL of 5% of 
NaHCO3, 10% of NaHSO3 (twice) and brine, and then dried over MgSO4. The solvent was removed under 
reduced pressure to yield, and the crude product was purified by column chromatography (1:1 
EtOAc/hexanes) to give 0.16 g of 31 in 90% as a yellowish oil. 1H NMR (400 MHz, CDCl3) δ 7.41-7.22 
(4H, m), 6.59 (1H, bs), 6.21 (1H, d, J = 5.0 Hz), 6.08 (1H, dd, J = 2.4, 10.8 Hz), 6.04 (1H, dd, J = 2.4, 10.0 
Hz), 5.80 (1H, dd, J = 2.4, 10.8 Hz), 5.39 (1H, d, J = 4.8 Hz). 13C NMR (400 MHz, CDCl3) δ 164.8, 159.9, 
132.5, 130.5, 128.8, 127.8, 127.0, 119.0, 118.9, 114.7, 58.5, 55.6. 
 
Procedure for synthesis of cis-3-Acryloyloxy-4-(2-chlorophenyl)-N-mehylthioazetidin-2-one (27): To a 
solution of 31 (414.5 mg, 1.65 mmol) in dry CH2Cl2 was added N-methylthiophthalimide 14 (287 mg, 1.48 
mmol) and Hunig’s base (640 mg, 4.95 mmol). The mixture was refluxed overnight and washed with 1% of 
KOH. The organic layer was dried over MgSO4. The solvent was removed under reduced pressure to yield, 
and the crude product was purified by column chromatography (1:1 EtOAc/hexanes) to give 400 mg of 27 
in 82 % as white solid. 1H NMR (400 MHz, CDCl3) δ 7.31-7.20 (4H, m), 6.15 (1H, d, J = 3.6 Hz), 5.98 (1H, 
dd, J = 2.4, 11.6 Hz), 5.75 (1H, dd, J = 2.2, 9.2 Hz), 5.62 (1H, dd, J = 2.4, 9.6 Hz), 5.47 (1H, d, J = 3.2 Hz), 
2.45 (3H, s).13C NMR (250 MHz, CDCl3) δ 168.5, 163.6, 132.8, 132.5, 130.7, 130.0, 129.7, 128.8, 126.9, 
126.8, 62.4, 55.4, 22.1. 
 
6.1.14 Enantiopure Acrylate Lactams (+)-27 and (-)-27 
 
N
AcO
O
OCH3
N
HO
O
OCH3
N
AcO
O
OCH3
+
Lipase PS-30
acetone
phosphate buffer,
 pH 7.2
8b racemic
28 (-) (3S, 4R) 29 (+) (3R 4S)
Cl Cl Cl
 
 
 
(-)-(3S,4R)-4-(2-Chlorophenyl)-3-hydroxy-N-(4-methoxyphenyl)azetidin-2-one (28): white solid, mp 
208 oC;  1 H NMR (250 MHz, CDCl3) δ 7.30-7.24 (6H, m), 6.82 (2H, q, J = 3.0 Hz), 5.60 (1H, d, J = 5.6 
Hz), 5.31 (1H, d, J = 4.4 Hz), 3.75 (3H, s). 
  
(+)-(3R,4S)-3-Acetoxy-4-(2-chlorophenyl)-N-(4-methoxyphenyl)azetidin-2-one (29): white solid. 1H 
NMR (250 MHz, CDCl3) δ 7.37-7.18 (6H, m), 6.74 (2H, d, J = 8.7 Hz), 6.08 (2H, d, J = 4.8 Hz), 5.71 (1H, 
d, J = 4.6 Hz), 3.68 (3H, s), 1.68 (3H, s). 
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(-)-(3S,4R)-3-Acryloyloxy-4-(2-chlorophenyl)-N-(4-methoxyphenyl)azetidin-2-one (32): white solid, 98 
% yield. 1 H NMR (250 MHz, CDCl3) δ 7.34-7.19 (6H, m), 6.76 (2H, d, J = 5.0 Hz), 6.20 (1H, dd, J = 5.0 
Hz), 6.03 (1H, dd, J = 5.0, 15.4 Hz), 5.76 (1H, d, J = 4.9 Hz), 5.71 (1H, dd, J = 4.6, 15.2 Hz,), 5.60 (1H, d, 
J = 4.97 Hz), 3.70 (3H, s). 
 
(-)-(3S,4R)-3-Acryloyloxy-4-(2-chlorophenyl)azetidin-2-one (33): yellow oil, 91 % yield. 1H NMR (250 
MHz, CDCl3) δ 7.29-7.19 (4H, m), 6.36 (1H, bs), 6.20 (1H, dd, J = 4.8 Hz), 6.01 (1H, dd, J = 5.6 Hz), 5.73 
(1H, d, J = 4.9 Hz), 5.66 (1H, dd, J = 5.2 Hz), 5.38 (1H, d, J = 4.8 Hz). 
 
(-)-(3S,4R)-3-Acryloyloxy-4-(2-chlorophenyl)-N-methylthio)azetidin-2-one ((-)-27): light yellow solid, 
78 % yield. 1 H NMR (250 MHz, CDCl3) δ 7.29-7.19 (4H, m), 6.12 (1H, dd, J = 4.8, 15.0 Hz), 6.00 (1H, dd, 
J = 5.6, 15.2 Hz), 5.73 (1H, d, J = 4.9 Hz), 5.64 (1H, dd, J = 5.2, 15.2 Hz), 5.43 (1H, d, J = 4.8 Hz), 2.43 
(3H, s). 
 
 
  
125
N
O
O
OCH3
acryloyl chloride
NaH, CH2Cl2
rt
98%
35
 14, NEt3,
89% 82%
O
N
O
O SCH3
(+)-27
ON
O
O H
36
OCl ClCl
N
AcO
O
OCH3
29
N
HO
O
34
KOH/MeOH
94%
OCH3
Cl Cl
 CAN/CH3CN
 
 
(+)-(3R,4S)-4-(2-Chlorophenyl)-3-hydroxy-N-(4-methoxyphenyl)azetidin-2-one (34): white solid, mp 
208 oC;  1 H NMR (250 MHz, CDCl3) δ 7.30-7.24 (6H, m), 6.82 (2H, q, J = 3.0 Hz), 5.60 (1H, d, J = 5.6 
Hz), 5.31 (1H, d, J = 4.4 Hz), 3.75 (3H, s). 
 
(+)-(3R,4S)-3-Acryloyloxy-4-(2-chlorophenyl)-N-(4-methoxyphenyl)azetidin-2-one (35): To the 
solution of lactam (50 mg) in 5 ml dry methylene chloride was added NaH (12 mg, 1.5 eq.).  After stirring 
for 15 mins, the solution became light yellow clear and acryloyl chloride (14.85 mg, 1.1 eq.) was added to 
the resulting solution. The solution turned into clear and TLC showed the whole consumption of the 
starting material after another 10-min stirring. The product was purified by column using methylene 
chloride to get rid of the mineral oil. White solid, 98 % yield. 1 H NMR (CDCl3) δ 7.34-7.17 (6H, m), 6.73 
(2H, d, J = 8.8 Hz), 6.2 (1H, dd, J = 5.0 Hz), 6.00 (1H, dd, J = 5.0 Hz), 5.74 (1H, d, J = 4.9 Hz), 5.62 (1H, 
dd, J = 4.9, 15.4 Hz), 4.99 (1H, d, J = 4.9 Hz), 3.68 (3H, s).  
 
(+)-(3R,4S)-3-Acryloyloxy-4-(2-chlorophenyl)azetidin-2-one (36): Light yellow oil, 89 % yield. 1 H 
NMR (CDCl3) δ 7.29-7.19 (4H, m), 6.36 (1H, bs), 6.20 (1H, dd, J = 4.8 Hz), 5.99 (1H, dd, J = 4.95 Hz), 
5.75 (1H, d, J = 4.9 Hz), 5.66 (1H, dd, J = 5.2 Hz), 5.38 (1H, d, J = 4.8 Hz). 
 
(+)-(3R,4S)-3-Acryloyloxy-4-(2-chlorophenyl)-N-(methylthio)azetidin-2-one (+ 27): White solid, 82 % 
yield. 1 H NMR (CDCl3) δ 7.29-7.19 (4H, m), 6.12 (1H, dd, J = 4.8, 15.2 Hz), 5.97 (1H, dd, J = 5.0, 15.2 
Hz), 5.73 (1H, d, J = 4.9 Hz), 5.62 (1H, dd, J = 5.2 Hz), 5.45 (1H, d, J = 4.8 Hz), 2.43 (3H, s). 
  
 
6.1.15 C4-Acrylate Lactam 37 
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Synthesis of cis-4-Acetoxyphenyl-N-(4-methoxyphenyl)imine (42): To a solution of p-anisidine (1.08 g, 
8.81 mmol) in 15 mL of CH2Cl2 was added p-hydroxybenzaldehyde (1.07 g, 8.81 mmol), and a catalytic 
amount of (+)-camphorsulfonic acid. The resultant mixture was stirred until TLC indicated the 
disappearance of starting materials. The resulting compound was used for the next step without further 
purification. To the solution of 4-hydroxyphenyl-N-(4-methoxyphenyl)-imine (1 eq.) was added 2 eq. of 
triethylamine and acetyl chloride (1.5 eq.) was then added dropwise to the solution. The resulting solution 
was stirred at r.t. for 15 mins, and then washed with H2O (2 × 20 mL). The organic layer was dried with 
anhydrous MgSO4, filtered, and evaporated to afford 42 as a light yellow solid in 92% yield, mp 95-96 oC. 
1H NMR (250 MHz, CDCl3) δ 8.39 (1H, s), 7.84 (2H, d, J = 8.5 Hz), 7.20-7.11(4H, m), 6.86 (2H, d, J = 8.8 
Hz), 3.77(3H, s), 2.26 (3H, s). 13C NMR (400 MHz, CDCl3) δ 168.2, 161.2, 159.0, 157.3, 144.4, 129.9(2C), 
128.8, 122.4, 122.2 (2C), 121.7, 114.6 (2C), 55.7, 21.4. 
 
cis-4-(4-propenoyloxyphenyl)-)-3-(methoxy)azetidin-2-one (46): white solid, 78 % yield; mp 94-96 °C; 
1H NMR (250 MHz, CDCl3): δ 7.33 (2H, d, J = 8.4 Hz), 7.09 (2H, d, J = 8.4 Hz), 6.55 (1H, d, J = 17.3 Hz), 
6.26 (1H, dd, J = 17.3, 10.4 Hz), 6.00 (1H, d, J = 10.4 Hz), 4.78 (1H, d, J = 4.5 Hz), 4.68-4.66 (1H, m), 
3.11(3H, s); 13C NMR (63 MHz, CDCl3): δ 168.0, 164.5, 150.5, 133.2, 132.9, 128.8, 127.7, 121.5, 116.0, 
86.6, 58.2, 57.5. 
 
cis-4-(4-propenoyloxyphenyl)-3-methoxy-1-(methylthio)azetidin-2-one (37): white solid; 89 % yield; 
mp 87-88 °C; 1H NMR (250 MHz, CDCl3): δ 7.29 (2H, d, J = 8.4 Hz), 7.08 (2H, d, J = 8.4 Hz), 6.50 (1H, d, 
J = 17.3 Hz), 6.21 (1H, dd, J = 10.3, 17.1 Hz), 5.92 (1H, d, J = 10.4 Hz), 4.75 (1H, d, J = 4.8 Hz), 4.69 (1H, 
d, J = 4.8 Hz), 3.05 (3H, s), 2.26 (3H, s); 13C NMR (63 MHz, CDCl3): δ 170.3, 164.2, 150.9, 132.9, 131.1, 
129.9, 127.7, 121.4, 86.5, 65.5, 58.3, 22.0. 
 
 
6.1.16 Diacrylate Lactam 38 
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Synthesis of cis-3-Acetoxy-4-(4-acetoxyphenyl)-N-(4-methoxyphenyl)azetidin-2-one (47): Imine 43 
(3.99 g, 14.8 mmol) was dissolved in 40 mL of freshly distilled CH2Cl2. The solution was cooled to 
approximately 5oC in an ice bath. Triethylamine (3 eq., 4.15 g, 44.0 mmol) was added followed by 
methoxyacetyl chloride (1.3 eq., 2.73 g, 19.2 mmol) dissolved in 5 mL of CH2Cl2. The reaction mixture 
was stirred until no further change in TLC was observed for 3 hr. The solvent was removed under reduced 
pressure and the crude material was purified by washing with ice cold MeOH and cold ether. The product 
was isolated in 65% yield, 3.49 g of 47, as a white solid, mp 143-144 oC. 1H NMR (250 MHz, CDCl3) δ 
7.32-7.27 (4H, m), 7.04 (2H, d, J = 8.3 Hz), 6.88 (2H, d, J = 6.4 Hz), 5.99 (1H, d, J = 4.8 Hz), 5.29 (1H, d, 
J = 4.6 Hz), 3.71 (3H, s), 2.22 (3H, s), 1.62 (3H, s). 13C NMR (400 MHz, CDCl3) δ 169.5, 169.3, 161.3, 
156.9, 151.2, 139.4, 130.3, 130.0, 129.2, 129.1, 121.9 (2C), 121.2, 119.0, 114.7 (2C), 61.1, 55.6, 21.3, 20.0. 
 
Synthesis of cis-3-Hydroxy-4-(4-hydroxyphenyl)-N-(4-methoxyphenyl)azetidin-2-one (48): To a 
solution of compound 47 (0.86 g, 2.32 mmol) in cold acetone (12 mL) was added a solution of KOH (0.26 
g, 4.64 mmol) in 3 mL of MeOH dropwise. The hydrolysis was complete after the addition of KOH/MeOH 
as indicated by TLC. The product precipitated out of the solution after stirring for 5 mins, and filtered and 
dried to give a white solid in 92% yield. mp 193-194oC. 1H NMR (400 MHz, CDCl3) δ 7.23-7.18 (4H, m), 
6.88 (2H, d, J = 6.4 Hz), 5.99 (1H, d, J = 4.8 Hz), 5.29 (1H, d, J = 4.6 Hz), 3.71 (3H, s). 13C NMR (400 
MHz, d-acetone) δ 161.8, 133.7, 129.2, 129.1, 122.7, 121.8, 121.2, 119.5, 119.0, 118.4, 114.7(2C), 80.9, 
66.4, 59.0. 
 
Synthesis of cis-3-Acryloyl-4-(4-acryloylphenyl)-N-(4-methoxyphenyl)azetidin-2-one (49): To a 
solution of 48 (0.31 g, 1.09 mmol) in 10 mL of CH2Cl2 was added triethylamine (0.22 g, 2.20 mmol). 
Acryloyl chloride (0.19 g, 2.20 mmol) was added dropwise to the solution at 0 oC. The resulting solution 
was stirred at r.t. for 15 mins, and then washed with H2O (2 × 10 mL). The organic layer was dried with 
anhydrous MgSO4, filtered, and evaporated. The crude material was purified by recrystallization in CH2Cl2 
to give a white solid in 93 % yield, mp 118-119 oC. 1H NMR (400 MHz, CDCl3) δ 7.27-7.19 (4H, m), 7.03 
(2H, d, J = 8.4 Hz), 6.75 (2H, d, J = 8.8 Hz), 6.51 (1H, dd, J = 2.4, 8.8 Hz), 6.21 (1H, dd, J = 2.4, 7.6 Hz), 
6.07 (1H, dd, J = 2.6, 10.0 Hz), 5.97 (1H, d, J = 4.8 Hz), 5.94 (1H, dd, J = 2.2, 10.4 Hz), 5.32 (1H, d, J = 
4.8 Hz), 3.73 (3H, s). 13C NMR (400 MHz, CDCl3) δ 164.8, 162.9, 161.7, 157.6, 151.4, 140.2, 133.1, 132.8, 
130.3, 130.0, 129.0, 127.9, 127.7, 126.5, 121.9(2C), 119.1, 114.7, 61.2, 55.7.  
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Synthesis of cis-3-Acryloyl-4-(4-acryloylphenyl)azetidin-2-one (50): To a solution of 49 (82.0 mg, 0.21 
mmol) in 3 mL of CH3CN was added a solution of ceric ammonium nitrate (342 mg, 0.62 mmol) dissolved 
in 3.1 mL of water. The reaction was allowed to stir for 15 min. The solution was extracted with EtOAc (3 
x 20 mL) and washed with 10 mL of water, 5% NaHCO3, 10% NaHSO3 and brine, and then dried over 
MgSO4. The solvent was removed under reduced pressure to yield, and the crude product was purified by 
column chromatography (1:1 EtOAc/hexanes) to 50 as a white solid in 84% yield. 1H NMR (400 MHz, 
CDCl3) δ 7.27 (2H, d, J = 8.4 Hz), 7.20 (2H, d, J = 8.0 Hz), 6.52 (1H, d, J = 17.2 Hz), 6.34 (1H, bs), 6.25 
(1H, dd, J = 2.4, 10.4 Hz), 6.02 (1H, d, J = 4.4 Hz), 5.74 (1H, dd, J = 3.6, 10.4 Hz), 5.36 (1H, dd, J = 2.2, 
9.4 Hz), 5.00 (1H, d, J = 4.8 Hz). 13C NMR (400 MHz, CDCl3) δ 165.7, 164.6, 164.3, 150.9, 133.1, 132.8, 
132.4, 130.3, 130.0, 128.8, 127.9, 126.6, 121.7, 78.3, 57.6.  
 
Synthesis of cis-3-Acryloyl-4-(4-acryloylphenyl)-N-methylthioazetidin-2-one (38): Compound 50 
(0.039 g, 0.10 mmol) was dissolved in dry CH2Cl2 (5 mL), and the solution of N-methylthiophthalimide 
(0.019 g, 0.10 mmol) was added. To the resulting solution was then added triethylamine (0.016 mL, 0.10 
mmol). The reaction was refluxed for overnight and then diluted with CH2Cl2 (20 mL). The resulting 
solution was washed with 1% aqueous KOH (2 x 10 mL). The organic layer was dried with anhydrous 
MgSO4, filtered, and evaporated to give 28 mg of 38 as a white solid in 72% yield. 1H NMR (400 MHz, 
CDCl3) δ 7.36 (2H, d, J = 8.4 Hz), 7.15 (1H, d, J = 8.4Hz), 6.61 (1H, dd, J = 10.4, 6.8 Hz), 6.00 (1H, dd, J 
= 10.4, 6.6 Hz), 4.80 (1H, d, J = 4.8 Hz), 4.75 (1H, d, J = 5.2 Hz), 3.15 (3H, s), 2.34 (3H, s). 13C NMR (400 
MHz, CDCl3) δ 168.2, 164.6, 164.0, 151.4, 135.4, 133.1, 133.0, 132.8, 130.3, 130.2, 129.8, 127.9, 127.7, 
126.4, 121.8(2C), 78.1, 65.5, 22.3.  
 
 
6.1.17 C3-Long Chain Lactam 39 
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Synthesis of cis-3-Acryloyloxy ethyl succinate-4-(2-chlorophenyl)-N-(4-methoxyphenyl) azetidin-2-
one (51): To the solution of hydroxyl lactam 9b (497.8 mg, 1.64 mmol) in 5 mL of CH2Cl2 was added 
mono-2-(acryloyloxy)ethyl succinate (345.9 mg, 1.6 mmol), EDC (306.7 mg, 1.6 mmol) and DMAP (196 
mg, 1.6 mmol) in an ice bath. Then the solution was warmed to r.t. and stir for overnight. The crude 
material was purified by column chromatography using EtOAc/Hexanes (1:1) to give 618.1 mg of 51 in 
77% yield as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.27-7.21 (6H, m), 6.81 (2H, d, J = 8.8 Hz), 
6.39 (1H, dd, J = 1.2, 10.8 Hz), 6.18 (1H, d, J = 4.8 Hz), 6.04 (1H, dd, J = 1.2, 10.4 Hz), 5.78 (1H, d, J = 
4.8 Hz), 4.32 (4H, q, J = 5.2 Hz), 3.74 (3H, s), 2.42-2.39 (1H, m), 2.33 (2H, t, J = 6.8 Hz), 2.22 -2.18 (1H, 
m). 13C NMR (400 MHz, CDCl3) δ 170.8, 169.9, 166.3, 161.8, 157.2, 134.1, 131.7, 130.1, 130.0, 129.6, 
129.4, 128.2(2C), 128.1, 127.1, 126.9, 118.9, 114.7, 62.6, 62.3, 60.0, 58.4, 55.7, 28.7, 28.6. 
 
Synthesis of cis-3-Acryloyloxy ethyl succinate-4-(2-chlorophenyl)azetidin-2-one (52): To a solution of 
51 (0.31 g, 0.62 mmol) in 3 mL of CH3CN was added a solution of ceric ammonium nitrate (1.00 g, 1.85 
mmol) dissolved in a minimum amount of water. The reaction was allowed to stir for 5 min. The solution 
was extracted with EtOAc (3 x 20 mL) and washed with 30 mL of 5% NaHSO3, 5% NaHCO3, and brine, 
and then dried over Na2SO4. The solvent was removed under reduced pressure to yield, and the crude 
product was purified by column chromatography (1:1 EtOAc/hexanes) to give 52 as yellow oil in 86% 
yield. 1H NMR (400 MHz, CDCl3) δ 7.33-7.24 (4H, m), 6.70 (1H, bs), 6.39 (1H, dd, J = 2.4, 10.4 Hz), 6.15 
(1H, d, J = 3.2 Hz), 6.12 (1H, dd, J = 2.2, 10.8 Hz), 5.83 (1H, dd, J = 2.4, 10.4 Hz), 5.36 (1H, d, J = 4.8 
Hz), 4.29 (2H, t, J = 4.4 Hz), 4.24 (2H, t, J = 2.8 Hz), 2.42-2.36 (1H, m), 2.32 (2H, t, J = 6.4 Hz), 2.24-2.20 
(1H, m). 13C NMR (400 MHz, CDCl3) δ 170.8, 169.9, 166.3, 161.0, 134.1, 129.4, 127.6, 124.7, 124.6, 
123.0, 121.8, 94.9, 80.1, 57.4, 57.1, 57.1, 28.7, 28.6. 
 
Synthesis of cis-3-Acryloyloxy ethyl succinate-4-(2-chlorophenyl)-N-methylthioazetidin-2-one (39): 
Compound 52 (0.039 g, 0.10 mmol) was dissolved in dry CH2Cl2 (5 mL), and the solution of N-
methylthiophthalimide (0.019 g, 0.10 mmol) was added. To the resulting solution was then added Hunig’s 
base (0.038 g, 0.30 mmol). The reaction was refluxed for overnight and then diluted with CH2Cl2 (20 mL). 
The resulting solution was washed with 1% aqueous KOH (2 x 10 mL). The organic layer was dried with 
anhydrous MgSO4, filtered, and evaporated, and the residue was chromatographed (1:2 EtOAc/hexanes) to 
give 28 mg of 39 as yellow oil in 72% yield. 1H NMR (400 MHz, CDCl3) δ 7.41-7.19 (4H, m), 6.35 (1H, 
dd, J = 2.2, 9.6 Hz), 6.11 (1H, d, J = 4.4 Hz), 6.02 (1H, dd, J = 2.4, 10.8 Hz), 5.73 (1H, dd, J = 2.4, 10.8 
Hz), 5.42 (1H, d, J = 4.9 Hz), 4.28 (2H, t, J = 3.6 Hz), 4.24 (2H, t, J = 2.8 Hz), 2.44 (3H, s), 2.36-2.30 (4H, 
m). 13C NMR (400 MHz, CDCl3) δ 171.4, 169.9, 168.3, 166.0, 134.6, 131.6, 130.6, 130.3, 130.2, 130.1, 
128.9, 128.1, 126.9, 62.6, 62.2, 28.6, 28.5, 22.1. 
 
 
6.1.18 Glycine-Attached Lactam 54 
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N-Acryloyl-glycine (53): White solid. mp 125-126 oC. 1H NMR (400 MHz, CDCl3) δ 6.13 (2H, m), 5.65 
(1H, d, J = 5.2 Hz), 3.91 (2H, s). 13C NMR (400 MHz, CDCl3) δ 176.0, 166.8, 130.8, 129.1, 48.6. 
 
cis-3-Acryloylamino-acetic ester-4-(2-chlorophenyl)-N-methylthioazetidin-2-one (54): White solid. 1H 
NMR (400 MHz, CDCl3) δ 7.43-7.38 (4H, m), 6.23 (2H, dd, J = 5.2, 13.2 Hz), 6.05 (1H, dd, J = 5.2, 13.2 
Hz), 5.77 (1H, bs), 5.68 (1H, d, J = 4.2 Hz), 5.54 (1H, d, J = 4.0 Hz), 3.98 (1H, dd, J = 4.0, 15.2 Hz), 3.68 
(1H, dd, J = 4.4, 15.2 Hz), 2.54 (s, 3H). 13C NMR (400 MHz, CDCl3) δ 176.0, 175.2, 166.7, 142.8, 130.8, 
129.1, 128.7, 127.6, 125.9, 82.2, 48.6, 50.4, 16.8. 
 
 
6.1.19 Alanine-Attached Lactam 56 
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N-Acryloyl-L-alanine (55): 1H NMR (250 MHz, CDCl3) δ 6.4 (1H, dd, J = 4.4, 15.2 Hz), 6.1 (1H, dd, J = 
4.0, 15.2 Hz), 5.7 (1H, dd, J = 4.4, 15.2 Hz), 4.6 (1H, q, J = 4.8 Hz), 1.4 (3H, d, J = 3.2 Hz) 
 
cis-3-(2-Acryloylaminopropionic ester)-4-(2-chlorophenyl)-N-methylthioazetidin-2-one (56): White 
solid. 13C NMR (400 MHz, CDCl3) δ 178.0, 176.3, 166.7, 142.8, 130.8, 129.1, 128.7, 127.6, 125.9, 82.3, 
48.6, 51.4, 16.6. 
 
 
6.1.20 Valine-Attached Lactam 58 
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N-Acryloyl-L-valine (57): 1H NMR (400 MHz, CDCl3) δ 6.3 (1H, dd, J = 2.0, 9.6 Hz), 6.1 (1H, dd, J = 2.0, 
9.6 Hz), 5.6 (1H, dd, J = 1.6, 9.6 Hz), 4.6 (1H, q, J = 4.8 Hz), 2.1 (1H, q, J = 5.6 Hz), 0.9 (6H, dd, J = 3.2, 
7.2 Hz). 
 
cis-3-(2-Acryloylamino-3-methyl-butyric ester)-4-(2-chlorophenyl)-N-methylthioazetidin-2-one (58): 
White solid. 1H NMR (400 MHz, CDCl3) δ 7.16-7.10 (4H, m), 6.68 (1H, bs), 6.02 (1H, dd, J =5.0, 11.2 Hz), 
5.83 (1H, d, J = 5.2 Hz), 5.78 (1H, dd, J = 5.2, 9.6 Hz), 5.76 (1H, dd, J = 4.7, 9.6 Hz), 5.31 (1H, d, J = 5.0 
Hz), 4.33 (q, 1H, J = 4.6 Hz), 2.32 (3H, s), 0.46 (3H, d, J = 5.8 Hz), 0.23 (3H, d, J = 5.8 Hz). 13C NMR 
(400 MHz, CDCl3) δ 177.2, 176.0, 166.7, 142.8, 130.8, 129.1, 128.7, 127.6, 125.9, 82.3, 61.7, 48.6, 51.4,  
27.2, 16.6 (2C). 
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Acryloyl-L-proline (59): White solid. mp 109-110 oC.1H NMR (400 MHz, CDCl3) δ 6.43 (2H, m), 5.78 
(1H, m), 4.62 (1H, d, J = 4.8 Hz), 3.69 (1H, m), 3.58 (1H, m), 2.30 (2H, m), 2.04 (3H, m).  
 
cis-3-(1-Acryloyl-pyrrolidine-2-carboxylic ester)-4-(2-chlorophenyl)-N-methylthioazetidin-2-one (60): 
White solid. 1H NMR (400 MHz, CDCl3) δ 7.16-7.10 (4H, m), 6.68 (1H, bs), 6.02 (1H, dd, J =5.0, 11.2 Hz), 
5.83 (1H, d, J = 5.2 Hz), 5.78 (1H, dd, J = 5.2, 9.6 Hz), 5.76 (1H, dd, J = 4.7, 9.6 Hz), 5.31 (1H, d, J = 5.0 
Hz), 4.62 (1H, d, J = 4.8 Hz), 2.30 (2H, m), 2.04 (4H, m). 13C NMR (400 MHz, CDCl3) δ 176.0, 174.8, 
166.7, 142.8, 130.8, 129.1, 128.7, 127.6, 125.9, 82.3, 58.1, 50.5, 42.6, 27.2, 22.8, 20.4, 16.6. 
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6.1.22 Methionine-Attached Lactam 62 
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N-Acryloyl-L-methionine (61): 1H NMR (400 MHz, CDCl3) δ 6.96 (1H, bs), 6.28 (1H, dd, J = 2.0, 10.4 
Hz), 6.12 (1H, dd, J = 2.0, 10.0 Hz), 5.65 (1H, dd, J = 1.6, 10.4 Hz), 4.71 (1H, q, J = 4.8 Hz), 2.50 (1H, t, J 
= 7.2 Hz), 2.18 (1H, t, J = 5.6 Hz), 2.02 (3H, s). 
 
cis-3-(2-Acryloylamino-4-methylsulfanyl-butyricester)-4-(2-chlorophenyl)-N-methylthioazetidin-2-
one (62): White solid. 1H NMR (400 MHz, CDCl3) δ 1H NMR (400 MHz, CDCl3) δ 7.16-7.10 (6H, m), 
6.88 (2H), 6.24 (1H, dd, J = 3.0, 9.6 Hz), 6.04 (1H, dd, J =3.0, 10.4 Hz), 5.87 (1H, dd, J = 2.8, 10.4 Hz), 
5.76 (1H, d, J = 5.0 Hz), 5.45 (1H, d, J = 5.2 Hz), 4.54 (1H, q,  J = 4.0, 9.2 Hz), 2.48 (2H, t, J = 7.2 Hz), 
2.38 (3H, s), 2.11 (2H, t, J = 5.6 Hz), 2.03 (3H, s). 13C NMR (400 MHz, CDCl3) δ 177.0, 174.2, 166.7, 
142.8, 130.8, 129.1, 128.7, 127.6, 125.9, 82.3, 58.1, 53.3, 33.2, 16.9, 9.8. 
 
 
6.1.23 Threonine-Attached Lactam 65 
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N-Acryl-L-threonine 64: White solid, mp 83-85oC, 84.1%. 1H NMR (400 MHz, CDCl3) δ 6.31 (1H, dd, J 
= 1.2, 10.4 Hz), 6.19 (1H, dd, J = 1.2, 10.0 Hz), 5.71 (1H, dd, J = 1.2, 10.4 Hz), 4.60 (1H, dd, J = 2.0, 8.8 
Hz), 4.30 (1H, m), 3.77 (3H, s), 2.20 (1H, bs), 1.22 (3H, d, J = 6.8 Hz). 
 
cis-4-(2-Chlorophenyl)-N-methylthio-3-(succinic acid-2-acryloylamino-2-methoxycarbonyl-1-methyl-
ethyl ester)azetidin-2-one (65): White solid. 1H NMR (400 MHz, CDCl3) δ 7.43-7.23 (4H, m), 6.31 (1H, 
dd, J = 1.2, 10.4 Hz), 6.19 (1H, dd, J = 1.2, 10.0 Hz), 6.02 (1H, d, J = 4.8 Hz), 5.71 (1H, dd, J = 1.2, 10.4 
Hz), 5.38 (1H, d, J = 4.8 Hz), 4.60 (1H, dd, J = 2.0, 8.8 Hz), 4.30 (1H, m), 3.77 (3H, s), 2.20 (1H, bs), 1.22 
(3H, d, J = 6.8 Hz). 13C NMR (400 MHz, CDCl3) δ 176.0, 175.4, 172.2, 166.7, 142.8, 130.8, 129.1, 128.7, 
127.6, 130.0, 125.9, 82.3, 59.1, 50.4, 33.2, 29.0, 28.3, 14.0. 
 
 
6.1.24 Methionine-Attached Lactam 67 
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cis-4-(2-Chlorophenyl)-1-(methylthio)-3-(methyloxy-4-oxobutanamido)-N-(methylthio) azetidin-2-one 
(67): White solid. 1H NMR (400 MHz, CDCl3) δ 7.43-7.23 (4H, m), 6.02 (1H, d, J = 4.8 Hz), 5.71 (1H, dd, 
J = 1.2, 10.4 Hz), 5.38 (1H, d, J = 4.8 Hz), 4.22 (1H, m), 3.77 (3H, s), 2.52 (4H, m), 3.27 (1H, dd, J = 2.0, 
8.8 Hz), 2.20 (3H, s);  13C NMR (400 MHz, CDCl3) δ 176.0, 175.4, 172.2, 166.7, 142.8, 130.8, 129.1, 128.7, 
127.6, 130.0, 125.9, 82.3, 59.1, 50.8, 50.4, 33.2, 29.4, 28.9, 16.8. 
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cis-3-Acetoxy-4-(4-acetoxyphenyl)-N-methylthioazetidin-2-one (69): White solid. 1H NMR (400 MHz, 
CDCl3) δ 7.26-7.20 (2H, m), 7.02-7.00 (2H, m), 5.77 (1H, d, J = 2.4 Hz), 4.94 (1H, d, J = 2.4Hz), 2.22 (3H, 
s), 1.63 (6H, s). 
 
cis-3-hydroxy-4-(4-hydroxyphenyl)-N-methylthioazetidin-2-one (68): White solid. 1H NMR (400 MHz, 
CDCl3) δ 7.26-7.20 (2H, m), 7.02-7.00 (2H, m), 5.77 (1H, d, J = 2.4 Hz), 4.94 (1H, d, J = 2.4Hz), 2.28 (3H, 
s). 
 
6.2 Emulsion Polymerization 
6.2.1 General procedure for preparation of emulsion polymerization 
The general emulsion polymerization procedure employed for this system involves dissolving a 
water-insoluble acrylated drug in a liquid acrylate, i.e. ethyl acrylate, at 70oC, and the mixture was then pre-
emulsified in purified water containing 3% w/w of sodium dodecylsulfate, a surfactant, with rapid stirring. 
The resulting homogenous solution of micelles was then treated with potassium persulfate (1% w/w), a 
radical initiator, to induce free radical polymerization. 
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6.2.2  Formulation of Emulsion Polymerization 
1. Formulation of emulsion polymerization of NP-4a 
 
Drug 27
Ethyl acrylate
Surfactant
Radical initiator
300 mg
1000 mg
30 mg
10 mg
Water 4 ml
components amount
FormulationandRxnConditions
Rxn Temp 70 oC                      
 
 
2. Formulation for emulsion polymerization of NP 4b-NP 12. 
 
 
Drug monomer
Butyl acrylate
Styrene
Surfactant
Radical initiator
10 mg
700 mg
300 mg
30 mg
10 mg
Water 4 ml
components amount
FormulationandRxnConditions
Rxn Temp 70 oC  
 
 
6.3 Physical Properties Analysis 
6.3.1 Particle size determination 
Dynamic light scattering data was acquired on a UPA Honeywell MicroTrac at the University of 
Florida Particle Engineering Research Center. One drop of concentrated emulsion solution was placed in a 
10 mL well filled with nanopure water. Analysis was performed for 3 runs of 180 seconds per run per 
sample. 
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6.3.2 Zeta Potential Analysis 
Zeta potential value of each emulsion was obtained on a Brookhaven ZetaPALS. The emulsion 
solution was diluted to 1.5% (~ pH = 7) of solid content using nanopure water for analysis and 2 × 10 runs 
per sample was performed. The dispersant viscosity of the emulsion solution is 0.8872cP, and the dielectric 
constant of the medium is 78.55.  
 
6.3.3 Microscopy 
The morphology and the particle size was performed scanning electron microscopy (SEM) in the 
college of Engineering at University of South Florida. The sample of nanoparticles was prepared by high 
DI water (3,000-fold) of the emulsion, with evaporation under a N2-stream prior to coating by gold sputter 
under high vacuum. The gold-coated nanoparticles were then observed by SEM (Hitach S 800). 
Transmission electron microscopy (TEM) analysis was performed on a FEI Morgagni 268D Electron 
Microscope in the biology department at University of South Florida. The initial emulsion solution was 
diluted down to a 10-10 concentration using nanopure water, then the solution was drop cast onto a 
Formvar-coated copper grid. The water content was evaporated by applying a cool stream of air to the drop, 
and the grid was subsequently view on the microscope. 
 
6.4 Microbiological Test Procedures  
 
The following bacteria were used for the antimicrobial evaluation of N-thiolated β-lactams: 
Bacillus anthracis (Sterne strain), Bacillus cereus (ATCC 14579), Bacillus coagulans (USF 546), Bacillus 
globigii (Department of Defense Reagents Program), Bacillus megaterium (ATCC 14581), Bacillus subtilis 
(ATCC 19569), Bacillus thuringensis (ATCC 10792), Bacteroides fragalis (obtained from Smith-Kline 
Laboratory), Staphylococcus aureus USF525 (ATCC 25923) Staphylococcus aureus USF652-658 
(obtained from Lakeland Regional Medical Center, β-lactamase positive). 
 
 
6.4.1 Antimicrobial Susceptibility Test  
Culture preparation: From a freezer stock in tryptic soy broth (Difco Laboratories, Detroit, MI) and 20% 
glycerol, a culture of each organism was grown on tryptic soy agar (TSA) plates (Becton-Dickinson 
Laboratories, Cockeysville, MD) at 37°C for 24 hours. A 108 suspension was then made in sterile 
phosphate buffered saline (pH 7.2) and swabbed across fresh TSA plates. 
 
Well method: A 108 standardized cell count suspension was then made in sterile phosphate buffered saline 
(pH 7.2) and swabbed across fresh TSA plates. Circular wells (6 mm in diameter) were cut into the 
inoculated plates and 20 µL of a 1 mg/mL stock solution of the test lactam in dimethylsulfoxide (DMSO) 
was pipetted into the wells. The plates were incubated for 24 hours at 37°C and the antimicrobial 
susceptibilities were determined by measuring the zones of growth inhibition around each well.  
 
6.4.2 MIC Determinations 
Media preparation: The minimum inhibitory concentrations were determined by the agar plate 
dilution. The test media were prepared in 24 well plates (Costar 3524, Cambridge, MA) by adding a known 
concentration of the test drug in DMSO together with a solution of Mueller-Hinton II agar (Becton-
Dickinson Laboratories, Cockeysville, MD) for a total volume of 1 ml in each well. Calculations of the 
overall concentration of antibiotic in the wells were standardized by measuring from a 1mg/ml stock 
solution of the test drug. At this concentration, the microliter quantity is equivalent to the micrograms in 
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solution. The amount of agar solution added to the wells was determined by subtracting 1000 µl from the 
quantity of test drug in each well to give a combined volume of 1 ml. Following preparation of the well 
plates, the media were allowed to solidify at room temperature for 24 hours before inoculation.  
Inoculation: From an 24 hour culture of each organism on tryptic soy agar (TSA) plates (Becton-
Dickinson Laboratories, Cockeysville, MD), the staphylococcal strains were grown overnight in 5 ml of 
tryptic soy broth (Difco Laboratories, Detroit, MI) at 37°C. One microliter of each culture was then applied 
to the appropriate well of agar and incubated at 37°C overnight. After 24 hr, the MICs were determined by 
examining the wells for growth.  
 
6.5 Interaction of Nanoparticles with S. aureus Cells 
 
6.5.1 Whole cell analysis 
S. aureus was grown up on TSA plates overnight at 37oC. The bacteria were then carried through a 
series of dilutions in order to obtain a concentration of 102 CFU/ml in trypticase soy broth (TSB). The cells 
were then exposed to a 10-10 concentration of control nanoparticles for 30 minutes. Thereafter, the broth 
was treated with 5 mL of 2.5% gluteraldehyde for 4 hours at 4oC. A solution of 102 CFU/ml S. aureus in 
TSB was also treated with 5 mL of 2.5% gluteraldehyde for 4 hours at 4oC and served as a control for the 
experiment. The broth suspension was then drop cast onto a formvar-coated copper grid and was allowed to 
dry at room temperature under a cool stream of air. The control cells and cells treated with control 
nanoparticles were then observed on the FEI Morgagni 268D transmission electron microscope. 
 
 
6.5.2 Sectioned cell analysis 
S. aureuswas grown up on TSA plates overnight at 37oC. The bacteria were then carried through a 
series of dilutions in order to obtain a concentration of 107CFU/ml in TSB. The diluted samples were then 
exposed to a concentration of 10-5 control nanoparticles for 30 minutes and then centrifuged at 10,000 xg 
for 5 minutes. The pellet was washed twice with PBS, then resuspended in 5 ml of PBS and fixed with 5ml 
of 2.5% glutaraldehyde for 4 hours at 4oC. The fixed cells were centrifuged at 10,000xg for 5 minutes and 
then resuspended in PBS supplemented with 0.1M sucrose. The cells were then centrifuged and 
resuspended twice in PBS at 10,000xg for 5 minutes. The cells were then centrifuged again at 10,000xg for 
5 minutes then the pellet was embedded in agar for easier handling. The agar blocks were then washed with 
PBS and postfixed in 2% osmium tetroxide for 1 hour at room temperature. The cells were then washed 
twice with PBS then once with 0.9% saline and stained with 1.5% uranyl acetate. The cell-containing agar 
blocks were then carried through a series of dehydrations using graded ethanol. The cells are then 
infiltrated and embedded in Spurr’s Plastic and ultrathin sections are cut using a Sorvall MT-2B 
ultramicrotome and placed on copper mesh grids. The grids are then examined on the FEI Morgagni 268D 
Electron Microscope. 
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CHAPTER 7 1H and 13 C NMR SPECTRA 
 
 
 
Spectrum 7.1: 1H NMR (250 MHz, CDCl3) (6b) 
 
 
Spectrum 7.2: 13 C NMR (63 MHz, CDCl3) (6b) 
 
 
 
  
139
Spectrum 7.3: 1H NMR (250 MHz, CDCl3) (6a) 
 
 
Spectrum 7.4: 1H NMR (250 MHz, CDCl3) (8a) 
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Spectrum 7.5: 1H NMR (250 MHz, CDCl3) (9a) 
 
 
 
 
Spectrum 7.6: 1H NMR (250 MHz, CDCl3) (10a) 
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Spectrum 7.7: 1H NMR (250 MHz, CDCl3) (11a) 
 
 
 
Spectrum 7.8: 1H NMR (250 MHz, CDCl3) (8b) 
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Spectrum 7.9: 1H NMR (250 MHz, CDCl3) (3a) 
 
 
Spectrum 7.10: 13C NMR (63 MHz, CDCl3) (3a) 
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Spectrum 7.11: 1H NMR (250 MHz, CDCl3) (10b) 
 
 
 
Spectrum 7.12: 13C NMR (63 MHz, CDCl3) (10b) 
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Spectrum 7.13: 1H NMR (250 MHz, CDCl3) (3b) 
 
 
Spectrum 7.14: 13C NMR (63 MHz, CDCl3) (3b) 
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Spectrum 7.15: 1H NMR (250 MHz, CDCl3) (10c) 
                                   
 
 
Spectrum 7.16: 13C NMR (63 MHz, CDCl3) (10c) 
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Spectrum 7.17: 1H NMR (250 MHz, CDCl3) (3c) 
 
 
Spectrum 7.18: 13C NMR (63 MHz, CDCl3) (3c) 
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Spectrum 7.19: 1H NMR (250 MHz, CDCl3) (15) 
 
 
 
Spectrum 7.20: 1H NMR (100 MHz, CDCl3) (16) 
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Spectrum 7.21: 1H NMR (250 MHz, CDCl3) (17) 
 
 
 
Spectrum 7.22: 1H NMR (250 MHz, CDCl3) (17) 
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Spectrum 7.23: 1H NMR (250 MHz, CDCl3) (10d) 
 
 
 
Spectrum 7.24: 13C NMR (63 MHz, CDCl3) (10d) 
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Spectrum 7.25: 1H NMR (250 MHz, CDCl3) (18) 
 
 
Spectrum 7.26: 1H NMR (250 MHz, CDCl3) (21a) 
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Spectrum 7.27: 1H NMR (250 MHz, CDCl3) (20) 
 
 
Spectrum 7.28: 13C NMR (63 MHz, CDCl3) (20) 
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Spectrum 7.29: 1H NMR (250 MHz, CDCl3) (22a) 
 
 
Spectrum 7.30: 1H NMR (250 MHz, CDCl3) (19b) 
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Spectrum 7.31: 1H NMR (250 MHz, CDCl3) (21b) 
 
 
 
Spectrum 7.32: 13C NMR (63 MHz, CDCl3) (21b) 
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Spectrum 7.33: 1H NMR (250 MHz, CDCl3) (22b) 
 
 
Spectrum 7.34: 13 C NMR (63 MHz, CDCl3) (22b) 
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Spectrum 7.35: 1H NMR (250 MHz, CDCl3) (21c) 
 
 
Spectrum 7.36: 13C NMR (63 MHz, CDCl3) (21c) 
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Spectrum 7.37: 1H NMR (250 MHz, CDCl3) (22c) 
 
 
Spectrum 7.38: 1H NMR (250 MHz, CDCl3) (19c) 
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Spectrum 7.39: 1H NMR (250 MHz, CDCl3) (21d) 
 
 
Spectrum 7.40: 1H NMR (250 MHz, CDCl3) (19d) 
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Spectrum 7.41: 1H NMR (250 MHz, CDCl3) (22d) 
 
 
Spectrum 7.42: 13C NMR (63 MHz, CDCl3) (22d) 
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Spectrum 7.43: 1H NMR (250 MHz, CDCl3) (23) 
 
 
Spectrum 7.44: 1H NMR (250 MHz, CDCl3) (19e) 
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Spectrum 7.45: 13C NMR (100 MHz, CDCl3) (30) 
 
 
Spectrum 7.46: 1H NMR (400 MHz, CDCl3) (31) 
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Spectrum 7.47: 1H NMR (400 MHz, CDCl3) (27) 
 
 
 
Spectrum 7.48: 13C NMR (100 MHz, CDCl3) (27) 
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Spectrum 7.49: 1H NMR (250 MHz, CDCl3) (28, 29) 
 
 
 
 
Spectrum 7.50: 1H NMR (400 MHz, CDCl3) (34) 
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Spectrum 7.51: 1H NMR (250 MHz, CDCl3) (29) 
 
Spectrum 7.52: 1H NMR (400 MHz, CDCl3) (32) 
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Spectrum 7.53: 1H NMR (400 MHz, CDCl3) (33) 
 
 
 
Spectrum 7.54: 1H NMR (250 MHz, CDCl3) (25) 
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Spectrum 7.55: 1H NMR (250 MHz, CDCl3) (42) 
 
 
Spectrum 7.56: 13C NMR (100 MHz, CDCl3) (42) 
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Spectrum 7.57: 1H NMR (400 MHz, CDCl3) (44) 
 
 
 
 
Spectrum 7.58: 1H NMR (400 MHz, CDCl3) (45) 
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Spectrum 7.59: 1H NMR (400 MHz, CDCl3) (47) 
 
 
 
Spectrum 7.60: 13C NMR (100 MHz, CDCl3) (47) 
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Spectrum 7.61: 13C NMR (100 MHz, CDCl3) (48) 
 
Spectrum 7.62: 1H NMR (250 MHz, CDCl3) (14) 
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Spectrum 7.63: 1H NMR (400 MHz, CDCl3) (49) 
 
Spectrum 7.64: 13C NMR (100 MHz, CDCl3) (49) 
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Spectrum 7.65: 1H NMR (400 MHz, CDCl3) (50) 
 
 
Spectrum 7.66: 13C NMR (100 MHz, CDCl3) (50) 
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Spectrum 7.67: 13C NMR (100 MHz, CDCl3) (38) 
 
 
 
Spectrum 7.68: 13C NMR (100 MHz, CDCl3) (51) 
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Spectrum 7.69: 13 C NMR (100 MHz, CDCl3) (39) 
 
Spectrum 7.70: 1H NMR (250 MHz, CDCl3) (56) 
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Spectrum 7.71: 1H NMR (400 MHz, CDCl3) (57) 
 
 
Spectrum 7.72: 1H NMR (400 MHz, CDCl3) (NP 6c) 
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Spectrum 7.73: 1H NMR (400 MHz, CDCl3) (NP 7) 
 
 
Spectrum 7.74: 1H NMR (400 MHz, CDCl3) (NP 6b) 
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